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Abstract!Hereditary#hyperplastic#gingivitis#(HHG)#is#a#benign#fibrous#enlargement#of#the#gingival#tissue#progressing#to#dental#encapsulation#in#ranched#silver#foxes#(Vulpes'
vulpes).#It#is#an#autosomal#recessive#condition#displaying#male#sex'biased#penetrance#HHG#demonstrates#a#pleiotropic#association#with#superior#fur#quality.#In#2004,#after#the#introduction#of#a#Finnish#fox#line,#HHG#emerged#in#Newfoundland#and#Labrador,#Canada.#While#the#underlying#HHG#aetiology#is#unknown,#an#analogous#condition#called#hereditary#gingival#fibromatosis#(HGF)#occurs#in#humans,#providing#a#platform#for#investigation#into#the#molecular#mechanisms#of#HHG.#A#mutation#in#the#son'of'sevenless'homolog'1#gene#causes#one#form#of#HGF.#Candidate#gene#sequencing#of#this#and#related#genes#including#epidermal'growth'
factor'receptor'(EGFR),#growth'factor'receptor'bound'protein'2,#and#mitogen=
activated'protein'kinase'kinase'6#did#not#uncover#any#putative#coding#sequence#or#splice'site#mutations.#HHG#was#also#examined#at#the#genomic#level,#integrating#knowledge#of#the#chromosomal#loci#associated#with#the#analogous#human#condition,#HGF.#This#exploration#was#divided#into#the#known#genetic#causes#of#isolated#HGF#and#HGF'associated#syndromes#characterized#by#both#gingival#and#hair#overgrowth.#Global#gene#expression#differences#between#affected#and#unaffected#foxes#pinpoint#
SOS2#and#RASA1#as#candidate#genes#for#HHG;#overall,#the#genomic#expression#patterns#strongly#indicate#the#involvement#of#the#mitogen'activated#protein#kinase#(MAPK)#signalling#pathway.#Specifically,#the#error#could#occur#prior#to#the#Rat#sarcoma#protein#in#this#pathway.#Future#exploration#of#this#pathway#could#elucidate#the#genetic#basis#of#HHG#and#more#broadly#the#molecular#aetiology#of#gingival#
 iii#
overgrowth#in#humans#and#canines.#Additional#information#regarding#the#HHG#phenotype#was#revealed,#including#the#potential#involvement#of#androgens#in#disease#severity.#The#steroid=5=alpha=reductase,'alpha'polypeptide'2#gene#was#found#to#be#up'regulated#in#the#HHG'affected#foxes,#and#the#link#between#androgens#and#gingival#sensitivity#in#dogs#might#help#explain#the#perceived#sex#biased#penetrance#originally#noted#in#HHG.#Overall#the#molecular#mechanisms#underpinning#the#HHG#phenotype#and#future#work#revolve#around#the#MAPK#signalling#pathway#including#influences#that#other#gene#products#like#androgens#have#on#it.################
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Introduction Hereditary hyperplastic gingivitis (HHG) is a benign, proliferative gingival overgrowth seen in foxes. It was first documented in the 1940s and to date the underlying molecular aetiology is still unknown (Dyrendahl and Henricson 1960). In 2004, HHG was documented for the first time in North America in farmed silver foxes after the introduction of a Finnish silver fox line (Clark et al. 2015). The emergence of this disease in Canada brought its aetiology to the forefront. Analogous conditions occur in other organisms, including humans and the domestic dog, which could provide clues to a common underlying aetiology to this disease.  Hereditary gingival fibromatosis (HGF) is a benign, proliferative gingival overgrowth affecting humans. Studies have demonstrated HGF to be a complex disease with numerous aetiologies. Broadly, these can be divided into three groups: isolated genetic inheritance, part of a genetic syndrome, or an acquired drug-induced phenotype (Shashi et al. 1999). Each of these categories can be further subdivided, further highlighting the complexity of this disease.   Gingival hyperplasia occurs in the domestic dog (Hale 2004). It has an association with certain breed dispositions, suggesting an underlying genetic aetiology; as well, there is an independent drug-induced phenotype. In either case, the underlying molecular mechanism is unknown.  
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 From an evolutionary standpoint the fox and domestic dog are closely related (Wayne et al. 1997). The publication of the canine genome in 2005 (Lindblad-Toh et al. 2005) has enabled genomic research in other closely-related species such as the fox, thus providing a new platform of investigation. A co-operative strategy incorporating what is known about HGF along with genomic technologies based on the dog genome will aid in creating a comprehensive platform for the assessment of HHG genetics in silver foxes.  
 
Fox farming and HHG In Canada, fox farming originated in 1895 on Prince Edward Island (Rubtsov 1998). As part of this practice, various coat colour variants were selected for breeding. In the 1940s the first case of HHG was noted in a Norwegian male silver fox with superior fur quality that had been imported into Sweden from Norway. The disease quickly spread through fox farms in both Sweden and Norway. In 1960 Dyrendahl and Henricson published a seminal paper describing the genetic inheritance of HHG in the farmed silver fox population (Dyrendahl and Henricson 1960). They examined 1,080 parents and 7,238 silver fox pups over a six-year period. The manifestation of HHG occurred at approximately two to three years of age, with tumour proliferation continuing throughout life and resulting in dental encapsulation. Pathology showed large epithelial extensions in the keratinized collagen of the gingival tissue. Genetic analysis found HHG to be an autosomal recessive disease demonstrating incomplete penetrance, with an increased incidence in males relative to females. In addition, a pleiotropic relationship between HHG and superior fur quality 
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(typically length and density of the guard hairs) was implicated. Shortly after, the global price for silver fox furs decreased significantly resulting in the reduction of silver fox stocks in many countries until the early 1970s when the fox lines were re-established (R. Hudson, personal communication, 2012).   While the majority of HHG cases are found in farmed foxes there was a report in 2008 of a case of severe HHG in a wild European red fox (Schulze et al. 2008). A male red fox of at least six years of age was investigated as part of a national regulatory program for protection against rabies. Gross clinical presentation showed severe papillomatous growth on the both upper and lower jaws, encapsulating the teeth, similar to the HHG seen in the farmed silver fox population.  In Canada, Newfoundland and Labrador has established the largest collection of farmed foxes in North America, where approximately 2,200 foxes are housed each year (Bursey 2001). HHG was first documented in North America in 2004 in Newfoundland and Labrador in a farmed fox population (Clark et al. 2015). With the emergence in Canada questions about the molecular aetiology is once again being brought to the forefront.  
Human hereditary gingival fibromatosis: clinical presentation HGF is a rare, pernicious disease of the oral cavity for which the underlying cellular aetiology is unknown. It has a phenotypic frequency of 1:175 000, affecting males and females equally (Fletcher 1966). HGF is a genetically and phenotypically heterogeneous 
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disease characterized by progressive benign fibrous enlargements of the maxillary and mandibular keratinized gingival tissue (Hart et al. 2002). On average, manifestation occurs at permanent dentition but cases have been reported demonstrating involvement in primary dentition and even at birth (Breen et al. 2009; Coletta and Graner 2006). Manifestations typically worsens during adolescence (Coletta and Graner 2006).  
 
Gross appearance Clinically, HGF occurs asymptomatically with benign, non-hemorrhagic, non-exudative gingival overgrowths (Bittencourt et al. 2000; Hakkinen and Csiszar 2007). The gingival tissue is of normal colour, with a firm consistency and stippling on the adjoining gingiva (Singer et al. 1993). This fibrous tissue can appear nodular or have a pebbled surface (Brown et al. 1995). Involvement of the buccal and lingual tissue on both the mandible and maxilla can occur, but does not extend beyond the mucogingival junction (Katz et al. 2002; Ramer et al. 1996).   Two different forms of HGF have been classified, nodular and symmetric, that can occur together or in isolation (Bittencourt et al. 2000; Ramer et al. 1996). The nodular phenotype contains multiple focal lesions into the dental papillae. This form commonly presents in the maxillary tuberosity and the molar area, predominantly on the palatal area (Katz et al. 2002). The symmetric form is more generalized showing a more uniform gingival pattern. This form is more common and affects both the maxilla and the mandible equally (Bittencourt et al. 2000).  
 6 
 More severe presentations of HGF can involve the anterior mandible with tooth encapsulation (Bittencourt et al. 2000; Breen et al. 2009). While the alveolar bone is not involved in this disease there can be alteration of the contour of the palate and pseudo-pocketing can occur from the excess gingival tissue (DeAngelo et al. 2007; Hakkinen and Csiszar 2007). Numerous other dental problems can subsequently result, including: diastemas; malpositioning of the teeth; prolonged retention of primary dentition and delayed eruption (Bittencourt et al. 2000). While HGF disease originates as a result of gingival overgrowth it has profound effects on the entire oral cavity.  
Microscopic structure Ultrastructure studies conducted on gingival overgrowth lesions from human samples showed predominantly myoblast-like cells and fibroblast-like cells (Takagi et al. 1991). Another prominent feature included large amounts of collagen fibrils in the extracellular matrix. Electron microscopy demonstrated an abnormal variety in the collagen bundle diameter (Barros et al. 2001). In addition, there was an increased level of oxytalan fibres and minimal elastic fibres were present.  Histological examination of the human HGF gingival samples characterized changes in epithelial thickness, cellular structures such as collagen bundles and fibroblast, and general abnormalities. The squamous epithelium contained acanthosis and elongated rete pegs (Sengun et al. 2007; Takagi et al. 1991). Epithelial hyperplasia was seen as a result of the 
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acanthosis in cases where chronic inflammation was present (Hakkinen and Csiszar 2007). The collagen bundles appeared coarse, mature and acellular and were arranged mostly in parallel bundles (Hakkinen and Csiszar 2007, Takagi et al. 1991). Two populations of fibroblast cells were identified (Collan et al. 1982; Sakamoto et al. 2002). One population contained little perinuclear cytoplasm and had dense collagen bundles. The second contained inactive fibroblasts with large amounts of smooth and rough endoplastic reticulum, Golgi apparati and mitochondria in the cytoplasm. There were minimal signs of inflammatory cells unless there was a background of chronic inflammation or in cases with pseudo-pockets of excess gingival tissue (Hakkinen and Csiszar 2007; Takagi et al. 1991). Extensive cellular degradation was seen with few vascular structures present. There were a number of abnormal findings present in some but not all cases, including: mucosal ulceration; amyloid, calcified particles; epithelial metaplasia and islands of odontogenic epithelium (Gunhan et al. 1995). HGF demonstrated numerous histological findings that were non-specific and thus cannot be used in making a diagnosis; rather diagnosis is based on family history and clinical presentation.   
Treatment Treatment has evolved from more extreme measures including tooth removal and removing portion of the alveolar bone to more conservative measures including quadrant by quadrant internal or external bevel gingivectomy or carbon dioxide laser removal (Coletta and Graner 2006; Ramer et al. 1996). Ideal timing for gingival removal is often debated between pre- or post-arrival of permanent dentition. Post- operative surgical 
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patients are required to follow an oral hygiene regime and are followed routinely as reoccurrence rates can be high, especially in children and adolescents (Ramer et al. 1996). Removal of the gingival growth is not curative as the gingival tissue will continue to grow and require future resections.  
Hereditary gingival fibromatosis: aetiology Broadly, HGF can be classified as primary or secondary  (Figure1.1) (Shashi et al. 1999). Primary HGF can be the result of an isolated disorder with a genetic cause, or a component of a larger syndrome. Secondary HGF is the result of an interaction with a drug that can induce the HGF phenotype. One approach to understanding the aetiology of HGF is to determine the genetic basis of isolated HGF and then examine the role that gene or genes play in syndromic form as well as in the genetic susceptibility for drug-induced HGF.  
Primary HGF: isolated HGF genetics HGF is a genetically heterogeneous disease with different patterns of inheritance including Mendelian autosomal dominant, Mendelian autosomal recessive, and maternal genome imprinting.   Mendelian HGF is predominantly autosomal dominant and displays incomplete penetrance and variable expression  
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     Figure 1.1: Schematic diagram depicting the known causes of human hereditary gingival fibromatosis (HGF).
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(Goldblatt and Singer 1992; Hart et al. 1998; Singer et al. 1993). Autosomal recessive HGF is rare and often is the result of de novo mutations and is associated with other abnormalities (Goldblatt and Singer 1992; Hart et al. 1998; Singer et al. 1993).  HGF inheritance via genome imprinting and maternal transmission (Zhu et al. 2007) has been linked to chromosome 11p15, which contains two imprinting clusters. The HGF phenotype has also been associated with chromosomal abnormalities involving chromosomal locations 7p, 8, and 14q22-q32 (Xiao et al. 2001).    While HGF has several modes of inheritance, the focus of research has been to elucidate the genes involved with the autosomal dominant forms of transmission. Autosomal dominant isolated HGF has been linked to three distinct chromosomal loci: HGF1 at 2p21-p22 (Hart 
et al. 1998; Xiao et al. 2001), HGF2 at 5q13-q22 (Xiao et al. 2001), and HGF3 at 2p22.3-p23.3 (Ye et al. 2005).  The HGF1 locus was mapped through analysis of a Brazilian family and further refined to a 37cM genetic interval (Shashi et al. 1999). Later a single nucleotide insertion in codon 1,083 of the Son of sevenless homolog 1 (SOS1) gene was found within the refined region and was proven to be the HGF1 causative mutation (Hart et al. 2002).  HGF2 was mapped to the locus 5q13-q22 using samples from a four generation Chinese family (Xiao et al. 2001). This region contains 45 known genes including genes involved in calcium signalling mechanisms and pathways. These could be involved in one of the pharmacologic mechanisms causing the HGF phenotype (Xiao et al. 2001). Despite identifying the HGF2 locus, no genes have been identified as putative HGF2 genes. The third HGF locus at 2p22.3-p23.3 was identified in a five generation Chinese family, and two genes, GRP113 and SELI, were screened and eliminated as carrying HGF3 mutations (Ye et al. 2005). This locus was 
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further refined to a 6.56cM interval by Pampel et al. (2010). While no putative mutation has been determined, greater attention through sequence analysis has been placed on those genes in the region that are involved with the RAS/MAPK signalling pathway based on its involvement with SOS1 in HGF1 as well as its involvement with several syndromic forms of HGF.   
Primary HGF: syndrome-associated HGF  HGF can occur as a part of a syndrome with high phenotypic variability (Haytac and Ozcelik 2007). For many syndromes the overall mode of inheritance is known but the specific mechanisms remain unknown (Table 1.1). Many of these syndromes have overlapping phenotypes and may represent a single common disorder with a spectrum of manifestations (Haytac and Ozcelik 2007). The most commonly associated presentation with HGF is hypertrichosis (Coletta and Graner 2006). This overgrowth of hair is reminiscent of the longer guard hairs present in the analogous silver fox version of this disease (Dyrendahl and Henricson 1960). In humans, this association can occur with or without mental retardation and has a dominant inheritance pattern (Coletta and Graner 2006). Haplotype analysis and linkage studies have demonstrated that when HGF with hypertrichosis occurs, it is not linked to HGF1 or HGF2, suggesting a distinct genetic form of HGF (Mangino et al. 2003) that needs to be characterized.  Hypertrichosis is defined as an abnormal excess of hair growth with either a generalized or localized distribution, that is neither primarily androgen-dependent    
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Table 1.1: General features, inheritance and age at onset of known syndromes where hereditary gingival fibromatosis can co-occur 
Syndrome Features (in addition to HGF) Age of HGF 
onset 
Mode of 
inheritance 
Reference 
Generalized gingival 
fibromatosis with 
hypertrichosis 
Hypertrichosis with/without mental retardation Within first year of life Autosomal dominant (Cuestas-Carnero and Bornancini 1988; Gorlin 
et al. 1990; Tay et al. 2001) 
Epilepsy  Seizures with or without mental retardation Age 5  Autosomal recessive (Gorlin et al. 1990) 
Murray-Puretic-
Drescher syndrome 
Multiple hyaline fibromas, white papules on the skin, flexion contractures, osteolytic lesions, recurrent infections and premature death Within first year of life Autosomal recessive (Gorlin et al. 1990; Piattelli et al. 1996) 
Rutherfurd syndrome Corneal opacities and delayed tooth eruption Not reported Autosomal dominant (Gorlin et al. 1990) 
Zimmermann-Laband 
syndrome 
Ear, nose abnormalities, hypoplastic changes in the terminal phalanges of the fingers and toes, hepatosplenomegaly Birth Autosomal dominant (Gorlin et al. 1990; Holzhausen et al. 2003) 
Cross syndrome Microphthalmia, mental retardation, athetosis, hyperpigmentation  Not reported Autosomal recessive (Gorlin et al. 1990) 
Ramon syndrome Cherubic faces, delayed/ incomplete tooth eruption, narrow palate, mild retardation, epilepsy, stunted growth, hypertrichosis  Age 2 Autosomal recessive (Gorlin et al. 1990) 
GF and growth 
hormone deficiency 
Growth retardation Prior to age 8 Autosomal recessive (Oikarinen et al. 1990) 
Costello syndrome Growth retardation, developmental delay, coarse face, decreased nasal bridge, full cheeks, thick lips, loose skin on hands and feet, deep palmer/plantar creases 
Childhood Autosomal dominant (Hennekam 2003) 
Jones syndrome Progressive deafness Not reported Autosomal dominant (Gorlin et al. 1990; Hartsfield et al. 1985) 
Prune-belly 
syndrome 
Facial dimorphism, abdominal defects  2 years Autosomal recessive with sex influence (Harrison et al. 1998) 
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nor influenced by race, sex or age (Beighton 1970). Estimates of the incidence of this rare 
condition	  in	  the	  early	  1900s	  were	  judged	  to	  be	  “one	  in	  a	  million”	  but	  this	  is	  believed	  to	  be	  an underestimate, as it does not account for the incidence of hypertrichosis in association with numerous syndromes (Beighton 1970; Garcia-Cruz et al. 2002). There are three main kinds of hair: lanugo, vellus and terminal, each inserting into different places within the skin (Wendelin et al. 2003). Lanugo hair occurs in utero, disappearing shortly after birth consisting of a fine longer hair (Duggins and Trotter 1950). Vellus hair is an intermediate hair that is short, non-pigmented and covers the majority of the body after birth excluding the scalp and eyebrows. Terminal hair is wider, pigmented with a coarse quality (Stenn and Paus 2001). In normal development, vellus hair transforms into terminal hair as a part of an androgen surge during sexual maturity by mechanisms that are not well understood (Wendelin et al. 2003). One mechanism of hypertrichosis involves this hair transition but in places where it does not normally occur. Another mechanism involves a change in the hair follicle cycle, which consists of growth, apoptosis and shedding phases (Wendelin et al. 2003). Hypertrichosis results when the cycle has been altered and the hair spends more time in the growth phase (Paus and Cotsarelis 1999). A third mechanism involves an alteration in the density of the hair follicles (Wendelin et al. 2003). While these are the established mechanisms for hypertrichosis there may be other mechanisms and mechanisms may work concurrently in the same hypertrichosis presentation. 
 Hypertrichosis can be broadly split into either congenital or acquired categories. Each category is further subdivided based on localized or general hair distribution. The acquired category also has a pharmaceutically induced hypertrichosis category. This is of particular 
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interest as phenytoin and cyclosporine are known to cause hypertrichosis as well as to induce gingival hyperplasia (Wendelin et al. 2003). There is a wide range of frequency of hypertrichosis with these medications but the hypertrichosis resolves with discontinuation of the medication. The mechanisms involved are unknown.  Within the congenital hypertrichosis category, the subtypes of interest are those cases occurring with gingival hyperplasia. They occur in syndromes where hypertrichosis is the primary symptom, including congenital hypertrichosis lanuginosa and gingival fibromatosis with hypertrichosis. In addition, osteochondrodysplasia hypertrichosis occurs within this congenital category but typically does not present with gingival fibromatosis (Czeschik et al. 2012). Its associated spectrum of disease, however, does have cases with gingival fibromatosis, making it another subtype of interest here.  Congenital hypertrichosis lanuginosa is often referred to as Ambras syndrome (Freire-Maia 
et al. 1976). The main features of this form of hypertrichosis are the excessive growth of lanugo hair and dental abnormalities (Garcia-Cruz et al. 2002). The lanugo hair generally covers the body but often recedes over the trunk and limbs later in childhood (Wendelin et 
al. 2003).  Typically the associated dental anomalies involve the delayed presentation of primary and secondary teeth as well as the absence of some teeth (Tadin et al. 2001). However, one sporadic case of hypertrichosis lanuginosa with mild gingival hyperplasia has been reported (Lee et al. 1993). Lee et al. (1993) commented on the association of hypertrichosis with congenital ectodermal or mesodermal defects, suggesting a common origin for both the gingival hyperplasia and the hypertrichosis as phenotypic variants of 
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the same defect. The majority of congenital hypertrichosis lanuginosa cases are the result of autosomal dominant inheritance but sporadic cases occur (Tadin et al. 2001). The chromosomal region for the autosomal dominant form of this disease has been narrowed to 8q22-q24 (Balducci et al. 1998; Tadin et al. 2001) but a specific causative gene mutation has not been determined.  Gingival fibromatosis with hypertrichosis presents as an autosomal dominant condition with terminal hair covering the face, trunk and eyebrow, with progressive gingival hyperplasia starting in childhood (Wendelin et al. 2003). Additionally, individuals can present with coarse facial features including a wide flat nose, thick lips and large ears, and, in 50% of cases, mental retardation (Garcia-Cruz et al. 2002; Wendelin et al. 2003). To assess genetic causation, copy number variation was explored by characterizing cases of microdeletions associated with the congenital hypertrichosis with terminal hair, with and without gingival fibromatosis (Sun et al. 2009). A significant association was found with chromosomal region 17q24.2-q24.3. This region contained three ATP binding cassette transporter family proteins (ABCA) and the mitogen-activated protein kinase kinase 6 (MAP2K6) gene. Conflicting reports both implicate and eliminate MAP2K6 involvement in this syndrome (Blyth et al. 2008, Sun et al. 2009). This suggests complex involvement of this chromosomal region, supported by the fact that other conditions with hypertrichosis have been linked to the same chromosome (Sun et al. 2009). Again, no specific genetic mutation has been elucidated.  
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Osteochondrodysplasia with hypertrichosis is an autosomal recessive condition that presents with generalized hypertrichosis, macrosomia and cardiomegaly. While typically this syndrome is not associated with gingival fibromatosis, it is thought to be apart of a spectrum of acromegaloid phenotypes, with or without hypertrichosis and gingival fibromatosis (Czeschik et al. 2012). For these conditions the putative mutation is in the ABCC9 gene, which encodes another member of the ATP binding cassette family of proteins, and is located at 12p12.1. The high homology within this family of proteins suggests the potential for the involvement of related proteins, encoded within the 17q24.2-q24.3 chromosomal region in gingival fibromatosis with hypertrichosis. 
 
Secondary HGF: drug-induced gingival overgrowth Three main categories of drugs have been extensively documented for inducing gingival overgrowth phenotypes: anticonvulsants, immunosuppressants, and calcium channel blockers (Marshall and Bartold 1999).  Pharmaceuticals that induce gingival overgrowth in the anticonvulsant category include phenytoin, sodium valproate, phenobarbitone and vigabatrin (Marshall and Bartold 1999). Notably, for phenytoin an average of 50% of patients report gingival hyperplasia (Hallmon and Rossmann 1999). The major immunosuppressant drugs that induce gingival overgrowth are cyclosporine and the tacrolimus medications (Ellis et al. 2004; Marshall and Bartold 1999). The prevalence of the cyclosporine-induced phenotype is approximately 25%, with some reports suggesting a higher prevalence in children than adults (Hassell and Hefti 1991; Nakib and Ashrafi 2011). Calcium channel blockers are used in the management of many cardiovascular diseases including hypertension, angina, some arrhythmias and myocardial infarctions. The main 
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drug in this class is nifedipine, for which 20-83% of patients report gingival hyperplasia (Barclay et al. 1992).   This diverse group of systemic medications does share commonalities in clinical presentation and potentially pathogenesis. Clinical manifestations of gum disease typically appear within the first three months of starting the medication (Hallmon and Rossmann 1999). Growth appears from the interdental papillae and extends to the facial and lingual portions of the gingival margin (Nakib and Ashrafi 2011). Similar to the other forms of HGF in severe cases the gingival tissue will encapsulate the teeth. Broadly, the histology shows a fibrotic change in the connective tissue as well as changes in the extracellular matrix, with variation in the number of immune cells (Nakib and Ashrafi 2011). Management involves excellent oral hygiene care to minimize plaque, discontinuation of the medication, and in severe cases gingival resection (Marshall and Bartold 1999). In many cases stopping or reducing the dosage of medication does diminish the phenotypic presentation.   The pathogenesis for each category of medication-induced overgrowth is controversial and poorly understood. The major areas of investigation include collagen production/degradation, fibroblasts, and inflammatory processes. There is an imbalance in the synthesis and degradation of collagen in the drug-induced gingival overgrowths. Despite decreases in collagen production, there is an accumulation of collagen, suggesting a decrease in collagen breakdown (Correa et al. 2011). Collagen is degraded both extracellularly and intracellularly (Ogino et al. 2005). Extracellular collagen is digested by collagenase and other matrix metalloproteins (MMP) (Correa et al. 2011). With respect to 
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the degradation by collagenase, all three classes of pharmaceuticals known to induce gingival overgrowth share a common feature: they induce a decrease in the influx of calcium into the cell through the sodium calcium exchanger (Brunet et al. 1996). This limits the amount of folic acid taken in by the cells, limiting the amount of collagenase produced. The other extracellular pathway involves MMPs that are controlled by tissue inhibitors (TIMPs) (Correa et al. 2011). In phenytoin-induced overgrowth TIMP mRNA is significantly increased, leading to increased inhibition of the MMPs (Kato et al. 2005). The levels of MMPs are also decreased, further reducing collagen degradation (Kato et al. 2005; Serra et 
al. 2010). Intracellular degradation of collagen is also reduced as the result of a decrease in collagen-binding α-2-β-1-integrin receptors (Kato et al. 2005). Through these numerous mechanisms the level of collagen degradation is decreased in drug-induced gingival overgrowth.  Like collagen, fibroblast cells are in greater numbers in gingival overgrowth tissue. There is some evidence to suggest that this is the result of altered apoptosis (Kantarci et al. 2007). A decrease in the death rate of fibroblast cells causes their accumulation in the extracellular matrix.  Anticonvulsants, calcium channel blockers and immuno-suppressants act to control the production of inflammatory factors. Inflammatory factors that are increased in gingival overgrowth tissue include interleukins 1 and 6, platelet derived growth factor, fibroblast growth factor-2, transforming growth factor β and connective tissue growth factor (Correa 
et al. 2011; Ellis et al. 2004; Wright et al. 2006). Transforming growth factor β regulates 
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collagen production, which, in combination with connective tissue growth factor, induces fibrosis (Correa et al. 2011).   These groups of medications are quite diverse each plays a role in the pathogenesis of the drug-induced HGF phenotype. Gaining a better understanding of the molecular aetiology of HGF might in turn aid in testing for genetic susceptibility to these broad classes of pharmaceuticals in the future. 
 
The RAS/ Mitogen activated protein kinase signalling pathway (MAPK) The RAS/MAPK signalling pathway is critical for normal mammalian development and has many roles including influencing cellular growth, differentiation and senescence, with cellular proliferation being of most importance (Rauen 2013, Bezniakow et al. 2014). The RAS superfamily is comprised of proteins that function as molecular switches through their GTPase activity (Wennerberg et al. 2005). Activation occurs when GTP is attached to the molecule. Its function can be altered through guanine nucleotide exchange factors (GEF) as well as GTPase activation proteins (GAP). A GAP increases the efficiency of GTP hydrolysis to GDP. GEFs work by exchanging the inactive GDP for GTP thus activating the protein. MAPK signaling is based upon activation through a phosphorylation event (Rauen 2013). Signalling in this pathway starts on the outside of the cell and finishes in the nucleus (Figure 1.2). Signalling is initiated by growth factors, hormones, cytokines, insulin or immune cells. For example epidermal growth factor activates a tyrosine kinase receptor resulting in receptor dimerization and autophosphorylation. The activated receptor interacts with growth factor receptor bound protein 2, resulting in son of sevenless (SOS) 
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  Figure 1.2: Diagram of several steps in the RAS/MAPK signalling pathway highlighting the proteins affected in various RASopthies. Adapted from Aoki and Matsubara 2013, Rauen 2013, Bezniakow et al. 2014, Tidyman and Rauen 2009     
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protein binding and recruitment to the membrane. SOS is a GEF and exchanges GDP with GTP bound to RAS. RAS proteins lead to a number of downstream pathways including the MAPK pathway. The MAPK signalling cascade follows a hierarchy of signalling from MAPK3K proteins which are also known as Raf family kinases to MAP2K, also known as the MEK kinases to MAPK, which are also known as the extracellular signal related kinases (ERK) (Bezniakow et al. 2014).  Activated ERK proteins translocate into the nucleus and phosphorylate transcription factors, resulting in the change of gene expression.  Broadly, mutations can occur in either the germline or somatic cell lines (Tidyman and Rauen 2009). When a mutation occurs in a germline it occurs in cells that will be used in gamete formation and thus will be passed on to the subsequent generation (Rauen 2013). Conversely, when mutations are acquired in a somatic cell line they are not inherited by offspring (Rauen 2013).  Twenty percent of malignancies are caused by somatic mutations in the RAS/MAPK signalling cascade (Tidyman and Rauen 2009).  Germline mutations found in the RAS/MAPK signalling pathways result in developmental disorders and are classified as RASopathies (Rauen 2013) (Figure1.2). The specific disorders include: autoimmune lymphoproliferative, capillary malformation– arteriovenous malformation, cardio-facio- cutaneous syndrome, CBL syndrome (Noonan syndrome like), Costello syndrome, hereditary gingival fibromatosis 1, Legius syndrome, Neurofibromatosis type 1, Noonan, Noonan syndrome with multiple lentigines, and Noonan-like disorder with loose anagen hair  (Table1.2) (Aoki and Matsubara 2013, Rauen 2013, Bezniakow et al.  
 22 
Table 1.2: Syndrome, gene location, protein and inheritance pattern for RASopathies in humans. (Aoki and Matsubara 2013, Rauen 2013, Bezniakow et al. 2014, Tidyman and Rauen 2009)  
Syndrome RAS/MAPK 
pathway 
gene 
Protein Chromosomal 
location 
Inheritance 
Autoimmune lymphoproliferative NRAS NRAS 1p15.2 Autosomal dominant (AD) Capillary malformation– arteriovenous malformation  
RASA1  p120-RASGAP  5q14.3  AD 
Cardio-facio- cutaneous syndrome  BRAF  MAP2K1  MAP2K2  
KRAS  
BRAF  MEK1  MEK2  KRAS  
7q34  15q22.31  19p13.3  12p12.1  
AD 
CBL syndrome (Noon syndrome like)  CBL CBL 11q23.3 AD Costello syndrome  HRAS  HRAS  11p15.5  AD Hereditary gingival fibromatosis 1 SOS1 SOS1 2p22.1 AD Legius syndrome  SPRED1  SPRED1  15q14  AD Neurofibromatosis type 1  NF1   Neurofibromin  17q11.2   AD Noonan PTPN11  
SOS1  
RAF1  
KRAS  
NRAS  
SHP2  SOS1  CRAF  KRAS  NRAS  
12q24.1  2p22.1  3p25.1  12p12.1  1p13.2  
AD 
Noonan syndrome with multiple lentigines  PTPN11  RAF1  SHP2 RAF1/CRAF  12q24.1  3p25.1  AD Noonan-like disorder with loose anagen hair  SHOC2 SHOC2 10q25 AD   
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2014, Tidyman and Rauen 2009). While each disorder has unique phenotypic features the group also has a spectrum of overlapping characteristics including: craniofacial dysmorphology, cardiac malformations and cutaneous, musculoskeletal and ocular abnormalities with varying degrees of neurocognitive impairment (Bezniakow et al. 2014). Collectively this group of RASopthies has a prevalence of one in 1000 individuals (Rauen 2013). Given the importance of the functions of this pathway modulation therapies including small molecule inhibition studies are currently under investigation (Rauen 2013).  
Canine gingival disease Canines can present with a spectrum of different gingival growths with infectious, inflammatory, benign and neoplastic aetiologies (Hale 2004). In addition, some breeds demonstrate a predisposition towards various kinds of growths. For example, the Collie, Great Dane, Dalmatian, Doberman and Boxer breeds show a higher propensity for generalized idiopathic gingival hyperplasia (Hale 2004). In particular, the Boxer breed is notorious for manifesting numerous types of tumourous growths including gingival hyperplasia and epulis. The presentation of canine gingival hyperplasia is comparable to that in foxes and humans.   
Presentation Broadly, gingival hyperplasia in the domestic dog (and also cat) is defined as an enlargement of the gingiva due to an increase in cell number that is not the result of an inflammatory process or the presence of a local irritation (Beckman 2010). In canines, the 
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gross appearance of gingival hyperplasia can be focal or generalized, manifesting as either a single, multiple or generalized growth (Beckman 2010; Hale 2004). The focal subtype appears as localized areas of redundant gingival tissue. There tends to be inflammation between these areas and the teeth. The histology is variable, ranging from islands of dystrophic calcifications to bony metaplasia (Hale 2004). The diagnosis is based on the histology of a biopsy sample.  Gingival hyperplasia has clinical implications for dogs. The growth itself is at risk for trauma from the opposing jaw. As the gingiva continues to grow the animal is no longer able to close its mouth and mastication is difficult and painful (Hale 2004). Given the force exerted by the tissue mass it can cause the underlying dentition to move. As the disease progresses, the gingiva expands both outwards and upwards along the teeth, engulfing them. This creates pseudo-pockets where bacteria can settle increasing the risk of infection, inflammation and periodontal disease. Periodontal disease then occurs secondary to the gingival hyperplasia, altering the clinical and histological appearance (Beckman 2010). Despite the extensive oral growth, there are no documented systemic symptoms associated with canine gingival hyperplasia.  
Causation Canine gingival hyperplasia can be divided into three categories: idiopathic, breed-predisposition, and drug-induced (Hale 2004). The aetiology for both the idiopathic and breed predisposition forms is not known. Similar to human HGF, three classes of drugs have been known to induce gingival hyperplasia: immuno-suppressants, calcium channel 
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blockers and anticonvulsant drugs. The commonality between these drugs is their alteration of calcium influx into the gingival cells.  Small dogs are prone to degenerative valvular heart disease as they age at which point calcium channel blockers like amlodipine are used to vasodilate blood vessels, decreasing peripheral resistance (Thomason et al. 2009). Thomason et al. (2009) demonstrated that 7/82 dogs developed gingival hyperplasia when placed on amlodipine. A minimum of five months on the drug was required before signs of growth were present. After discontinuation of amlodipine the gingival hyperplasia regressed partially within two to eight weeks with complete regression taking up to six months. This is not restricted to smaller canine breeds, as is evident by a case of gingival hyperplasia in a Great Dane on amlodipine (Pariser and Berdoulay 2011). The exact mechanism behind this drug-induced gingival hyperplasia is unclear. Some theories implicate testosterone, as calcium channel blockers result in the up-regulation of circulating androgens causing stimulation of the androgen sensitive gingiva (Pariser and Berdoulay 2011). This theory was further supported when castration of dogs with calcium channel blocker-induced gingival hyperplasia showed regression of the disease (Dayan et al. 1998). Other theories suggest that calcium channel blockers block other calcium-dependent enzymes involved in the apoptotic pathway, thus preventing cell death (Pariser and Berdoulay 2011). For this rare form of canine gingival hyperplasia, the underlying mechanism appears multifactorial and complex.  
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Immune-suppressing agents like cyclosporine are known to induce gingival hyperplasia in canines. The pathophysiology shows a link to calcium, similar to calcium channel blockers (Beckman 2010). A decrease in calcium levels induces a decrease in transglutinase, a protein that plays a role in regulating apoptosis. When transglutinase levels are reduced apoptosis is reduced, possibly contributing to the hyperplasia. A case was reported of cyclosporine-induced gingival hyperplasia in a long-haired Dachshund (Namikawa et al. 2012). Similar to other drug-induced forms of gingival hyperplasia, as the dose of the drug was reduced the hyperplasia regressed. The incidence of cyclosporine-induced gingival hyperplasia is anticipated to increase as the licensing of this compound for use in the pet population has increased.  Anticonvulsants such as phenytoin cause gingival hyperplasia in dogs, as well as cats (Beckman 2010). Little is known about these gingival growths as they have not been observed in rodent or other small-animals (Hassell and Hefti 1991). In felines, cells similar to fibroblasts are activated and thought to contribute to the gingival overgrowths (Beckman 2010). This mechanism may relate to the hypothesized role of TGFE signalling in human HGF.  
Treatment Treatment is dependent on the cause of the disease. For the drug-induced phenotype stopping the medication that led to the induction of gingival overgrowth can reverse the phenotype. There is no curative treatment for idiopathic canine gingival hyperplasia. Severe disease can be managed with resection but the gingiva will continue to grow.  
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A canine disease model Overall, the gingival disease in the canine is quite similar to human HGF. This allows the dog to be an excellent bridging point for research into HHG in foxes.   Publication of the domestic dog genome in 2005 greatly facilitates genomic research with phylogenetically related species such as the fox (Kohn et al. 2006; Lindblad-Toh et al. 2005). Vulpes vulpes and Canis lupus familiaris are both members of the mammalian family Canidae, and last shared a common ancestor 12 to 15 million years ago (Wayne et al. 1997). Karyotyping, cytogenic genome markers, and gene sequences have been examined in the red fox using the canine genome for comparison (Switonski et al. 2009). There is strong evidence supporting the close relationship between the two species. For instance, a 97.3% similarity between the red fox and dog coding sequences for the SRY (sex determining region Y) gene (Nowacka-Woszuk and Switonski 2009; Switonski et al. 2009). The dog genome has proven to be a useful model system for human disease as a potential bridge between human and mouse genetic studies as mice have a higher rate of evolution than humans creating more sequence divergence (Boyko 2011). For both foxes and humans, the dog has proven to be a suitable model for research.  The Canidae group consists of four groups:  fox-like canids; wolf-like canids; South American canids; and island foxes (Lindblad-Toh et al. 2005). Canidae underwent rapid speciation resulting in the rearrangement of their chromosomes (Becker et al. 2011). The domestic dog (Canis lupus familiaris), a wolf-like canid, has 78 diploid chromosomes while 
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the red fox (Vulpes vulpes), a fox-like canid, has 34 (Becker et al. 2011). Mapping of the red fox genome began in the 1980s (Switonski et al. 2009). Early work established the chromosome assignment of numerous gene loci on most of the autosomes and fine mapping continued with canine microsatellite markers and aligned them with its canine counterpart (Kukekova et al. 2004). After microsatellite mapping was completed a linkage map of various fox pedigrees was constructed (Kukekova et al. 2011; Switonski et al. 2009). Once the framework for fox genomics was established, it opened the gates for many types of research including disease models, functional genetics, and behavioral studies. 
 
Goals and outline of thesis (Figure 1.3) Hereditary hyperplastic gingivitis is a progressive growth of gingival tissues in foxes resulting in dental encapsulation (Dyrendahl and Henricson 1960). Genetically, it is an autosomal recessive condition displaying a sex-biased penetrance, with an association with superior fur quality. This disease has been primarily described in European farmed foxes. 
Chapter 2 documents the emergence of HHG in Canada. The goal was to perform a detailed examination of the history of HHG including what is known about its genetic aetiology and histology in Europe, and then extend this examination to the emergence of HHG in Newfoundland and Labrador again with respect to both the genetics and histology of the condition.   HHG and HGF are analogous conditions with very similar manifestations and disease progression. The known molecular basis of one form of HGF, the goal of chapter 3 was to 
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  Figure 1.3: Schematic overview of thesis chapters 
 30 
perform functional candidate gene analysis as a means to establish or eliminate particular gene mutations as causative of HHG in foxes. The premise of this functional candidate gene approach was the implication that a mutation causative of a disease in one organism may be the causative mutation of the analogous condition in another organism (Aguirre-Hernandez and Sargan 2005). The DNA sequences of the exonic coding regions, exon-intron boundaries and partial introns of SOS1, the known causative gene in HGF1 in humans, the closely-associated GRB2, and EGFR genes from both affected ranched silver foxes and unaffected wild red foxes were compared to determine if any fixed difference exist. Inferences were also made about the rates and patterns of evolution of the SOS1, GRB2 and 
EGFR genes to assess their likelihood of association with disease.   A comprehensive examination of the genetic aetiology of HHG requires a multi-tier strategy. In addition to investigating specific candidate genes, examining global gene expression levels can provide additional insight. The goal of chapter 4 of this thesis was to integrate the current knowledge of HGF with access to genomic technologies based on the dog genome to examine potential pathways involved in silver fox HHG. This was conducted using the Affymetrix GeneChip Canine Genome 2.0 Array to compare the global gene expression patterns of HHG-affected farmed silver foxes and HHG-unaffected silver foxes. This section of the thesis explored the many potential factors contributing to the HHG phenotype by reviewing the HGF literature and comparing it to the HHG genome expression, as well as looking for any new insights.  
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HHG can occur as an isolated genetic condition or as part of a syndrome, which most often presents with hypertrichosis. The HGF-associated syndrome with hypertrichosis is similar in presentation to the HHG-affected foxes with longer and denser fur. Exploring the connection between hypertrichosis and HGF could provide further insight into the molecular mechanisms of HHG.  In chapter 5 of this thesis the goal was to combine the current knowledge of HGF-associated syndromes with hypertrichosis with the genome-enabling capabilities of the dog genome to examine potential pathways involved in silver fox HHG.  HHG and its analogous condition, HGF, are heterogeneous conditions with potentially complex molecular mechanisms. To gain a better understanding of the underlying aetiology of each a cooperative, multi-faceted examination is required. Examining HHG in light of known HGF information at both the gene and genome level creates a platform to accomplish this goal.          
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Chapter!two:!
Index!case!report!of!hereditary!hyperplastic!gingivitis!in!North!American!
farmed!silver!fox,!Vulpes'vulpes!!!!!!! A!version!of!this!chapter!was!published!in!the!Canadian!veterinary!journal:!!Clark,!JA,!Hudson!RC,!Marshall,!HD!(2015)!Hereditary!hyperplastic!gingivitis!in!North!American!farmed!silver!fox!(Vulpes!vulpes).!Can!Vet!J.!56,!408Q411!!!!!!!!
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Hereditary!hyperplastic!gingivitis!(HHG)!presents!as!a!tumourQlike!growth!of!the!gingival!tissue!on!the!mandible!and!maxilla!in!farmed!silver!foxes!(Dyrendahl!and!Henricson!1960),!a!coat!colour!variant!of!the!American!subspecies!(Vulpes#vulpes#
fulva)!of!the!red!fox!(Vulpes#vulpes).!It!is!an!autosomal!recessive!inherited!disease,!with!predominance!in!males,!and!is!correlated!with!superior!fur!quality!(Dyrendahl!and!Henricson!1960).!Until!2008,!HHG!had!only!been!described!in!the!farmed!fox!population,!at!which!time!a!case!in!a!wild!red!fox!was!reported!in!Germany!(Schulze!et!al.!2008).!In!Canada!and!the!rest!of!North!America,!this!condition!has!never!previously!been!documented!in!the!fox!population.!This!chapter!will!review!the!origins!of!HHG!and!detail!its!discovery!and!manifestation!in!farmed!silver!foxes!in!Newfoundland,!Canada.!!Fox!farming!in!Canada!originated!in!the!late!1800s!in!Prince!Edward!Island!(PEI),!with!the!successful!raising!of!wild!silver!foxes!in!captivity!and!the!pioneering!of!selective!breeding!in!foxes,!resulting!in!the!first!commercial!production!of!silver!fox!pelts.!The!interest!in!this!profitable!new!industry!led!to!national!distribution!of!breeding!stock!and!exportation!to!the!United!States!and!Europe!(Canada!1979;!Colpitts!1997).!The!European!fur!farming!industry!began!with!the!importation!of!two!silver!foxes!from!Canada!into!Norway!in!1914.!!Norway!went!on!to!pioneer!numerous!silver!fox!colour!mutations.!The!first!documented!case!of!HHG!in!Europe!was!in!Sweden!around!1940!in!a!young!male!fox!with!superior!fur!quality!that!had!been!imported!from!Norway!(Dyrendahl!and!Henricson!1960).!!
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Since!the!1940s!there!have!been!two!main!aetiologies!described!for!the!silver!fox!gingival!overgrowth.!K.E.!Kull,!Swedish!veterinarian,!described!it!as!a!recessive!sexQbiased!disease,!more!common!in!males!than!in!females,!where!disease!phenotype!is!induced!by!a!viral!infection!(R.!Hudson,!personal!communication,!2004).!This!theory!was!reiterated!in!the!1982!publication!of!Kangas’!book!entitled!“Kettujen!ja!supikoirien!sairaudet”!(The!Diseases!of!Foxes!and!Raccoon!Dogs)!(Kangas!1982).!In!1960,!Dyrendahl!and!Henricson!published!an!extensive!review!of!HHG!(Dyrendahl!and!Henricson!1960).!They!stated!that!pronounced!manifestation!of!HHG!occurs!at!approximately!two!to!three!years!of!age,!with!gingival!proliferation!continuing!throughout!life,!resulting!in!dental!encapsulation.!They!concluded!that!HHG!was!an!autosomal!recessive!disease!demonstrating!incomplete!penetrance,!with!an!increased!incidence!in!males!relative!to!females!(Dyrendahl!and!Henricson!1960).!In!addition,!there!was!a!pleiotropic!relationship!between!HHG!and!high!fur!quality!(typically!length!and!density!of!the!guard!hairs)!(Dyrendahl!and!Henricson!1960).!Pathology!indicated!large!epithelial!extensions!in!the!keratinized!collagen!of!the!gingival!tissue.!Schulze!et!al.!documented!the!first!case!of!HHG!in!the!wild!fox!population.!In!this!case,!both!macroscopic!and!histopathological!examination!confirmed!the!diagnosis!of!HHG!rather!than!a!viral!induced!papillomatous!growth!(Schulze!et!al.!2008).!Meanwhile,!despite!the!rapid!expansion!using!a!limited!gene!pool,!the!Canadian!stock!had!not!shown!any!signs!of!HHG!before!2004.!!!In!Newfoundland!and!Labrador,!twenty!male!and!twenty!female,!tenQmonthQold!silver!foxes!were!imported!from!Finland!in!January!2003.!By!May!2004,!five!of!the!
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male!Finnish!imported!foxes!were!manifesting!gingival!proliferation.!The!extent!of!the!gingival!involvement!varied!with!one!fox!displaying!complete!encapsulation!of!the!incisors!with!symmetrical!coverage!extending!back!to!the!molars!on!both!arcades!of!the!maxilla!and!mandible.!Neither!the!Finnish!females!nor!any!Canadian!foxes!housed!in!the!same!shed!had!any!obvious!signs!of!gingival!proliferation.!!All!foxes!were!fed!a!relatively!soft!diet!of!commercial!fox!pellets!softened!with!water!and!mixed!with!ground!chicken.!All!foxes!appeared!healthy!and!were!in!good!body!condition.!!!In!June!2004,!all!imported!Finnish!foxes!underwent!thorough!manual!oral!examinations!performed!by!a!provincial!veterinarian.!Six!males!were!severely!affected!with!gum!tissue!hyperplasia!and!encapsulated!teeth;!twelve!had!mild!to!moderate!hyperplasia!and!two!were!unaffected.!Seventeen!of!the!twenty!females!examined!showed!mild!to!moderate!gum!hyperplasia!that!was!more!pronounced!around!the!molars!and!premolars!than!the!incisors.!In!addition,!a!one!QyearQold!male!from!a!mating!of!a!Finnish!male!to!a!Canadian!female!in!2003!clearly!showed!early!signs!of!the!disease.!ReQexamination!in!December!2004!demonstrated!rapid!progression!of!the!hyperplasia.!Severe!cases!also!showed!gingivitis,!plaque!covered!teeth,!and!irregular!positioning!of!some!teeth.!!Due!to!animal!welfare!concerns!and!the!genetic!implications!of!this!disease,!the!severely!affected!animals!were!removed!from!breeding!stock!and!pelted.!In!subsequent!breeding!seasons,!the!disease!continued!to!be!evident!in!offspring!from!crosses!between!remaining!original!foxes!
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and!from!crosses!with!Canadian!foxes.!It!was!not!present!in!every!generation!nor!did!it!progress!as!rapidly,!or!developed!as!severely,!as!in!the!original!Finnish!foxes.!!Two!additional!trips!were!made!to!Norway!to!obtain!fox!breeding!stock.!In!December!2004,!thirty!Norwegian!males!and!thirty!females!were!selected.!Individual!clinical!examinations!of!prospective!candidates,!as!well!as!familial!examinations!dating!back!two!subsequent!generations,!were!performed!to!ascertain!whether!the!disease!was!present!in!their!pedigree.!These!animals!arrived!in!January!2005!and!did!not!develop!any!signs!of!hyperplasia!during!the!first!year!after!importation!but!it!became!evident!in!a!few,!as!they!grew!older.!It!was!also!evident!in!subsequent!generations!suggesting!many!of!the!original!imports!were!nonQsymptomatic!carriers.!The!final!trip!was!to!select!thirty!male!Norwegian!foxes!with!rare!silver!fox!colour!mutations.!They!were!selected!in!December!2005!and!arrived!in!January!2006.!Again,!meticulous!examinations!were!performed!on!all!possible!candidates!for!acquisition!but!fewer!familial!connections!were!available!for!examination.!Several!of!these!males!did!show!HHG!within!the!first!year!after!importation!and!many!of!their!offspring!mated!with!the!previously!imported!Norwegian!silver!foxes!did!go!on!to!manifest!gingival!hyperplasia.!!Gross!examination!of!the!affected!silver!fox!gingival!tissue!identified!proliferative!gingival!tissue!with!a!red!granular!surface!(Figure!2.1).!A!grading!system!from!zero!(normal!gingival!tissue)!to!five!(most!severe!gingival!hyperplasia)!was!developed!to!!!!
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!A.!!!
! ! !B.! ! ! ! ! ! C.!!!!Figure!2.1:!A.!An!original!Finnish!silver!fox!gingival!overgrowth!upon!full!examination!in!2004.!B.!An!original!Finnish!silver!fox!postQmortem!demonstrating!gingival!overgrowth!resulting!in!dental!rearrangement.!C.!An!unaffected!Canadian!silver!fox!(Photographs!provided!by!Robert!Hudson)!!!!!!
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quantify!the!degree!of!gingival!hyperplasia!(Figure!2.2).!The!tissue!bled!easily!and!profusely!with!minimal!trauma!to!which!the!animals!appeared!insensitive.!Surgical!biopsy!samples!contained!a!rich!vascular!fibrous!tissue!that!was!tough!and!resilient!when!cut!below!the!mucosa.!In!all!affected!gingiva,!the!hyperplastic!tissue!occurred!outward!along!the!lingual!and!buccal!aspects,!and!then!extended!up!or!down,!covering!a!variable!amount!of!the!crowns!of!the!teeth.!The!gingival!hyperplasia!was!initially!bilaterally!symmetrical,!but!often!progressed!to!surround!some!teeth!more!than!others.!In!moderate!to!advanced!cases,!the!incisors!were!completely!buried!in!the!convergence!of!hyperplasic!tissue!from!both!the!lingual!and!buccal!sides.!In!advanced!cases,!the!proliferative!gingiva!on!the!buccal!side!formed!large!multilobular,!cauliflowerQlike!masses!that!often!completely!obscured!the!teeth.!Post!mortem!examination!of!the!severely!affected!fox!heads!obtained!after!pelting!in!2004!showed!the!hyperplastic!gum!tissue!to!be!pale,!lacking!firm!consistency!with!occasional!areas!of!necrosis!in!the!flattened!multilobulated!masses.!Deep!pockets!containing!food!and!debris!were!present!between!large!gingival!tissue!flaps!and!the!teeth!on!both!the!buccal!and!lingual!sides.!This!provided!the!environment!for!premature!periodontal!disease!and!may!explain!irregular!teeth!placement!and!asymmetrical!dental!arcades!noticed!in!the!advanced!cases.!!Histological!sections!were!taken!from!a!variety!of!fox!gingival!samples,!representing!a!range!of!gingival!proliferation!from!normal!to!severe.!In!all!affected!samples,!thick!collagen!bundles,!a!few!fibroblast!cells!and!small!blood!vessels!expanded!the!submucosa!(Figure!2.3).!The!degree!of!submucosal!expansion!ranged!from!mild!to!!
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Figure!2.2:!Silver!fox!gingival!hyperplasia!grading!system!!A.!Grade!0!(normal):!The!gingiva!is!pale!pink,!smooth!and!relatively!flat.!B.!Grade!1:!A!thin!layer!of!gingival!tissue!at!its!margin!with!the!crown!of!the!tooth!is!slightly!raised,!red!and!granular.!There!may!be!enlargement!of!the!interdental!papillae.!C.!Grade!2:!A!somewhat!thicker!layer!of!the!gingiva!is!moderately!rounded,!mildly!thickened,!red!and!covers!up!to!approximately!a!third!of!the!crown!of!at!least!some!teeth.!Most!times!it!is!bilaterally!symmetrical!at!this!stage,!affects!both!upper!and!lower!jaws!equally,!and!is!clearly!evident!on!both!the!buccal!and!lingual!gingival!as!raised!red!tissue.!At!this!stage!all!teeth!are!still!clearly!visible.!D.!Grade!3:!The!gingiva!is!diffusely!raised,!thickened,!red!and!rounded!and!covers!a!half!to!almost!all!of!the!crowns!of!most!teeth.!The!tips!of!the!crown!of!the!teeth!are!still!visible!in!most!cases,!but!the!development!of!large!flaps!and!nodules!are!now!clearly!visible!and!there!may!be!total!encapsulation!of!some!teeth,!but!the!majority!of!the!tips!of!the!crowns!are!still!visible.!E.!Grade!4:!The!dental!arcade!is!almost!completely!covered!by!diffusely!thickened,!red!and!proliferative!gingival!tissue,!forming!confluent!multiQnodular!masses!with!large!lateral!flaps!resulting!in!numerous!teeth!becoming!encapsulated.!The!tips!of!the!crowns!of!a!few!teeth!are!visible.!By!this!stage!the!canine!teeth!are!at!least!50%!encapsulated!F.!Grade!5:!The!dental!arcade!is!completely!covered!by!large!cauliflower!like!masses!of!red,!friable!granular!tissue.!Only!a!few!teeth!are!visible!and!at!least!three!quarters!of!the!canine!teeth!are!buried!in!the!masses.!!Massive!gum!proliferation!is!evident!everywhere.!(Photos!provided!by!Robert!Hudson)!!!!!!!!!!
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! !A.!! ! ! ! ! B.!Figure!2.3:!Histology!slides!viewed!at!25X!magnification!of!hereditary!hyperplastic!gingivitis!(HHG)!silver!fox!gingival!samples.!A.!Histological!presentation!of!mild!HHG.!B.!Histological!presentation!of!severe!HHG.!Arrow!demonstrating!the!thickness!of!the!submucosa.!(Photographs!provided!by!Laura!Rogers)!!!!!!!!!!!!!!!
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marked,!corresponding!to!the!degree!of!gingival!proliferation.!In!all!affected!histology!sections,!the!mucosa!was!undermined!by!moderate!numbers!of!lymphocytes!and!plasma!cells!whereas!the!normal!gingival!sections!contained!minimal!numbers!of!lymphocytes!and!plasma!cells.!Based!on!histology!the!diagnosis!was!fibrous!gingival!hyperplasia!ranging!in!severity!from!mild!to!marked.!!!The!Newfoundland!and!Labrador!fox!farming!industry!underwent!rapid!expansion!during!the!1980s!with!the!addition!of!many!new!farms!and!increases!in!the!size!of!existing!farms.!Despite!the!increased!inbreeding!that!resulted!from!the!demand!for!more!breeding!stock,!there!was!no!evidence!of!HHG!in!the!Newfoundland!and!Labrador!farmed!fox!population!until!after!the!introduction!of!Scandinavian!foxes!in!2003.!Similarly!in!the!maritime!provinces!and!the!rest!of!Canada,!a!century!of!breeding!silver!foxes!from!the!original!PEI!stock,!as!well!as!cross!breeding!with!animals!imported!from!Scandinavia,!including!colour!mutations,!had!not!resulted!in!any!documented!cases!of!HHG!prior!to!2003.!Histologically,!the!presence!of!expanded!submucosa!due!to!increased!collagen!in!the!2004Q2006!cases!in!Newfoundland!were!congruent!with!both!the!original!HHG!description!and!the!HHG!case!in!a!wild!fox,!supporting!the!HHG!diagnosis!(Dyrendahl!and!Henricson!1960;!Schulze!et!al.!2008).!Original!HHG!descriptions!suggest!an!autosomal!recessive!mode!of!inheritance.!Prior!to!the!Scandinavian!importation!of!foxes!to!Newfoundland!and!Labrador!in!2003,!this!disease!was!not!documented!in!Canada.!In!addition,!since!2004!the!disease!has!not!been!present!in!every!subsequent!
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generation!from!imported!foxes,!suggesting!a!complex!process!behind!the!development!of!HHG.!!This!disease!impacts!both!economics!and!animal!welfare.!As!this!disease!appears!more!often!when!selecting!for!superior!fur!quality!in!affected!populations,!it!has!the!potential!for!high!propagation!and!wide!dissemination.!As!the!aetiology!is!genetic,!the!only!prevention!of!further!propagation!of!the!disease!is!cessation!of!breeding!of!the!affected!animals!and!potential!carriers!of!the!genes!for!this!disease.!Also,!affected!animals!often!have!to!be!culled!prematurely!before!living!out!a!normal!productive!life!and!this!can!have!an!enormous!economic!impact!on!the!fox!farming!industry.!This!disease!may!come!with!a!high!cost!as!animal!welfare!concerns!are!being!heightened!globally.!!Hereditary!hyperplastic!gingivitis!also!has!the!potential!to!affect!wild!populations!creating!a!potential!ecosystem!health!concern,!if!affected!or!carrier!animals!inadvertently!escape!from!captivity!and!breed!with!indigenous!populations.!The!industry!would!benefit!from!a!thorough!understanding!of!the!genetics!of!this!disease!as!well!as!a!commercial!genetic!test!that!could!be!used!to!help!farmers!select!stock!that!are!free!of!the!undesirable!gene.!!!The!disease!can!still!be!found!today!in!the!offspring!of!the!original!imported!foxes.!The!next!step!in!understanding!this!disease!is!to!investigate!its!underlying!genetic!mechanisms.!This!work!is!currently!ongoing,!utilizing!coQoperative!strategies!such!as!candidate!gene!sequencing!and!whole!genome!microarray!expression!techniques!based!on!canine!genome!resources.!
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Chapter!three:!
Sequence!analysis!of!the!RAS7MAPK!pathway!genes!SOS1;%EGFR%&!GRB2%%
in!silver!foxes!(Vulpes%vulpes):!candidate!genes!for!!
hereditary!hyperplastic!gingivitis!
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Introduction!Hereditary"hyperplastic"gingivitis"(HHG)"is"a"rare"disease"of"the"oral"cavity"that"occurs"primarily"in"captive"silver"foxes"(a"coat"colour"variant"of"the"red"fox,"Vulpes%
vulpes),"and"is"characterized"by"progressive"proliferation"of"the"gingival"tissues"starting"at"two"to"three"years"of"age."The"fibrous"overgrowths"eventually"lead"to"encapsulation"of"the"teeth"and"inhibition"of"normal"function."HHG"is"inherited"in"an"autosomal"recessive"pattern,"with"sexIbiased"penetrance"favouring"males"over"females"(Dyrendahl"and"Henricson"1960)."HHG"frequently"coIoccurs"with"superior"fur"quality"(length"and"thickness"of"guard"hairs)"suggesting"the"possibility"that"a"pleiotropic"gene"is"responsible"for"both"phenotypes."Its"pathology"indicates"large"epithelial"extensions"in"the"keratinized"collagen"of"the"gingival"tissue."In"2004"HHG"was"first"documented"in"Newfoundland"and"Labrador,"Canada,"in"a"farmed"fox"population"after"importation"of"European"silver"fox"lines"(Clark"et%al."2015)."Gross"examination"demonstrated"proliferative"gingival"tissue"containing"a"red"granular"surface."The"histology"demonstrated"thick"collagen"bundles."These"results"were"in"keeping"with"both"the"original"Dyrendahl"and"Henricson"report"as"well"as"with"those"reported"by"Schulze"et%al."(2008),"who"documented"the"first"case"of"HHG"in"a"wild"fox"(Clark"et%al."2015;"Dyrendahl"and"Henricson"1960;"Schulze"et%al."2008)."However,"despite"initial"documentation,"the"underlying"genetics"and"cellular"mechanisms"causing"HHG"remain"unknown."""An"analogous"condition"that"affects"humans"is"hereditary"gingival"fibromatosis"(HGF)."HGF"typically"manifests"with"the"onset"of"permanent"dentition"and"results"in"
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slow,"progressive,"benign"fibrous"enlargements"of"the"maxillary"and"mandibular"keratinized"gingival"tissue"(Hart"et%al."2002;"Ye"et%al."2005)."HGF"is"both"functionally"and"aesthetically"problematic."Treatment"involves"quadrantIbyIquadrant"gingivectomy,"but"there"is"a"common"recurrence"of"the"overgrowth"(Ramer"et%al."1996)."The"majority"of"HGF"cases"show"autosomal"dominant"inheritance,"with"autosomal"recessive"cases"occurring"rarely"(Goldblatt"and"Singer"1992;"Shashi"et%al."1999)."HGF"is"a"genetically"heterogeneous"disease"that"can"occur"as"an"isolated"condition,"part"of"an"underlying"syndrome"or"chromosomal"abnormality,"or"in"a"nonIhereditary"form"where"it"occurs"in"association"with"certain"pharmacological"agents"(Shashi"et%al."1999)."Linkage"analysis"of"isolated"cases"has"mapped"HGF"to"three"different"chromosomal"locations:"2p21Ip22,"5q13Iq22"and"2p22.3Ip23.3"(Hart"
et%al."2002;"Ye"et%al."2005)."At"2p21Ip22,"the"causative"mutation"is"a"single"nucleotide"insertion"in"codon"1083"of"the"Son%of%sevenless%homolog%1%(SOS1)"gene"(Hart"et%al."2002)."This"causes"a"frameshift"mutation,"leading"to"the"premature"truncation"of"the"CIterminal"domain"and"resulting"in"constitutive"activation"of"its"downstream"products."Within"the"5q13Iq22"loci"the"RAS"pathway"genes"G%protein%
coupled%receptor%113%(GPR113)"and"ethanolaminephosphotransferase%1"(SELI)"have"been"screened"with"no"reported"causative"mutations"(Ye"et%al."2005)."The"2p22.3Ip23.3"locus"has"recently"been"refined"to"a"6.56cM"region"(Pampel"et%al."2010),"within"which"no"causative"mutations"have"been"reported."""HHG"and"HGF"are"analogous"conditions"with"very"similar"manifestations"and"disease"progression."A"family"has"been"reported"that"displays"hypertrichosis"
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(excessive"hair"growth)"in"addition"to"the"gingival"overgrowth"(Mangino"et%al."2003),"which"may"be"reminiscent"of"the"dense"fur"of"HHGIaffected"silver"foxes."Given"the"strong"similarity"between"the"human"and"fox"diseases"and"the"known"molecular"basis"of"one"form"of"HGF,"our"goal"was"to"perform"functional"candidate"gene"analysis"as"a"means"to"establish"or"eliminate"particular"gene"mutations"as"causative"of"HHG"in"foxes."The"premise"of"this"functional"candidate"gene"approach"is"the"implication"that"a"mutation"or"gene"associated"with"a"disease"in"one"organism"may"be"associated"with"the"analogous"condition"in"another"(AguirreIHernandez"and"Sargan"2005)."Additionally,"candidate"genes"can"be"identified"on"the"basis"that"disruption"of"their"predicted"gene"function"may"be"expected"to"result"in"the"disease"phenotype."""Here"we"report"and"compare"the"DNA"sequences"of"three"candidate"genes"for"HHG"in"silver"foxes:"SOS1"(KP099615),"where"the"single"known"causative"mutation"of"HGF"is"located,"and"the"closelyIassociated"Growth%factor%receptor%bound%2%protein%(GRB2)%(KP099613)%and%Epidermal%growth%factor%receptor%(EGFR)"(KP099614)"genes."These"three"genes"encode"components"of"the"RAS"cell"signalling"pathway."The"pathway"is"initiated"by"ligand"binding"to"the"epidermal"growth"factor"receptor"(EGFR)"which"results"in"activation"of"its"tyrosine"receptor"kinase,"which"then"activates"Growth"factor"receptor"bound"2"protein"(GRB2)"(Qian"et%al."2000)."GRB2"sequesters"SOS1"to"the"cell"membrane,"which"binds"to"form"a"GRB2ISOS1"complex."Then"SOS1"activates"RAS"via"its"guanine"nucleotide"exchange"factor"function."Once"initiated,"RAS"activates"numerous"pathways"involved"in"the"cell"cycle,"cell"migration"
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and"cell"proliferation."To"perform"candidate"gene"analysis,"exonic"coding"regions,"exonIintron"boundaries,"and"partial"introns"of"these"three"genes"were"sequenced"from"both"affected"ranched"silver"foxes"and"unaffected"wild"and"farmed"red"foxes"and"compared."To"further"interpret"any"candidate"mutations"identified,"we"also"examine"rates"and"patterns"of"molecular"evolution"in"SOS1,%GRB2"and%EGFR%genes"among"mammals.!
!
Materials!and!Methods!
Sample%collection%and%DNA%extraction%In"2004,"provincial"government"veterinarian,"Robert"Hudson,"on"a"fox"farm"in"Newfoundland"and"Labrador,"Canada,"first"documented"the"presence"of"HHG"(Figure"3.1)."It"was"determined"that"the"affected"silver"foxes"were"either"original"Finnish"silver"foxes"imported"for"their"superior"fur"quality"or"first"generation"descendants"of"a"cross"between"the"new"Finnish"silver"fox"males"with"the"Canadian"silver"fox"females"(Clark"et%al."2015).""HHGIaffected"and"unaffected"silver"foxes"were"obtained"from"the"same"Newfoundland"fox"farm."Provincial"government"veterinarians"examined"these"animals"and"after"gross"manual"examination"determined"the"presence"or"absence"of"HHG."HHG"showed"phenotypic"variation"in"severity,"with"diagnosis"being"made"in"the"early"stages"of"the"disease"when"there"was"the"presence"of"a"thin"layer"of"gingival"tissue"at"the"dental"margin"with"the"crown"of"the"tooth"that"was"slightly"raised,"red"and"granular"(Hudson"2014)."Provincial"government"veterinarians""
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"A" " " " " " B"""Figure"3.1:"A."Silver"fox"with"no"gingival"overgrowth"in"2004."B."Original"Finnish"Silver"fox"with"gingival"overgrowth"documented"in"2004"(Photos"provided"by"Robert"Hudson)"""""""""""""""
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anesthetized"these"animals"and"small"gingival"sections"were"collected."Additionally,"gingival"and"skeletal"muscle"samples"were"obtained"from"both"HHGIaffected"and"unaffected"foxes"postImortem"during"pelting"season."The"Newfoundland"and"Labrador"Department"of"Environment"and"Conservation"Wildlife"Division"and"Department"of"Natural"Resources"Animal"Health"Division"provided"wild"unaffected"red"fox"samples."The"wild"unaffected"foxes"from"the"Newfoundland"and"Labrador"Department"of"Environment"and"Conservation"Wildlife"Division"were"captured"from"the"area"surrounding"the"St."John’s"International"Airport"and"skeletal"muscle"was"sampled."Animal"Health"Division"unaffected"foxes"were"obtained"during"a"rabies"eradication"program"where"salivary"glands"were"sampled."All"sampling"was"compliant"with"Canadian"Council"on"Animal"Care"regulations,"and"approved"by"the"Memorial"University"Institutional"Animal"Care"Committee.""DNA"extractions"were"performed"with"the"QiaAmp"DNA"Mini"kit"(Qiagen"Inc.,"Mississauga,"Canada)"according"to"the"manufacturer’s"tissue"protocol.""
Primer%design%Primers"were"designed"using"Canis%lupus%familiaris"sequences"with"GenBank"Accession"Numbers"NC_006600.3,"NC_006591.3,"and"NC_006599.3,"as"references"for"
EGFR"found"on"chromosome"18,"GRB2%found"on"chromosome"9"and"SOS1"found"on"chromosome"17,"respectively,"according"to"their"reported"sequences"from"2008I2011."Primer"pairs"were"selected"from"the"intronic"regions"flanking"each"target"region"using"either"Primer3"(Rozen"and"Skaletsky"2000)"or"Oligo"4.1"(Molecular"
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Biology"Insights,"Inc.,"Cascade,"USA)."The"following"criteria"were"used"to"choose"primer"pairs"in"Primer3:"23I29"bp"length;"20I80%"GC"content;"primer"Tm"range"57I63°C;"and"expected"amplicon"size"700I800"bp."The"following"criteria"were"used"to"choose"primer"pairs"using"Oligo"4.1:"20I22"bp"length;"40I60%"GC"content;"Tm"difference"for"the"pair"less"than"12°C;"expected"amplicon"size"128I1500"bp;"optimal"annealing"temperature"50I57°C."Some"primers"were"tailed"with"standard"M13"forward"or"reverse"sequences"for"subsequent"sequencing.""Primers"were"manufactured"by"Operon"(Huntsville,"USA).""
Polymerase%Chain%Reaction%(PCR)%and%DNA%sequencing%Each"PCR"contained"2.5"µL"10X"buffer,"0.5"µL"dNTPs"(New"England"Biolabs"Ltd.,"Whitby,"Canada),"1"µL"of"10"µM"forward"primer,"1"µL"of"10"µM"reverse"primer,"0.2"
µL"Hot"Star"Taq"Plus"(Qiagen"Inc.,"Mississauga,"Canada),"19"µL"distilled"water"and"1"
µL"template"DNA."The"thermal"profile"used"was"95°C"for"15"minutes,"followed"by"40"cycles"of"93°C"for"30"seconds,"targetIspecific"annealing"temperature"for"30"seconds,"and"72°C"for"2"minutes,"followed"by"72°C"for"6"minutes."Amplified"PCR"products"were"purified"using"either"Pall"Life"Sciences"MultiIWell"Plate"Manifolds"(Pall"Corporation,"Port"Washington,"USA)"or"the"QIAquick"PCR"purification"kit!(Qiagen"Inc.,"Mississauga,"Canada)."TargetIspecific"annealing"temperatures"were"as"recommended"by"the"primer"selection"software."For"detailed"primer"pair"sequences,"annealing"temperatures"and"amplicon"lengths"refer"to"Appendix"1.""
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DNA"sequencing"reactions"were"performed"with"both"forward"and"reverse"primers"for"each"PCR"amplicon"using"BigDye"Terminator"v3.0"chemistry"(Applied"Biosystems"Inc.,"Foster"City,"USA)"utilizing"the"following"thermal"profile:"96°C"for"6"minutes,"then"25"cycles"of"96°C"for"10"seconds,"50°C"for"5"seconds,"60°C"for"4"minutes.""Sequencing"reaction"purification"was"carried"out"using"either"ethanol"precipitation"or"an"Agencourt"CleanSeq"method"(Beckman"Coulter"Inc.,"Danvers,"USA)."Purified!DNA"sequencing"reactions"were"electrophoresed"on"the"Applied"Biosystems"Inc."3730"DNA"Analyzer,"in"the"GaP"Facility"of"the"CREAIT"Network"at"Memorial"University"of"Newfoundland.""
Data%analysis%Raw"data"was"collected"using"Sequence"Analysis"v5.2"(Applied"Biosystems"Inc.,"Foster"City,"USA)"and"imported"into"Sequencher"v4.8"(Gene"Codes"Corp.,"Ann"Arbor,"USA)."Contigs"were"created"by"assembling"reads"to"the"reference"sequence"using"an"85%"minimum"gap"percentage"and"a"20%"minimum"overlap,"followed"by"manual"trimming"and"editing"of"sequence"each"read."For"each"gene"individual"foxes"with"maximum"sequence"data"were"used"for"comparisons."Consensus"sequences"for"each"individual"animal"for"each"gene"were"constructed"and"exported."""For"each"of"the"three"genes"examined,"HHGIaffected"farm"foxes"and"wild"HHG"unaffected"foxes"were"sequenced."Initial"sequence"comparisons"were"performed"using"the"HHGIaffected"and"wild"HHGIunaffected"foxes."For"any"DNA"sequence"that"demonstrated"a"trend"segregating"the"HHGIaffected"farm"foxes"and"HHG"unaffected"
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wild"foxes,"additional"samples"including"HHGIunaffected"farm"foxes"with"no"direct"familial"relation"to"the"HHGIaffected"farm"foxes"were"sequenced"to"explore"any"true"segregating"sequence"differences"between"affected"and"unaffected"groups"of"foxes.""Analyses"of"molecular"evolution"were"conducted"within"MEGA"5.0"(Tamura"et%al."2011)."These"included"rates"of"synonymous"and"nonIsynonymous"sequence"variation"(NeiIGojobori"algorithm),"ZItests"of"selection"(using"NeiIGojobori"proportions),"and"HyPhy"tests"of"siteIspecific"selection."Three"levels"of"taxonomic"hierarchy"were"considered"for"each"gene:"within"Vulpes%vulpes;"between"V.%vulpes"and"Canis%lupus%familiaris"(domestic"dog);"and"among"mammals"using"sequences"accessed"from"GenBank"(Bos%taurus,"Mus%musculus,"Rattus%norvegicus,"Pan%
troglodytes,"Homo%sapiens)."For"intraspecies"comparisons"maximum"sequence"data"available"for"each"individual"was"used."For"interspecies"comparisons"consensus"sequence"data"was"used."For"the"EGFR"gene,"a"McDonaldIKreitman"test"of"selection"(MacDonald"and"Kreitman"1991)"was"performed"and"a"test"of"lineageIspecific"selection"was"conducted"by"comparing"a"model"with"a"fixed"dN/dS"(ω)"ratio"parameter"to"a"model"in"which"this"parameter"was"free"to"vary,"using"the"logIlikelihood"ratio"test"implemented"in"PAML"v4.5"(Yang"2007).""
!
Results!
Mutational%differences%between%affected%and%unaffected%foxes%The"EGFR"gene"was"sequenced"for"19"unaffected"foxes"and"13"HHGIaffected"foxes;"the"total"coverage"for"each"individual"ranged"from"2,731"to"9,418"bp."The"SOS1"gene"
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was"sequenced"for"15"unaffected"foxes"and"14"HHGIaffected"foxes."The"total"coverage"for"each"individual"for"this"gene"ranged"from"194"bp"to"12,454"bp."The"
GRB2"gene"was"sequenced"for"12"unaffected"foxes"and"10"HHGIaffected"foxes,"and"the"total"coverage"for"this"gene"for"each"individual"ranged"from"318"bp"to"2,139"bp."For"each"gene,"there"was"100%"coverage"of"the"proteinIcoding"region"and"the"intron/exon"boundaries"for"all"HHGIaffected"and"wild"unaffected"foxes.""There"were"no"fixed"mutations"segregating"the"HHGIaffected"from"the"unaffected"sets"of"samples"in"any"coding"portions"or"intron/exon"boundaries"of"the"EGFR,"SOS1"or"
GRB2"genes."There"were"no"heterozygous"sites"conserved"across"affected"foxes"in"any"of"these"gene"regions,"as"may"be"expected"for"a"dominant"mutation.""The"5’"regulatory"region"of"the"EGFR"gene"was"examined."In"humans,"this"region"is"still"not"fully"characterised"but"it"contains"several"features"within"the"500"bp"upstream"of"the"5’"start"codon."This"is"a"GC"rich"section"(GC"content"of"88%)"that"contains"multiple"transcriptional"start"sites"and"several"CCGCCC"repeats"(Ishii"et%al."1985;"Liu"et%al."2005)."Here,"1,775"bp"upstream"of"the"5’start"codon"of"the"EGFR"gene"using"the"19"unaffected"foxes"and"13"HHGIaffected"fox"sequences"were"examined"and"no"CCGCCC"repeat"was"present."In"the"500"bp"immediately"upstream"of"the"EGFR"start"codon"in"foxes"the"GC"content"was"52.4%"(158"Gs"and"104"Cs)."This"region"did"not"contain"any"fixed"differences"between"the"HHGIaffected"and"unaffected"foxes."In"humans,"a"polymorphism"at"position"I216"G/T"is"associated"with"increased"promoter"activity"(Liu"et%al."2005)."This"site"was"an"invariant"G"in"foxes.""
 67 
Molecular%evolution%of%the%EGFR,%GRB2,%and%SOS%genes%in%foxes%and%other%mammals%"Across"all"measures"of"sequence"diversity"at"all"hierarchical"levels"EGFR"demonstrated"the"highest"level"of"variation"among"the"three"genes"(Table"3.1)."SOS1"was"more"variable"than"GRB2"at"nonIsynonymous"sites,"but"less"so"at"synonymous"sites"(Table"3.1)"both"between"canids"and"among"mammals."Variability"of"all"genes"was"consistent"with"purifying"selection"(ZItest"dN/dS"<<"1;"P=0)"with"the"highest"functional"constraints"associated"with"GRB2"and"the"lowest"with"EGFR."As"the"ZItest"is"a"very"conservative"test"of"positive"selection"requiring"dN/dS"(ω)">"1"to"reject"neutrality,"we"used"siteIspecific"test"of"selection"(HyPhy)"for"all"genes,"and"a"McDonaldIKreitman"test"of"selection"for"the"EGFR"gene,"where"the"most"variability"was"observed."HyPhy"tests"did"not"reveal"evidence"of"siteIspecific"selection"in"any"gene"(P>0.15"for"all"sites"in"EGFR;"P>0.29"for"all"sites"in"SOS1;"P>0.67"for"all"sites"in"
GRB2)."The"McDonaldIKreitman"ratio"of"nonIsynonymousItoIsynonymous"changes"was"higher"between"Vulpes%vulpes"and"Canis%lupus%familiaris"(20/20)"than"within"
Vulpes%vulpes"(4/7),"suggestive"of"positive"selection,"but"the"difference"was"not"significant"(Fisher"exact"test"P=0.298)."""A"lineageIspecific"test"of"selection"was"performed"using"phylogenetic"analysis"by"maximum"likelihood"(PAML)"with"the"branchIsite"model"for"the"multispecies"phylogeny"of"the"EGFR"gene"(Yang"2007)."The"PAML"model"allowing"ω"(dN/dS)"ratios"to"vary"was"significantly"more"likely"than"the"model"in"which"they"were"fixed"(χ2=32.7;"P=0),"to"suggest"the"possibility"of"positive"selection"affecting"amino"acid"sequence"evolution"in"some"of"the"mammalian"lineages."The"branch"model"indicated""
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Table"3.1:"Measures"of"sequence"diversity"in"the"coding"portions"of"the"EGFR,"GRB2,"and"SOS1"genes,"within"Vulpes%vulpes,"between"Vulpes%vulpes"and"Canis%familiaris,"and"among"mammals"(pairwise"averages)""Comparison" Gene"(nt)"" EGFR"(3543)" GRB2"(654)" SOS1"(4032)"Within"V.%vulpes" " " "No."variable"sites"(%)" 12"(0.339)" 2"(0.306)" 4"(0.099)""""""Nonsynonymous" 4" 0" 0""""""Synonymous" 8" 2" 4"
V.%vulpes"vs."C.%familiaris" " " "No."variable"sites"(%)" 41"(1.157)" 5"(0.760)" 19"(0.470)""""""Nonsynonymous"(dN)" 20"(0.008)" 0"(0)" 9"(0.003)""""""Synonymous"(dS)" 21"(0.031)" 5"(0.036)" 10"(0.011)"Among"Mammals" " " "pIdistance" 0.129" 0.062" 0.069"dN" 0.047" 0.001" 0.014"dS" 0.401" 0.288" 0.257"dN/dS"ZItest"PIvalue" 0.118"0"(purifying)" 0.003"0(purifying)" 0.054"0"(purifying)"""""""""""""""""""""""""
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a"range"of"lineageIspecific"ω"ratios"from"0.0453"for"Homo%sapiens"to"0.2627"for"Canis%
familiaris%(Table"3.2)."The"highest"ω"ratios"were"seen"in"the"Canis"(0.2627)"and"
Vulpes"(0.2580)"lineages,"suggesting"the"possible"presence"of"positive"selection"in"these%lineages.""
!
Discussion!HHG"is"an"autosomal"recessive"gum"disease"occurring"almost"exclusively"in"ranched"silver"foxes"(Dyrendahl"and"Henricson"1960)."While"nothing"is"known"about"the"underlying"genetic"mutation(s)"leading"to"its"prolific"gingival"overgrowth"phenotype,"an"analogous"condition"occurring"in"humans,"HGF,"has"a"known"causative"genetic"mutation"(Hart"et%al."2002)."In"the"present"study,"we"explore"the"gene"containing"this"mutation,"SOS1,"and"two"genes"with"functions"in"the"same"cell"signalling"pathway,"EGFR%and"GRB2,"to"determine"if"these"genes"carry"any"potential"HHG"causative"mutations,"in"addition,"to"elicit"the"molecular"evolutionary"patterns"of"these"genes"in"foxes"and"compare"to"other"canids"and"mammals"to"assess"the"likelihood"that"mutations"in"these"genes"could"drastically"change"the"phenotype."
%
Mutational%differences%between%HHGRaffected%and%unaffected%foxes%Since"research"into"HGF"suggests"involvement"of"the"RAS"signalling"pathway"(Xiao"et%
al."2001),"our"aim"was"to"start"with"the"known"HGFIassociated"gene%SOS1,"then"examine"the"closelyIassociated"GRB2"gene"and"the"adjacent"upstream"pathway"gene"
EGFR,"to"determine"whether"any"mutational"differences"exist"between"HHGIaffected""
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Table"3.2:"LineageIspecific"rates"of"nonsynonymous"(dN)"and"synonymous"(dS)"substitution"in"the"EGFR"gene"of"mammals,"and"their"ratio"(ω),"determined"using"phylogenetic"analysis"by"maximum"likelihood"(PAML)"branchIsite"model""Species" dN" dS" ω"
Rattus%norvegicus% 0.0088" 0.1353" 0.0652"
Mus%musculus% 0.0097" 0.0987" 0.0980"
Homo%sapiens% 0.0075" 0.0165" 0.0453"
Pan%troglodytes% 0.0019" 0.0122" 0.0603"
Vulpes%vulpes% 0.0062" 0.0241" 0.2580"
Canis%familiaris% 0.0019" 0.0074" 0.2627"
Bos%taurus% 0.0370" 0.2754" 0.1343""
!
!
!
!
!
!
!""
!
!
!
!
!
!
!
 71 
and"unaffected"foxes"that"could"affect"protein"function"and"potentially"be"causative"of"HHG."""The"SOS1"gene"in"humans"spans"138,915"bp,"contains"23"exons"and"encodes"a"seven"domain"protein"consisting"of"a"histone"folding"domain,"a"Dbl"homology"domain,"a"Pleckstrin"homology"domain"cassette,"a"helical"linker,"a"RAS"exchange"motif,"a"Cdc25"domain"and"a"proline"rich"CIterminal"which"binds"to"GRB2"(Findlay"and"Pawson"2008)."The"human"GRB2"gene"is"located"at"chromosomal"position"17q24Iq25,"spans"87,634"bp,"and"consists"of"five"exons."The"ubiquitously"expressed"GRB2"protein"contains"three"domains:"a"Src"homology"2"(SH2)"domain"flanked"on"either"side"by"SH3"domains"(Dharmawardana"et%al."2006)."The"SH2"domain"binds"to"tyrosine"phosphorylated"regions"while"the"SH3"domains"bind"to"other"proline"rich"regions"on"other"proteins"such"as"to"the"CIterminal"domain"of"the"SOS1"protein."Duplication"of"the"GRB2"gene"has"been"associated"with"leukemia’s"and"tumours"(Dharmawardana"
et%al."2006)."""The"results"of"sequence"analyses"of"both"the"SOS1"and"GRB2"genes"in"HHGIaffected"and"unaffected"fox"demonstrated"similar"findings."Neither"gene"showed"any"fixed"differences"between"these"two"groups"that"could"represent"putative"causative"mutations"of"HHG"in"either"the"coding"regions"or"at"the"exonIintron"boundaries."There"were"very"few"polymorphic"sites"in"these"genes"among"foxes,"and"no"nonIsynonymous"changes."These"findings"do"not"rule"out"the"possibility"that"a"mutation"could"exist"in"the"upstream"promoter/enhancer"regions"for"either"of"these"genes,"or"
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potentially"elsewhere"in"the"introns."Nonetheless,"they"do"suggest"that"amino"acid"differences"in"the"protein"products"of"these"genes,"frameshift"mutations"leading"to"truncation"or"extension"of"the"protein"product,"or"failure"to"correctly"excise"introns,"which"would"radically"alter"the"protein"product,"are"not"the"cause"of"the"gum"disease"phenotype"in"foxes."We"can"confirm"that"the"known"HGF"causative"mutation"in"SOS1"is"not"found"in"HHGIaffected"foxes."""The"188,307"bp"human"EGFR"gene,"located"on"chromosome"7"position"p12,"consists"of"34"exons"that"are"expressed"as"four"protein"variants"(Lurje"and"Lenz"2009)."All"EGFR"protein"variants"contain"three"domains:"a"variable"extracellular"receptor"domain;"a"short,"hydrophobic,"membraneIspanning"domain;"and"a"tyrosine"kinase"intracellular"carboxyIterminal"domain"(Scaltriti"and"Baselga"2006)."Ligand"binding"results"in"a"conformational"change"in"the"extracellular"domain"leading"to"receptor"dimerization"and"subsequent"autophosphorylation"of"the"intracellular"tyrosine"residues,"enabling"the"“docking”"and"activation"of"the"GRB2"protein."Constitutive"activity"of"this"gene"has"been"linked"to"cancer"and"cancer"progression,"and"EGFR"has"been"researched"as"a"target"for"drug"therapies"(Scaltriti"and"Baselga"2006).""Here,"no"mutational"differences"separated"HHGIaffected"foxes"from"unaffected"ones,"indicating"that"similar"to"GRB2"and"SOS1,"structural"differences"in"the"encoded"protein"are"not"associated"with"HHG.""In"humans,"the"5’"regulatory"region"of"the"EGFR"gene,"unlike"most"eukaryotic"5’"regulatory"regions,"does"not"contain"TATA"or"CAAT"boxes."Instead"this"region"has"a"GC"content"of"~88%,"and"contains"several"CCGCCC"repeats"and"multiple"RNA"
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initiation"sites."A"polymorphism"at"position"I216G/T"acts"independently"of"other"promoter"region"sequences"to"bind"specificity"protein"1"(Sp1),"a"transcription"factor"required"for"promoter"activity"(Liu"et%al."2005);"the"thymine"causes"an"increase"in"promoter"activity.""We"found"no"fixed"differences"in"the"region"immediately"upstream"of"the"EGFR"gene"in"the"two"groups"of"foxes,"including"at"position"I216,"hence"have"no"evidence"to"suggest"a"promoter"difference"as"causative"of"HHG."But,"the"GC"content"in"foxes,"similar"to"Canis%familiaris,%was"not"as"high"as"would"be"expected"if"this"region"functions"the"way"it"does"in"humans,"so"further"exploration"of"the"promoter"region"will"be"required"before"this"gene’s"involvement"in"HHG"can"be"eliminated."However"there"are"fewer"CpG"islands"in"promoter"regions"in"canines"than"in"humans"(Auton"et%al."2013),"which"could"account"for"the"lower"CG"content"seen"in"the"upstream"region"of"the"EGFR"gene"in"both"Canis"and"Vulpes.""
Molecular%evolution%of%the%SOS1,%GRB2,%and%EGFR%genes%in%mammals%The"SOS1"and%GRB2%genes"showed"similar"molecular"evolutionary"patterns"to"each"other,"in"that"both"genes"were"highly"conserved"at"the"intraspecies,"intraIfamily,"and"amongIgeneral"levels"in"mammals.""Less"than"1%"of"sites"were"variable"in"either"gene"between"the"domestic"dog"and"the"fox,"separated"by"~"15"million"years"of"evolution,"while"among"mammals"~6%"of"sites"varied"in"pairwise"comparisons"(Wayne"et%al."1997)."Additionally,"nonIsynonymous"substitutions"and"ω"ratios"were"low"for"both"these"genes,"especially"GRB2,"consistent"with"strong"functional"constraints.""The"GRB2"protein"functions"as"an"adapter"protein"between"a"receptor"and"the"cytoplasmic"kinases"(Kraskouskaya"et%al."2013),"while"SOS1"is"a"nucleotide"exchange"factor"activating"both"the"RAS"and"RAC"cascade"pathways"(Pierre"et%al."
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2011)."Consistent"with"high"conservation,"disruptions"in"both"these"genes"have"known"disease"consequences;"the"absence"of"GRB2"protein"in"mice,"for"example,"is"incompatible"with"life"(Cheng"et%al."1998),"and"in"humans,"mutations"in"SOS1"lead"to"diseases"like"HGF1"and"Noonan"syndrome"(Pierre"et%al."2011)."""Unlike"SOS1"and"GRB2,"EGFR"showed"high"levels"of"sequence"variation"at"both"synonymous"and"nonIsynonymous"sites,"and"EGFR’s"ω"ratio"was"about"40"times"greater"than"GRB2."Elevated"synonymous"substitution"rates"may"indicate"a"high"mutation"rate,"relaxed"selection"related"to"alternative"codon"usage,"or"a"recombination"hotspot"(Auton"et%al."2013;"Comeron"and"Aguade"1998)."Elevated"dN"rates"and"ω"values"suggest"either"reduced"functional"constraints"or"positive"Darwinian"selection."To"determine"which,"we"considered"four"tests"of"selection."The"ZItest"could"not"be"rejected,"but"this"test"is"known"to"be"conservative,"requiring"ω"ratios"greater"than"unity."Nonetheless,"siteIspecific"tests"also"did"not"indicate"positive"selection"at"any"codon"sites"(P">"0.15)"nor"could"the"McDonaldIKreitman"test"reject"the"equality"of"the"nonIsynonymousItoIsynonymous"ratios"of"polymorphisms"within"Vulpes"to"fixed"differences"between"Vulpes"and"Canis."However,"the"latter"was"higher,"consistent"with"adaptive"evolution;"furthermore,"of"the"20"fixed"nonIsynonymous"differences"between"Canis"and"Vulpes,"eight"(40%)"were"located"in"the"third"FU"(FurinIlike"repeat)"domain"while"only"seven"were"between"domains."The"PAML"lineageIspecific"test"of"selection"supported"a"model"allowing"the"ω"ratio"to"vary"among"lineages,"pointing"to"the"possibility"of"positive"
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selection)in)certain)lineages)(Yang)2007).)Notably)the)Canis,)Vulpes,,and,Bos,ω)values)are)the)highest)among)mammals.)))Why)might)there)be)positive)selection)in)EGFR)in)the)Vulpes,)Canis,)or)Bos)lineages?)One)possibility)is)that)selection)pressure)is)diversifying)this)receptor’s)ability)to)respond)to)different)stimuli)or)participate)in)multiple)pathways.))The)EGFR)ω)ratios)pattern)supports)the)deep)evolutionary)divergence)between)the)clade)of)mammals)containing)the)primates)and)rodents)relative)to)the)one)containing)the)Cetartiodactyla)64H104)million)years)ago)(Murphy)et,al.)2001),)so)the)molecular)evolutionary)pattern)of)either)relaxed)functional)constraints)or)positive)selection)we)observe)in)EGFR)may)date)to)this)divergence.)Nonetheless)this)pattern)suggests)that)mutations)in)EGFR)may)be)more)readily)tolerated)and)less)likely)to)lead)to)disease)than)those)in)GRB2)or)SOS1.)
,
Conclusions,We)have)determined)that)HHGHaffected)silver)foxes)do)not)carry)the)same)SOS1)mutation)that)causes)HGF)in)humans.)We)ruled)out)the)involvement)of)coding)region)or)exonHintron)boundary)mutations)in)two)adjacent)RAS)pathway)genes,)EGFR)and)GRB2,)although)we)cannot)eliminate)the)possibility)that)promoter,)upstream)binding,)or)other)regulatory)mutations)might)be)changing)gene)expression)patterns)of)these)genes)in)affected)versus)unaffected)foxes.))It)is)possible)that)the)mutation)still)lies)in)a)gene)somewhere)within)the)RAS)pathway.)We)have)also)demonstrated)high)evolutionary)conservation)of)the)SOS1)and)
GRB2)genes)among)mammals.)The)EGFR)gene)is)more)highly)variable)than)the)other)two)genes,)in)a)pattern)consistent)with)relaxed)functional)constraints)or)possibly)even)positive)Darwinian)selection)especially)in)the)lineage)containing)Canis)and)Vulpes.))))
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Chapter four: 
Genome-wide expression analysis of hereditary hyperplastic gingivitis in 
silver foxes (Vulpes vulpes) using canine microarrays   A version of this paper was published in Genome: Clark, JA, Booman M, Hudson RC, Marshall HD (2014) Genome-wide expression analysis of hereditary hyperplastic gingivitis in silver foxes (Vulpes vulpes) using canine microarrays. Genome. 57, 449-57         
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aspects of the research; iii) data analysis; and iv) manuscript preparation.  i) Design and identification of the research proposal All experiments in this chapter by Jo-Anna B.J. Clark with interest in the fox gum disease initiated by Robert Hudson and the concept of a transpecies microarray platform for identification of functional candidate genes by H. Dawn Marshall as part of an NSERC Discovery Grant. Jo-Anna B.J. Clark carried out gene selection and RT-qPCR study design.  ii) Practical aspects of the research Jo-Anna B.J. Clark identified all pairs of foxes that were used in this study, and obtained the necessary tissue samples, working with a veterinarian at the fox farm. RNA preparation and quantification for the microarrays was conducted by Jo-Anna B.J. Clark and sent to The Center for Applied Genomics in Toronto where the microarray experiments were performed. For the first batch of RT-qPCR reactions, cDNA was prepared by Jo-Anna B.J. Clark while RT-qPCR was conducted by a student research assistant	  under	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  supervision. When additional RT-qPCR 
 82 
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iii) Data analysis 
Jo-Anna B.J. Clark from raw data files completed all microarray and RT-qPCR data analysis and interpretation with guidance provided by Marije Booman.    iv) Manuscript preparation Jo-Anna B.J. Clark prepared the manuscripts with critical review and editing provided by H. Dawn Marshall and Marije Booman.              
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Introduction Hereditary hyperplastic gingivitis (HHG) presents as tumourous growths of the gingival tissue on the mandible in the farmed silver fox, a coat colour variant of the red or coloured fox (Vulpes vulpes). Its pathology includes large epithelial extensions in the keratinized collagen of the gingival tissue (Dyrendahl and Henricson 1960). Pronounced manifestation of HHG occurs at approximately two to three years of age, with tumour proliferation continuing throughout life, resulting in dental encapsulation. HHG is an autosomal recessive disease demonstrating incomplete penetrance, with an increased incidence in males relative to females. In addition, a pleiotropic relationship between HHG and high fur quality, typically length and density of the guard hairs, has been implicated. While most cases of HHG are found in fox farms, there was a report in 2008 of a case of severe HHG in a wild European red fox (Schulze et al. 2008). Although HHG was first discovered in Sweden in the 1940s, and has been described in different parts of Europe since then, it was only documented in Newfoundland and Labrador, Canada, in 2004 (Figure 4.1), and its molecular aetiology remains unknown (Clark et al. 2015).  Hereditary gingival fibromatosis (HGF) in humans is an analogous condition to HHG. HGF is characterized as a genetically heterogeneous disease with progressive benign fibrous enlargements of the maxillary and mandibular keratinized gingival tissues (Hart et al. 2002). HGF is a rare disease with a phenotypic frequency of 1:175 000 individuals, affecting males and females equally (Fletcher 1966). Clinically, HGF presents with benign, non-haemorrhagic, non-exudative gingival overgrowths  
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 A.    B.   C. Figure 4.1: A, B, C: Hereditary hyperplastic gingivitis (HHG) in several original Finish foxes in 2004. Each panel demonstrates a different case of HHG (Photographs by Robert Hudson)                  
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(Bittencourt et al. 2000; Hakkinen and Csiszar 2007). Manifestation occurs approximately at the advent of permanent dentition with progressive worsening during adolescence (Coletta and Graner 2006). Treatment involves quadrant by quadrant gingivectomy (Coletta and Graner 2006; Ramer et al. 1996), and despite resection, the gingival tissue continues to proliferate. HGF has a heterogeneous aetiology, occurring either because of an underlying isolated genetic cause, in association with other symptoms as a syndrome, or as the result of a drug interaction (Shashi et al. 1999). Inheritance patterns of the genetic forms include Mendelian autosomal inheritance and maternal genome imprinting.  Mendelian autosomal inheritance is primarily dominant with rare case reports of autosomal recessive transmission (Goldblatt and Singer 1992; Hart et al. 1998; Singer et al. 1993). Maternal imprinting has been linked to two imprinting clusters on chromosome 11p15 (Zhu et al. 2007). To date, the focus has been on elucidating the mechanisms of autosomal dominant transmission.  Autosomal dominant HGF displays incomplete penetrance and variable expression (Hart et al. 1998) and has been linked to three chromosomal loci: HGF1 at 2p21-p22 (Hart et al. 1998; Xiao et al. 2000); HGF2 at 5q13-q22 (Xiao et al. 2001); and HGF3 at 2p22.3-p23.3 (Ye et al. 2005). Only HGF1 has a known causative mutation, which affects codon 1083 of the Son of sevenless homolog 1 (SOS1) gene, the guanine nucleotide exchange factor involved in signal transmission from the receptor tyrosine kinase to the rat sarcoma viral (RAS) protein in the mitogen-activated protein kinase (MAPK) signalling cascade (Hart et al. 2002). Given the strong 
 86 
similarity between human HGF and fox HHG, the known molecular basis of one form of HGF establishes a basis for the study of the analogous gum disease in the fox.   The publication of the domestic dog (Canis lupus familiaris) genome (Lindblad-Toh 
et al. 2005) greatly facilitates genomic research with closely related species such as the red fox (Kohn et al. 2006; Lindblad-Toh et al. 2005). Vulpes vulpes and Canis 
lupus familiaris are both members of the mammalian family Canidae and last shared a common ancestor 12 to 15 million years ago (Kukekova et al. 2004; Wayne et al. 1997). There is strong molecular evidence supporting the close relationship between the two species, such as a 97.3% similarity between their sex determining 
region Y (SRY) gene coding sequences (Nowacka-Woszuk and Switonski 2009; Switonski et al. 2009). Mouse genetic studies are hampered by the high evolutionary rate of the rodent lineage (Boyko 2011). The dog genome has proven to be a useful model system for human diseases and as a potential bridge between human and mouse studies.  Interpreting genome-wide HHG expression patterns in the silver fox in the context of the genetics of HGF should provide insights into many facets of this disease; specifically it can be used as a gene discovery tool to identify putative genes involved. The goal of this study was to integrate genetic knowledge of HGF with genomic technologies accessible from the dog genome to examine molecular pathways involved in silver fox HHG. We used the Affymetrix GeneChip Canine Genome 2.0 Array, which contains over 20 000 non-redundant predicted genes as 
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well as 18 000 C. familiaris mRNA/EST-based transcripts, to compare the global gene expression patterns within gum tissue from farmed HHG-affected and unaffected silver foxes. We evaluated our findings with a focus on the genes within the known HGF chromosomal regions and, additionally, the RAS/ MAPK pathway thought to be involved in HHG, demonstrating differential expression between HHG-affected and HHG-unaffected silver foxes.   
Materials and Methods 
Sample collection Diagnosis of HHG was made based on early markers of the disease where red, raised, granular gingival tissue was present at the dental margins on the crowns of the teeth. Provincial government veterinarians, based on gross manual examination 
of	  each	  fox’s	  gingival	  tissue,	  made	  this	  diagnosis	  (Hudson 2014, Personal communication).  A phenotypic severity scale was created ranging from no signs of disease at zero to severe disease at five to document severity of initial presentation and for monitoring disease progression. Samples of HHG-affected and HHG-unaffected gum tissues were taken from a total of thirty-two foxes from a Newfoundland and Labrador fox farm. All HHG-unaffected samples displayed normal pale pink, smooth, flat gingival tissue (a zero on the phenotypic severity scale). The HHG-affected samples ranged from a two (a moderately thick, rounded red layer of gingiva, that is bilateral, with no complete dental encapsulation) to a four (the dental arcade is mostly covered by diffusely thickened, red and proliferative gingival tissue, forming confluent multi-nodular masses with large 
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lateral flaps resulting in numerous encapsulated teeth) on the phenotypic severity scale.  Eight of the samples (five HHG-affected and three HHG-unaffected) were used for the microarray experiment and the remainder for reverse quantitative transcriptase polymerase chain reaction (RT-qPCR) experiments (eleven HHG-affected and thirteen HHG-unaffected samples). Within the microarray samples, there were two pairs of related foxes (Figure 4.2) and four individuals sharing no direct familial connections.   Gingival samples were collected either during pelting season or in the late spring after whelping season. During pelting season, samples were collected immediately after the animal was euthanized. Samples collected after whelping season were taken from live anesthetised foxes. Provincial government veterinarians performed all sampling and the Institutional Animal Care Committee at Memorial University of Newfoundland approved use of samples for this research, in accordance with Canadian Council of Animal Care guidelines. Gingival sections (<500 mg) were immediately placed into 5 mL of RNAlater (Qiagen Inc., Mississauga, Canada) for four hours followed by storage at -20qC.  
RNA preparation RNA was extracted using an RNeasy Fibrous Tissue Mini kit, according to protocol specifications (Qiagen Inc., Mississauga, Canada).  An additional off-column DNase procedure was performed to ensure the quality of the RNA (Qiagen Inc., Mississauga, Canada). RNA quality was assessed using 1.5% agarose gel  
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 A.     B. Figure 4.2: Pedigrees of two separate silver fox families (A and B) demonstrating the relationship between a hereditary hyperplastic gingivitis (HHG)-affected members and HHG-unaffected members             
 
 
 90 
electrophoresis and spectrophotometry using the NanoDrop ND1000 (NanoDrop Technologies, Inc., Wilmington, USA).   
Microarray experiments RNA samples were sent to the Microarray Facility at the Toronto Centre for Applied Genomics, Hospital for Sick Children, in Toronto, Canada, where RNA integrity was assessed using the Agilent BioAnalyzer (Affymetrix Inc. and Agilent Technologies 
Inc.,	  Santa	  Clara,	  USA).	  RNA	  was	  labeled	  using	  the	  Affymetrix	  3’IVT	  Express	  kit	  
(Affymetrix	  Inc.,	  Santa	  Clara,	  USA)	  according	  to	  the	  manufacturer’s	  protocol. Each sample was hybridized to an Affymetrix GeneChip Canine Genome 2.0 Array and scanned using an Affymetrix GeneChip Scanner 3000 (Affymetrix Inc., Santa Clara, USA).   
Data analysis 
Microarray	  ‘.CEL’	  files	  were	  analyzed	  using	  a Bioconductor ‘gcrma’	  package (Gentleman et al. 2004, Wu and Gentry 2014). Raw data was converted to expression measures using a GCRMA normalization and summarization algorithm. Non-parametric Mann-Whitney U-tests were used to test for statistical significance of differential expression values. Data was submitted to NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). Gender was initially assessed but did not create a bias. Multiple comparisons of the means were completed however given the diversity of the near-wild animal a reliable list was not obtained.   
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Lists of probesets showing statistically significant differential expression between affected and unaffected animals were compiled, annotated with gene names and functions using NetAffx Analysis Centre (Affymetrix Inc., Santa Clara, USA), and placed in Wikipathways to search for involvement in known canine signalling pathways (Kelder et al. 2011). Using the NCBI human genome build 36.3 (http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9606&query=human&SITE=HumanGuide&SUBMIT=y&submit=Go) lists of the genes found within the chromosomal loci known to be associated with HGF2 and HGF3 were created and then cross-referenced to the microarray expression gene lists.  
 Reverse transcription quantitative PCR (RT-qPCR) cDNA was transcribed from total RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems Inc., Foster City, USA).  Initial RT-qPCR assays were conducted in house or at the Microarray Facility at the Toronto Centre for Applied Genomics, Hospital for Sick Children in Toronto, Canada (see Appendix 2). For each assay, 
cDNA	  was	  combined	  with	  10	  μL	  Taqman	  Master	  Mix	  (2X)	  and	  1	  μL	  Taqman	  Gene	  Expression Assay (20X; 900 nM primer and 250 nM probe) (Applied Biosystems Inc., Foster City, USA.). Reaction mixtures were placed into MicroAmp Fast Optical 96-Well Reaction Plates (Applied Biosystems Inc., Foster City, USA) and subjected to thermal cycling in the StepOnePlus Real Time PCR System (Applied Biosystems Inc., Foster City, USA) according to the following profile: 50qC for 2 minutes, 95qC for 10 minutes, and 40 cycles of 95qC for 15 seconds, 60qC for 1 minute. Six genes that are involved in MAPK signalling were selected for RT-qPCR: Son of sevenless homolog 1 
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(SOS1) (Cf02704868_m1), Son of sevenless homolog 2 (SOS2) (Cf02699545_m1), RAS 
p21 protein activator 1 (RASA1) (Cf02676354_m1), protein	  kinase	  C,	  ζ (PRKCζ) (Cf02655062_m1), mitogen-activated kinase kinase kinase 1 (MAP3K1) (Cf02635276_m1) and Finkel–Biskis–Jinkins murine osteogenic sarcoma virus (FOS) (Cf02741684_m1). As the endogenous control gene, elongation factor, RNA 
polymerase II (ELL2) (Cf02707156_m1) was selected for the in house RT-qPCR, and the breakpoint cluster region (BCR) (Cf02664178_m1) for the remaining RT-qPCR samples (see Appendix 2). Genes were selected either due to relation to the MAPK pathway or from literature reviews or based out of interest from the microarray data.   Relative quantification of each gene was	  calculated	  using	  the	  ΔΔCT	  method	  (Livak	  and Schmittgen 2001). For the in house RT-qPCR the unaffected sample with the lowest standard error was selected as the reference sample while for the remaining RT-qPCR tests the unaffected sample with the lowest expression was selected as the reference sample. Fold changes were calculated using Log2RQ method and the relative fold changes were tested for significance with two-tailed t-tests. All samples were tested in triplicate and samples with a standard deviation greater than 0.5 were removed from the dataset. Any samples that were identified as outliers within biological groups according to Data Assist v3.0 (Life Technologies, Grand Island, USA) were also discarded. Validation experiments were conducted to standardize amplification efficiency.  
 93 
Results 
Differential gene expression in HHG-affected versus HHG-unaffected silver foxes The analysis generated a list of 1,154 probesets demonstrating a statistically significant differential gene expression when comparing the HHG-affected to HHG-unaffected samples (Mann-Whitney U-test P < 0.05) (see Appendix 3). Of these 1,154 differentially expressed probesets, 563 were significantly down-regulated in the HHG-affected versus HHG-unaffected samples and 591 were significantly up-regulated. Probesets representing genes with no known function as identified through the NetAffx Analysis Centre were removed from the list, and the remaining probesets represent 671 unique genes. Wikipathways analysis showed that of the 671 genes, over 135 were associated with known Canis lupus familiaris pathways, several of which were related to cell differentiation and proliferation and thus could be related to HHG aetiology (Table 4.1).  
RT-qPCR  RT-qPCR assays were performed for 6 genes, with fold changes that generally support the trend observed with the microarray data (Table 4.2). Of the 6 genes, FOS demonstrated a statistically significant differential expression at a relaxed significance criterion of P<0.10, which was used to account for non-model organism biological diversity (Table 4.2). Figure 4.3 demonstrates the general expression trend comparison between the HHG-affected and unaffected samples for the genes involved in the MAPK signalling cascade.  
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Table 4.1: Microarray-identified genes significantly differentially expressed in hereditary hyperplastic gingivitis (HHG) affected foxes relative to unaffected foxes that have roles in signalling pathways involved in cell differentiation and proliferation  
Gene 
symbol 
Gene title Affymetrix probe ID Fold 
change  
Mann 
Whitney U-
test P value 
Pathways 
ADCY2 Adenylate cyclase 2 Cfa.19117.1.S1_s_at  -1.143  0.036 Guanine nucleotide binding protein (G protein) ALPL Alkaline phosphatase Cfa.13804.1.A1_at  1.251  0.036 Tumour	  necrosis	  factor	  α	  (TNFα) ATG7 Autophagy related 7 Cfa.14549.1.A1_at  1.257  0.036 Senescence and autophagy BIRC3 Baculoviral IAP repeat containing 3 CfaAffx.23263.1.S1_at  1.194 0.036 TNFα,	  Apoptosis CASP6 Caspase 6 CfaAffx.17770.1.S1_at  -1.213 0.036 Mitogen activated protein kinase (MAPK), Apoptosis CDC37 Cell division cycle 37 homolog  CfaAffx.27245.1.S1_s_at  1.282 0.036 TNFα CMA1 Chymase 1, mast cell CfaAffx.19295.1.S1_s_at  1.372 0.036 TNFα E2F4 E2F transcription factor 4 CfaAffx.31199.1.S1_at  -1.234 0.036 Transforming growth factor β	  (TGFβ) EGF Epidermal growth factor Cfa.3524.1.S2_at  1.216 0.036 Epidermal growth factor receptor 1 (EGFR1), MAPK, 
TGFβ FNTA Farnesyltransferase Cfa.18192.1.S1_at -1.293 0.036 TGFβ FHL2 Four and a half LIM domains 2 Cfa.1493.1.A1_at -1.269 0.036 Wingless/integrated (Wnt) FZD7 Frizzled family receptor 7 Cfa.15623.1.A1_at 1.251 0.036 Wnt and pluripotnecy 
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 GJA1 Gap junction protein, alpha 1 Cfa.119.1.S1_at  -5.484 0.036 EGFR1 GYG1 Glycogenin 1 Cfa.4710.1.A1_at 2.078 0.036 Insulin GNAI1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 
CfaAffx.25135.1.S1_s_at  -1.870 0.036 G protein 
INS Insulin Cfa.18796.1.S1_s_at  -1.053 0.036 Insulin, senescence and autophagy IRF3 Interferon regulatory factor 3 Cfa.18322.1.S1_at  1.234 0.036 Apoptosis 
IL1β Interleukin	  1,	  β CfaAffx.11741.1.S1_s_at  1.189 0.036 MAPK, senescence and autophagy KTN1 Kinectin 1  CfaAffx.23345.1.S1_s_at -1.114 0.036 TNFα LAMP1 Lysosomal-associated membrane protein 1 CfaAffx.10473.1.S1_s_at  -2.425 0.036 Senescence and autophagy MAP3K10 Mitogen-activated protein kinase kinase kinase 10 CfaAffx.9015.1.S1_at  -1.168 0.036 Insulin MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 CfaAffx.9778.1.S1_s_at  -1.267 0.036 MAPK, Insulin NUP214 Nucleoporin 214kDa CfaAffx.30488.1.S1_s_at  -1.376 0.036 TGFβ 
PRKCζ Protein	  kinase	  C,	  ζ Cfa.19185.2.A1_at  -1.204 0.036 EGFR1,	  MAPK.	  TNFα,	  Wnt	  and pluripotency, Insulin, G protein PRKD1 Protein kinase D1 Cfa.12558.1.A1_s_at  -1.612 0.036 EGFR1, Wnt and pluripotnecy RALBP1 RalA binding protein 1 Cfa.14547.1.A1_at  2.421 0.036 EGFR1 
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RNF25 Ring finger protein 25 Cfa.11589.1.A1_at  1.192 0.036 TNFα ROCK1 Rho-associated, coiled-coil containing protein kinase 1 CfaAffx.27952.1.S1_at  1.240  0.036 TGFβ RRAD RAS-related associated with diabetes Cfa.17583.1.S1_at  1.874 0.036 Insulin SH3GL3 SH3-domain GRB2-like 3 CfaAffx.20540.1.S1_at  1.160 0.036 EGFR1 TNFSF15 Tumour necrosis factor (ligand) superfamily, member 15 CfaAffx.5977.1.S1_at  1.220 0.036 Senescence and autophagy USP6NL USP6 N-terminal like Cfa.19504.1.S1_at  1.392 0.036 EGFR1                   
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Table 4.2: Differential expression in hereditary hyperplastic gingivitis (HHG) affected foxes compared to unaffected foxes of genes from RT-qPCR validation assays, compared with fold-change found by microarray analysis  
Gene symbol Gene title RT-qPCR 
Fold change 
t-test 
P Value 
Microarray 
Affymetrix  
probe ID 
 
Fold change 
 
Mann Whitney 
student U-test P 
value FOS* Finkel–Biskis–Jinkins murine osteogenic sarcoma virus 
3.385  0.077  CfaAffx.26065.1.S1_at  2.863  0.393  
MAP3K1 Mitogen-activated protein kinase kinase kinase  
-2.313  0.112  Cfa.19524.1.S1_at  -1.959  0.071  
PRKCζ Protein kinase 
C,	  ζ 1.299  0.382  Cfa.19185.2.A1_at  -1.204  0.036  RASA1 RAS p21 protein activator 1 3.727 0.116  Cfa.350.1.S1_at  1.344  0.071  SOS1* Son of sevenless homolog 1 -1.225  0.406  CfaAffx.10496.1.S1_s_at   -1.400   0.250   SOS2 Son of sevenless homolog 2 1.214  0.182  CfaAffx.22062.1.S1_s_at  1.000 1.000  *RT-qPCR gene assays conducted in house
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   Figure 4.3: Mean log2 relative expression (log2RQ) values for RT-qPCR genes in the hereditary hyperplastic gingivitis (HHG)-affected and HHG-unaffected fox samples. Standard errors are indicated by the bars.          
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Comparison of HHG microarray gene lists with known HGF genes and chromosomal 
loci Human HGF has been linked to three loci: HGF1(Hart et al. 1998; Xiao et al. 2000), HGF2 (Xiao et al. 2001), and HGF3 (Ye et al. 2005). Genes located within all three loci were compared to the HHG microarray gene lists. A mutation in the SOS1 gene has been identified as the causative mutation in HGF1 (Hart et al. 2002). This gene was represented on the canine microarray by three probes, all of which showed down-regulation (1.14, 1.25 and 1.40-fold) of the gene in the HHG-affected foxes compared to the HHG-unaffected foxes, although this down-regulation was not statistically significant (Mann-Whitney U-test P>0.10). This result is opposite from what would be expected if SOS1 were involved in HHG similarly to HGF, as in HGF mutation in the SOS1 gene leads to a constitutively active gene (Hart et al. 2002).  HGF2 was mapped to the locus 5q13-q22 using a four-generation Chinese family (Xiao et al. 2001). This chromosomal region spans approximately 500 genes according to NCBI human genome build 36.3 (accessed July 2013). After removing those with unknown function or redundancy the remaining genes were cross-referenced to the canine genome and their Affymetrix gene IDs determined. The entire microarray gene list was queried with these IDs, generating a list of 273 Affymetrix probe set IDs, where some genes were represented more than once. Of these, six showed a statistically significant differential expression (Mann-Whitney U-test P<0.05) when comparing the HHG-affected to the HHG-unaffected samples (Table 4.3); two up-regulated and four down-regulated. Relaxing the required  
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Table 4.3: Microarray analysis of differential expression in hereditary hyperplastic gingivitis affected foxes compared to unaffected foxes for genes found in the human chromosome loci associated with hereditary gingival fibromatosis (HGF)  
HGF 
subtype 
Gene 
symbol 
Gene title Fold 
change 
Mann 
Whitney U-
test P value HGF2 ANKRD31  Ankyrin repeat domain 31 1.100  0.036  HGF2 CHD1    
Chromodomain helicase DNA binding protein 1 1.347    
0.036    HGF2 CMYA5  Cardiomyopathy associated 5 -1.210  0.036  HGF2 MCTP1    
Multiple C2 domains, transmembrane 1 -1.233    
0.036    HGF2 TMEM161B  Transmembrane protein 161B -1.523  0.036  HGF2 XRCC4     
X-ray repair complementing defective repair in Chinese hamster cells 4 -1.538     
0.036     HGF2 AGGF1  Angiogenic factor with G patch and FHA domains 1 -1.190  0.071  HGF2 FAM174A   Family with sequence similarity 174, member A -1.560   0.071   HGF2 RASA1   RAS p21 protein activator (GTPase activating protein) 1 1.344   0.071   HGF2 TRIM36  Tripartite motif containing 36 1.239  0.071  HGF3 GTF3C2  General transcription factor IIIC, polypeptide 2 -1.182  0.036  HGF3 SLC30A3   Solute carrier family 30 (zinc transporter), member 3 1.234   0.036   HGF3 SRD5A2   Steroid-5-alpha-reductase, alpha polypeptide 2 1.162   0.036   HGF3 ZNF512 Zinc finger protein 512 -1.172 0.071 
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significance level to P=0.10 to accommodate high biological variability among the samples generated an additional four differentially-expressed genes (Table 4.3), two up-regulated and two down-regulated in affected versus unaffected animals.   The third HGF locus was originally mapped to 2p22.3-p23.3 (Ye et al. 2005);  this was subsequently refined to a 6.56cM interval within which 112 genes were found (Pampel et al. 2010). According to NCBI human genome build 36.3 (accessed July 2013), the 2p22.3-p23.3 chromosome region contains 158 genes of which 84 have canine equivalents. Three of these genes showed a statistically significant differential expression when comparing the HHG-affected to the HHG-unaffected microarray samples using a P<0.05 criterion (Table 4.3). Two were up-regulated in the HHG-affected samples relative to the unaffected samples, and one was down-regulated. One additional differentially expressed gene was identified with a relaxed P<0.10 criterion (Table 4.3). The additional gene was down-regulated in the HHG-affected samples. None of these genes were found to be associated with known signalling pathways.   
Comparison of HHG microarray genes lists to MAPK pathway genes  Involvement of genes in the MAPK signalling pathway in the HGF phenotype has been suggested (Hart et al. 2002; Xiao et al. 2001). The canine MAPK signalling pathway was examined using Wikipathways (Kelder et al. 2011) to determine if any significantly differentially expressed genes within the fox HHG-affected vs. HHG-unaffected microarray comparison could be identified. Three genes showed 
 102 
statistically significant differential expression (Mann-Whitney U-test P< 0.05) and six in total with a relaxed Mann Whitney criterion (P< 0.10) (Table 4.4). Of these six genes, three showed up-regulation in the HHG-affected samples and three showed down-regulation in the HHG-affected samples compared to the HHG-unaffected samples. 
 
Discussion Microarray analysis revealed a substantial list of genes expressed differentially in gum tissue from HHG-affected silver foxes compared with unaffected foxes. This gene list implicated numerous cell signalling pathways including epidermal growth factor receptor 1 (EGFR1), mitogen-activated protein kinase (MAPK), tumour necrosis factor alpha (TNFD), wingless/integrated (Wnt), insulin signalling, senescence and cell autophagy (Table 4.1). We first interpreted these gene lists and pathways in the context of genes or loci associated with human HGF, and then discuss new insights into the molecular and cellular mechanisms underlying expression of the HHG phenotype.   HGF genetics includes cases of maternal imprinting, chromosomal abnormalities, and autosomal recessive and autosomal dominant aberrations. With our microarray experimental design, chromosomal aberrations cannot be distinguished nor can maternal imprinting clusters be identified. Autosomal recessive cases of HGF appear sporadically throughout the literature (Goldblatt and Singer 1992; Hart et al. 1998; Singer et al. 1993). Given the rareness of the autosomal recessive mode of HGF  
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Table 4.4: Microarray analysis of differential expression in hereditary hyperplastic gingivitis (HHG)-affected foxes compared to unaffected foxes for genes found in the extracellular signal-regulated kinases portion of the mitogen-activated protein kinase (MAPK) signalling cascade 
 
Gene 
symbol 
Gene title Fold 
change 
Mann Whitney 
U-test P value EGF Epidermal growth factor  1.216  0.036  MAP3K1   Mitogen-activated protein kinase kinase kinase 1  -1.959   0.071   MAPK3  Mitogen-activated protein kinase 3-like 1.541  0.036  MAPK4  Mitogen-activated protein kinase 4  -1.285  0.071  
PRKCζ Protein	  kinase	  C,	  ζ -1.204 0.036 RASA1   RAS p21 protein activator (GTPase activating protein) 1  1.344   0.071               
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inheritance, there have been no definitive causative genes isolated and the penetrance and expression patterns are unknown, although novel mutations are thought to be responsible. The lack of understanding of the recessive HGF aetiology makes it difficult to explicitly compare to the HHG microarray data, but an autosomal recessive mode of inheritance of HHG in the farmed fox population cannot be ruled out and indeed was the conclusion drawn by Dyrendahl and Henricson (1960). Autosomal dominant isolated HGF is associated with three known chromosomal loci and we discuss each of these below.   
Comparison of HHG microarray gene lists with known HGF genes and chromosomal 
loci HGF1 at 2p21-p22 (Hart et al. 1998; Xiao et al. 2000) is the only locus with a known aetiology. A single nucleotide insertion in codon 1,083 of the Son of sevenless 
homolog 1 (SOS1) gene was found within the refined chromosomal region and proven to be the HGF1 causative mutation (Hart et al. 2002). This insertion results in a protein with constitutive membrane recruitment, which allows constitutive activation of the MAPK pathway leading to cell proliferation (Pierre et al. 2011). In both the microarray and RT-qPCR experiments, SOS1 is expressed at a lower level in the HHG-affected foxes when compared to the unaffected foxes, although neither result was statistically significant. Given that the mutation causing HGF1 results in constitutive membrane recruitment of the SOS1 protein, it is possible that the mutation does not result in increased gene expression and thus would not appear up-regulated in the HHG-affected foxes compared to the unaffected foxes. Further 
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investigation of fox SOS1, (Clark et al. 2014a) has shown that there are no mutations within the coding region or within the intron-exon boundaries of this gene in the HHG-affected silver fox population. This conclusively rules out the same nucleotide insertion in SOS1 that causes HGF1 as causative of HHG or any other structural change in the SOS1 protein.   We also consider the possibility of a putative mutation in the SOS2 gene. While located on different chromosomes, the SOS1 and SOS2 proteins share a high amino acid similarity (overall 65%), especially at their amino termini, but not at their carboxy termini (Yang et al. 1995). The carboxy-terminal end of SOS2 contains several proline rich areas whereas SOS1 only contains one such region. These proline rich regions confer a stronger affinity for the SH3 domain of the GRB2 protein, which is an activator of SOS2. While both SOS1 and SOS2 are present in most human cells, they have different signalling capabilities (Qian et al. 2000). Both interact with the MAPK pathway through the extracellular signal-regulated kinase path, but SOS1 has the capability to elicit both long- and short-term signalling, while SOS2 can only participate in short-term signalling. The RT-qPCR data shows a small up-regulation in the SOS2 gene in the HHG-affected foxes compared with the unaffected foxes (fold change 1.214, P=0.182). This minor increase in fold change is likely insufficient to implicate the SOS2 gene as a candidate gene; however, it is possible that a nucleotide alteration exists which would change the structure of the expressed protein without resulting in increased gene expression. Given the high similarity and similar function of the two SOS homologs, it is possible that the 
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causative mutation of HHG occurs in the SOS2 gene rather than SOS1 but does not cause up-regulation of the gene.  HGF2 was mapped to 5q13-q22 (Xiao et al. 2001). Of particular interest in this region are the genes involved in the cell cycle and calcium signalling. Of the ten genes in Table 4.3 two are involved in known canine pathways, XRCC4 (X-ray repair cross-complementing protein 4) and RASA1 (rat sarcoma viral p21 protein activator 1). RASA1 was highlighted by Xiao et al. (2001) as a potential candidate gene. The known pathways involving RASA1 include MAPK signalling pathway, EGFR1 signalling pathway, EPO receptor signalling, signalling of hepatocyte growth factor receptor, IL-4 signalling pathway, Kit receptor signalling pathway, T cell receptor signalling pathway, and B cell receptor signalling pathway (Kelder et al. 2011). Given its involvement in MAPK signalling and its up-regulation in HHG-affected foxes, RASA1 is an excellent candidate for involvement, either directly or through a subsequent pathway, in the HHG phenotype.   A third HGF locus was determined at 2p22.3-p23.3 and two genes within this region, 
GRP113 and SELI, were screened and ruled out as not containing putative HGF3 causative mutations (Ye et al. 2005). This locus was further refined to a 6.56cM interval (Pampel et al. 2010). Based on the canine microarray data, none of the genes showed a statistically significant expression difference in this region, including SLC30A3, GTF3C2 and ZNF512. Of interest is the Steroid-5-alpha-reductase, 
alpha polypeptide 2 (SRD5A2) which encodes an enzyme that converts testosterone 
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into a more potent androgen (Ye et al. 2011).  The SRD5A2 gene was significantly up-regulated in HHG-affected foxes. In dogs, a similar gingival hyperplasia occurs as a result of pharmaceutical interaction (Pariser and Berdoulay 2011). The proposed mechanism for this involves blocking of calcium channels resulting in testosterone sensitive gingival tissue. Although the fox gum condition is not drug-induced, the underlying mechanism may be similar as SRD5A2 results in a higher potency androgen, resulting in androgen sensitive gingival tissue.  
Comparison of HHG microarray gene lists to MAPK pathway genes  
Particular emphasis has been placed on the MAPK signalling pathway as it has a direct link to HGF1 (Hart et al. 1998) and a suggested link to HGF2 (Hart et al. 1998; Xiao et al. 2001). MAPK signalling incorporates a multi-tier cascade of kinase phosphorylations whereby a mitogen-activated protein kinase kinase kinase (MAP3K) phosphorylates a mitogen-activated protein kinase kinase (MAP2K), which phosphorylates the MAPK (Yang et al. 2013). In mammals, MAPK signalling broadly consists of four major pathways: the extracellular signal-regulated kinase (ERK1/2), extracellular signal-regulated kinase 5 (ERK5), c-Jun N-terminal kinase (JNK), and p38 pathway (Krishna and Narang 2008; Wang and Tournier 2006). The HGF1 and HGF2 studies place emphasis on the ERK1/2 pathway and its activation by growth factors.  
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The general mechanism of the ERK pathway in both humans and canines starts at the tyrosine kinase receptor EGFR. Once activated by a ligand, the receptor undergoes autophosphorylation (Pierre et al. 2011).  GRB2 acts as an adaptor between the EGFR and SOS1 or SOS2 proteins. It binds to the intracellular component of the transmembrane EGFR, resulting in relocation of the SOS1 or SOS2 protein to the membrane where it also binds to GRB2. The SOS protein in turn interacts with the rat sarcoma viral (RAS) protein through two domains: one that is the active site for nucleotide exchange and the other that is responsible for autoinhibition. The phosphorylation cascade continues on to rapidly accelerated fibrosarcoma 1 (Raf1), followed by MAP2K then MAPK (Roskoski 2012). The MAPK then interacts with transcription factors c-Myc and SAP-1 (Whitmarsh and Davis 1996). These transcription factors interact with one of the three transcriptional control elements of the Finkel–Biskis–Jinkins murine oestrogenic sarcoma virus (FOS) promoter to enhance transcription of FOS protein which forms transcription factor complexes which alters cellular growth and differentiation (Figure 4.4).  
 
Within the ERK1/2 pathway several genes showed statistically significant expression changes between the HHG-affected and HHG-unaffected foxes with the microarray or RT-qPCR data. The protein kinase C zeta (PRKC]) and RAS p21 protein 
activator (GTPase activating protein) 1 (RASA1) genes were of particular interest.  
PRKC] is a member of the AGC Ser/Thr protein kinase family, belonging to the atypical protein kinase C subfamily that works independently of calcium 
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!!Figure!4.4:!Diagram!of!several!steps!in!the!extracellular!signal<regulated!kinase!(ERK)!sub<pathway!of!the!mitogen<activated!protein!kinase!(MAPK)!pathway!in!canines,!highlighting!genes!differentially!expressed!on!the!microarray!or!in!the!RT<qPCR!results!in!foxes!affected!with!hereditary!hyperplastic!gingivitis!(HHG).!Adapted!from!Kelder,!van!Iersel,!Hanspers,!Kutmon,!Conklin,!Evelo!and!Pico!2011.
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(Hirai!and!Chida!2003).!RASA1!is!an!inhibitor!of!RAS!by!accelerating!the!GTPase!hydrolysis!reaction!converting!guanosine@5'@triphosphate!(GTP)!to!guanosine@5'@diphosphate!(GDP)!thus!inactivating!RAS!(Rudack!et'al.!2012).!In!the!ERK!pathway!both!gene!products!act!upon!RAS:!PRKCζ!activates!it!while!RASA1!inhibits!it!(Figure!4.4).!According!to!the!microarray!data,!PRKCζ'is!significantly!down@regulated!in!HHG@affected!foxes,!while!RASA1!is!significantly!up@regulated.!The!combined!effect!of!the!differential!expression!of!these!two!genes!results!in!the!decreased!activity!of!
RAS.!!!One!hypothesis!for!the!differential!expression!of!the!ERK!pathway!in!HHG!is!that!the!putative!mutation!occurs!before!the!RAS!gene.!Upstream!of!the!RAS!gene!in!this!signalling!cascade,!two!other!genes!demonstrated!an!up@regulation!in!the!HHG@affected!compare!to!the!HHG@unaffected!foxes!in!the!microarray!analysis,!the!
epidermal'growth'factor!(EGF)!and!son'of'sevenless'homolog'2!(SOS2)!genes.!The!hypothesis!is!that!if!the!EGF!signal!is!mutated,!then!the!downstream!SOS2!gene!product!would!in!turn!be!up@regulated!in!the!HHG@affected!samples.!Alternatively,!given!the!similarity!between!SOS1!and!SOS2,!and!the!fact!that!SOS1!contains!the!putative!mutation!for!HGF1!in!humans,!perhaps!SOS2'carries!the!HHG!causative!mutation.!The!differential!expression!of!RASA1!and!PRKCζ'could!then!represent!a!compensatory!mechanism!to!offset!increases!in!RAS!expression.!Nonetheless!the!up@regulation!of!FOS!downstream!in!the!pathway!(statistically!significant!with!the!RT@qPCR!assay)!indicates!that!this!strategy!is!only!partially!successful,!and!further!implicates!this!pathway!in!HHG.!
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qPCR assay) indicates that this strategy is only partially successful, and further implicates this pathway in HHG.  Interpreting global expression data is a complex process whereby it can be difficult to determine how the normal expression pattern changes in response to the disease process. In the case of HHG, the disease process can be altering several pathways simultaneously, some directly due to the underlying disease mutation and others in response to the disease process. In addition HHG is associated with a superior fur quality meaning that the complex process might change depending on the tissue type that is being examined. To help eliminate some of this complexity our study design only examined gene expression in the gingival tissue. In addition, we utilized known and speculated genetic information about the analogous disease HGF as a starting point when exploring potential pathways, to help determine what pathways were more likely involved in pathogenesis as opposed to in reaction to the disease.   The canine genome has enabled genetic investigation in Vulpes (Kukekova et al. 2004). While conducting a microarray experiment based upon genomic similarities between these species enables new avenues for research in non-traditional model organisms, it creates new challenges. This study dealt with two major challenges. The first was the cross-species microarray hybridization. While the dog and fox are evolutionarily closely-related, a non-exact match to a probe set could result in the loss of signal and thus loss of the ability to detect potential differential expression (Kukekova et al. 2004; Wayne et al. 1997). The second major obstacle was utilizing 
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near-wild animal samples in a controlled experimental design. While the fox samples collected were from fox farms, the animals are still biologically diverse when compared to laboratory-bred model organisms. These obstacles might account for some of the discrepancies seen between the microarray and RT-qPCR data. This however does not discount the general trends that we discuss.   
Conclusions  Thorough examination of the genetic loci involved in HGF in comparison to the fox HHG microarray experiment has led to several significant findings. First, the SOS1 mutation that causes HGF1 is not causative of HHG, a result confirmed by sequence analysis (Clark et al. 2014a). Second, we find evidence that androgens play a role in the HHG phenotype, as indicated by the increased expression of SRD5A2 in the HHG-affected foxes. Third, microarray and RT-qPCR analysis support the involvement of the MAPK pathway in HHG, as has been suggested for HGF1 and HGF2. We recommend further investigation of this pathway, specifically with respect to pathway members upstream of RASA1, including EGF and SOS2, to determine the HHG-causative mutation, both with single gene sequencing, and whole exome sequencing. 
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Chapter Five: 
Examination of hereditary hyperplastic gingivitis in association with superior 
fur quality in farmed silver foxes using canine microarrays and candidate 
gene sequencing  
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Introduction Hereditary hyperplastic gingivitis (HHG) presents as tumour-like growths of the gingival tissue on the mandible in farmed silver foxes, a coat colour variant of the red fox (Vulpes vulpes) (Dyrendahl and Henricson 1960). HHG is characterized by progressive proliferation of the gingival tissues starting at approximately two to three years of age leading to the encapsulation of the teeth and inhibition of normal function. The HHG inheritance pattern is autosomal recessive with sex-biased penetrance displaying an increased occurrence in males over females (Dyrendahl and Henricson 1960). HHG frequently co-occurs with superior fur quality, described as length and thickness of guard hairs, suggesting that a pleiotropic relationship is responsible for both phenotypes. Despite its discovery in Sweden in the 1940s (Dyrendahl and Henricson 1960) this disease was only documented in Newfoundland and Labrador, Canada, in 2004, when Finnish foxes selected for their denser, longer fur quality were introduced into the breeding population of farmed Canadian silver fox lines (Figure 5.1) (Clark et al. 2015). The molecular aetiology of HHG and its association with fur quality remain unknown.  Human hereditary gingival fibromatosis (HGF), an analogous condition to HHG, is a rare disease of the oral cavity with progressive benign fibrous enlargements of the maxillary and mandibular keratinized gingival tissue (Hart et al. 2002). HGF affects both sexes equally and average disease onset occurs during permanent dentition, with progression worsening through adolescence (Breen et al. 2009; Coletta and Graner 2006; Fletcher 1966). While its underlying origin and cellular mechanisms  
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  Figure 5.1: Initial hereditary hyperplastic gingivitis presentation in original Finnish silver foxes in 2004 (Photos provided by Robert Hudson)                                 
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are still mostly unknown, HGF can be broadly classified as primary or secondary HGF (Shashi et al. 1999). Primary HGF can be further divided into genetic aetiologies and HGF-associated syndromes, while secondary HGF involves an acquired drug-induced HGF phenotype. The focus to date has been on the understanding the genetic aetiologies of HGF with little focus on the HGF-associated syndromes.    Syndrome-associated HGF presents with high phenotypic variability (Haytac and Ozcelik 2007). The most commonly associated presentation with HGF is hypertrichosis (Coletta and Graner 2006). This association can occur with or without mental retardation and displays a dominant inheritance pattern (Coletta and Graner 2006). Haplotype analysis and linkage studies have demonstrated that when HGF with hypertrichosis occurs, it is not linked to two other known, genetic forms of HGF (HGF1 and HGF2) suggesting a distinct genetic form and aetiology of HGF (Mangino et al. 2003).   Hypertrichosis is defined as an abnormal excess of hair growth that is not primarily androgen dependent nor influenced by race, sex or age (Beighton 1970).  The incidence estimates of this rare condition have been about one in a billion but as these do not account for hypertrichosis in association with numerous syndromes they are probably under-estimates (Beighton 1970; Garcia-Cruz et al. 2002). Hypertrichosis can be broadly split into congenital or acquired categories, and the congenital category is divided based on a general or localized hair distribution. The generalized distribution is considered a syndrome and is further subdivided 
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according to whether the hypertrichosis is the primary or secondary syndrome characteristic. The subtypes with gingival hyperplasia are classified as syndromes with hypertrichosis as the primary symptom, and include congenital hypertrichosis lanuginose (CHL) and gingival fibromatosis with hypertrichosis. In addition, there is a group of syndromes with hypertrichosis and acromegaloid facial features with or without gingival fibromatosis, for example Cantu syndrome, that are thought to be phenotypic variations of the same disease (Czeschik et al. 2012).   HHG and HGF are diseases with similar manifestations and presentations; in particular the HGF-associated syndrome with hypertrichosis is similar in presentation to HHG-affected foxes with longer denser fur qualities. The goal of this study was to combine the current knowledge of HGF-associated syndromes with hypertrichosis with the genome-enabling capacity of the dog genome to examine potential molecular and cellular pathways involved in silver fox HHG. Utilization of a cross-species platform is supported by karyotyping, cytogenetic genome markers and gene sequence comparisons between Vulpes vulpes and Canis lupus familiaris that provide strong evidence supporting the close relationship between the two species (Switonski et al. 2009). Specifically, the Affymetrix GeneChip Canine Genome 2.0 Array was employed to compare the global gene expression patterns of HHG-affected farmed silver foxes and HHG-unaffected farmed silver foxes. We conducted an extensive review of the congenital forms of hypertrichosis with gingival fibromatosis in humans and examined their known chromosomal regions and in the context of the HHG microarray expression patterns. In addition we report candidate 
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gene sequencing based mutational analysis of the mitogen activated protein kinase 
kinase 6 (MAP2K6) gene in the silver fox, for which a role in hypertrichosis has been debated (Sun et al. 2009).  
 
Materials and Methods Please see chapter four (Pages 87-92) for description of sample collection, RNA preparation and microarray experiment and analysis.  
 
Microarray analysis Using the NCBI human genome build 36.3 gene lists were created based on the genes found within the chromosomal loci 17q24.2-q24.3 and 8q22, which are known to be associated with hypertrichosis with gingival fibromatosis (http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9606&query=human&SITE=HumanGuide&SUBMIT=y&submit=Go). These gene lists were cross-referenced to the microarray expression results and annotated with gene names and functions using NetAffx Analysis Centre (Affymetrix Inc., Santa Clara, USA). Additionally, genes were placed in Wikipathways to investigate involvement in known canine signalling pathways (Kelder et al. 2011).   
Reverse transcription quantitative PCR (RT-qPCR) cDNA was transcribed from total RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems Inc., Foster City, USA).  Initial RT-qPCR assays were conducted in house or at the Microarray Facility at the Toronto Centre for Applied Genomics, 
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Hospital for Sick Children in Toronto, Canada (see Appendix 2). For each assay, 
ͳͲɊȋʹȌͳɊ
ne Expression Assay (20X; 900 nM primer and 250 nM probe) (Applied Biosystems Inc., Foster City, USA.). Reaction mixtures were placed into MicroAmp Fast Optical 96-Well Reaction Plates (Applied Biosystems Inc., Foster City, USA.) and subjected to thermal cycling in the StepOnePlus Real Time PCR System (Applied Biosystems Inc., Foster City, USA.) according to the following profile: 50qC for 2 minutes, 95qC for 10 minutes, and 40 cycles of 95qC for 15 seconds, 60qC for 1 minute. A selection of MAPK signalling pathway genes (Assay ID) were selected for RT-qPCR testing including: Ⱦ͹ (
	Ⱦ͹) (Cf02625275_m1), mitogen-
activated protein kinase kinase kinase 6 (MAP2K6) (Cf02683089_m1) and mitogen-
activated kinase kinase kinase 1 (MAP3K1) (Cf02635276_m1). As the endogenous control gene, elongation factor, RNA polymerase II (ELL2) (Cf02707156_m1) was selected for the in house RT-qPCR, and the breakpoint cluster region (BCR) (Cf02664178_m1) for the remaining RT-qPCR samples.  Relative quantifiȟȟ (Livak and Schmittgen 2001). For the in house RT-qPCR the unaffected sample with the lowest standard error was selected as the reference sample while for the remaining RT-qPCR samples the unaffected sample with the lowest expression was selected as the reference sample. Fold changes were calculated using Log2RQ method and the relative fold changes were tested for significance with two-tailed t-tests. All samples were tested in triplicate and samples with a standard deviation greater than 0.5 
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were removed from the dataset. Any samples that were identified as outliers within biological groups according to Data Assist v3.0 (Life Technologies, Grand Island, USA) were also discarded. Validation experiments were conducted to standardize amplification efficiency.  
Primer design for candidate gene sequencing Primers were designed using the Canis lupus familiaris sequences with GenBank Accession Number NC_006591.3, found on chromosome 9, for the MAP2K6 gene (http://www.ncbi.nlm.nih.gov/). Primer pairs were selected from the intronic regions flanking each target region using NCBI Primer Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All parameters were set to default except for the ǲPrimer Melting Temperaturesǳ which were as follows: 
ǣ͸ͷͼǢǣͷͲͼǢ
ǣͷ͹ͼǤs were manufactured by Operon Inc. as PCReady primers (Huntsville, USA). Refer to Appendix 1 for primer sequences.  
DNA preparation and polymerase chain reaction (PCR) DNA extractions were performed with the QiaAmp DNA Mini kit (Qiagen Inc., Mississauga, CȌǯ for six HHG-affected and six HHG-unaffected samples. Each PCR contained 2.5 PL of 10X buffer, 0.5 PL dNTPs (New England Biolabs Ltd., Whitby, Canada), 1 PL of 10 PM forward primer, 1 PL of 10PM reverse primer, 0.2 PL of ͷȀɊHot Star Taq Plus (Qiagen Inc., Mississauga, Canada), 15 PL distilled nuclease free water and 1 PL 
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template DNA. The thermal profile used was 95°C for 5 minutes, followed by 35 cycles of 94°C for 30 seconds, target-specific annealing temperature for 30 seconds, and 72°C for 1 minute, followed by 72°C for 10 minutes. Amplified PCR products were purified using either Pall Life Sciences Multi-Well Plate Manifolds (Pall Corporation, Port Washington, USA) or the QIAquick PCR purification kit (Qiagen Inc., Mississauga, Canada). Target-specific annealing temperatures were as recommended by the primer selection software. PCR products were tested using 1.5% agarose gel electrophoresis  
DNA sequencing and analysis DNA sequencing reactions were performed with both forward and reverse primers for each PCR amplicon using BigDye Terminator v3.0 chemistry (Applied Biosystems Inc., Foster City, USA) utilizing the following thermal profile: 96°C for 6 minutes, then 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes.  Sequencing reaction purification was carried out using either ethanol precipitation or an Agencourt CleanSeq method (Beckman Coulter Inc., Danvers, USA). Purified DNA sequencing reactions were electrophoresed on the Applied Biosystems Inc. 3730 DNA Analyzer, in the GaP Facility of the CREAIT Network at Memorial University of Newfoundland and at Genome Quebec located at McGill University. For detailed primer pair sequences, annealing temperatures and amplicon lengths refer to Appendix 1.  
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Raw data was collected using Sequence Analysis v5.2 (Applied Biosystems Inc., Foster City, USA) and imported into Sequencher v4.8 (Gene Codes Corp., Ann Arbor, USA). Contigs were created by assembling reads to the reference sequence, Accession Number NC_006591.3 (chromosome 9) using an 85% minimum gap percentage and a 20% minimum overlap, followed by manual trimming and editing of each sequence read. Sequence was submitted to NCBI.   
Results Differential gene expression in HHG-affected compared to HHG-unaffected silver foxes based on the Affymetrix GeneChip Canine Genome 2.0 Array, 43,035 gene ID probes in both the HHG-affected and HHG-unaffected groups were analyzed. Of these, 1,154 probesets demonstrated a statistically significant differential gene ID probe expression when comparing the HHG-affected to HHG-unaffected samples as determined by a Mann-Whitney t-test (P< 0.05). 508 probesets demonstrated at least a two-fold differential up-regulation when comparing HHG-affected foxes to HHG-unaffected foxes and 446 Probe IDs demonstrated a least a two-fold differential down-regulation when making the same comparison.  Figure 5.2 demonstrates the general expression trend comparison between the HHG-affected and unaffected samples for a selection of RT-qPCR genes involved in the MAPK signalling cascade. The 
	Ⱦ͹ gene showed a statistically significant fold change (P<0.05) (Table 5.1). 
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 Figure 5.2: Mean log2 relative expression (log2RQ) values for RT-qPCR genes in the hereditary hyperplastic gingivitis (HHG)-affected and HHG-unaffected fox samples. Standard errors are indicated by the bars.            
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Table 5.1: Differential expression of genes in hereditary hyperplastic gingivitis-affected foxes compared to unaffected foxes from quantitative polymerase chain reaction (RT-qPCR) validation assays, compared with fold-change found by microarray analysis   
Gene 
symbol 
Gene name RT-qPCR Microarray 
  Fold 
change 
P 
value 
Affymetrix  
probe ID 
Fold 
change 
P value 
 MAP2K6 Mitogen-activated protein kinase kinase 6 
-1.106  NA* CfaAffx.16824.1.S1_at  -1.203  0.250  
MAP3K1 Mitogen-activated protein kinase kinase kinase  
-2.313  0.112  Cfa.19524.1.S1_at  -1.959  0.071  

	Ⱦ͵ Transforming growth factor beta 3 3.603  0.026  CfaAffx.26185.1.S1_at  1.084  0.788 
 *NA Insufficient samples present in triplicate to perform a t-test               
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Comparison of gene expression patterns from microarrays to chromosomal loci 
associated with hypertrichosis with gingival fibromatosis  There are a number of congenital hypertrichosis syndromes that occur with gingival overgrowth, including CHL, Cantu syndrome and hypertrichosis with gingival  fibromatosis (Garcia-Cruz et al. 2002). Genes within the loci for each of these syndromes were examined and compared with the differential expression HHG-affected versus HHG-unaffected microarray data in the silver fox samples.  In humans, CHL is associated with chromosomal region 8q22-24 (Tadin et al. 2001). NCBI human genome build 36.3 contained 215 genes in this chromosomal region (accessed July 2013). Eighty-two of those genes correspond to equivalent known canine genes. On the Affymetrix GeneChip Canine Genome 2.0 Array those 82 genes were represented by 170 probesets. Five of those probe IDs demonstrated statistically significant expression differences (Mann Whitney P<0.05) and an additional nine when the requirement for statistical significance was relaxed to P<0.10 to account for the high biological diversity of the samples (Table 5.2). These 14 probe IDs represented 11 different genes with three that were differentially up-regulated in the HHG-affected versus HHG-unaffected fox samples and eight that were differentially down-regulated in the same comparison.   Cantu syndrome in humans has a putative causative mutation in the ATP-binding 
cassette, sub-family C member 9 (ABCC9) gene (Czeschik et al. 2012). There is a   
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Table 5.2: Microarray-identified differential expression in hereditary hyperplasticgingivitis (HHG)-affected foxes to unaffected foxes for genes found in the human chromosome loci associated with hypertrichosis occurring with gingival overgrowth  
Gene 
symbol 
Gene name Human 
chromosome 
region 
Fold change P value 
ABCA5 
 
 
ATP-binding cassette, sub-family A, member 5  17q24.2-q24.3   1.022   0.393   ABCA6 ATP-binding cassette, sub-family A, member 6  17q24.2-q24.3   1.014   0.571   MAP2K6 Mitogen-activated protein kinase kinase 6 17q24.2-q24.3  -1.203  0.250  PITPNC1 Phosphatidylinositol transfer protein, cytoplasmic 1 17q24.2-q24.3   1.358   0.036 OXR1 Oxidation resistance 1 8q22 -1.288 0.036 NCALD Neurocalcin delta 8q22 -1.232 0.036 MED30 
 
Mediator complex subunit 30 8q22 -1.789 0.036 COL14A1 
 
Collagen, type XIV, alpha 1 8q22 1.242 0.036 AZIN1 Antizyme inhibitor 1 8q22 -1.228 0.036 TAF2 
 
 
TATA box binding protein associated factor 8q22 -1.258 0.071 RPL30 Ribosomal protein L30 8q22 -1.303 0.071 RAD21 RAD21 homolog 8q22 -1.431 0.071 NUDCD1 
 
NudC domain containing 1 8q22 -1.551 0.071 KIAA1429 KIAA1429 ortholog 8q22 1.124 0.071 CPQ 
 
Carboxypeptidase Q  8q22 1.122  0.071        
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homologous gene in the canine microarray represented by two probe IDs. Both probe IDs demonstrated an up-regulation in the HHG-affected compared to the HHG-unaffected microarray fox samples but not significantly so (P>0.10). The ABCC9 protein is part of an ATP potassium-sensitive channel composed of four pore-forming subunits of either KCNJ8 or KCNJ11 and four regulatory subunits of the ABCC9 protein (Harakalova et al. 2012). KCNJ8 and KCNJ11 microarray gene expression levels were examined and neither showed any statistically significant differential expression (P>0.10). Hypertrichosis with gingival fibromatosis is associated with the chromosome region 17q24.2-q24.3 in humans (Sun et al. 2009) and this region contains the following genes: ABCA5, ABCA6, ABCA10 and MAP2K6.  ABCA10 was not on the Affymetrix GeneChip Canine Genome 2.0 Array, nor was a description of the gene found in NCBI for canines. The remaining genes were compared to the HHG microarray data but none yielded a statistically significant differential expression with a Mann Whitney t-test at P<0.05  (Table 5.2). The 
MAP2K6 gene did show statistically significant (P<0.05) differential expression in the RT-qPCR assay with a down-regulation of the gene in the HHG-affected foxes compared to the unaffected foxes (Table 5.1). NCBI human genome build 36.3 listed 36 genes within that chromosome region (accessed July 2013). Of these there were 20 canine equivalents that were represented on the Affymetrix GeneChip Canine Genome 2.0 Array by 46 probe IDs. Of those probe IDs, the Phosphatidylinositol 
Transfer Protein, Cytoplasmic 1 (PITPNC1) gene showed was significantly (P<0.05) differentially up-regulated in the HHG-affected versus HHG-unaffected microarray fox samples. 
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Mutational differences between affected and unaffected foxes in the MAP2K6 gene The MAP2K6 gene was sequenced for six HHG-unaffected foxes and six HHG-affected foxes. There was 100% coverage of the protein-coding region and the intron/exon boundaries for several HHG-affected and several HHG-unaffected animals.  There were no fixed mutations segregating the HHG-affected from the HHG-unaffected sets of samples in any of coding portions or intron/exon boundaries of the MAP2K6 gene, nor were there any apparent fixed heterozygous sites.   
Comparison of HHG microarray gene lists to MAPK pathway genes  The canine c-Jun N-terminal kinase (JNK), and p38; portions of mitogen-activated protein kinase (MAPK) signalling cascade; were examined using Wikipathways (Kelder et al. 2011) to determine if any significantly differentially expressed genes within the fox HHG-affected vs. HHG-unaffected microarray comparison could be identified. Three genes showed statistically significant differential expression (Mann-Whitney t-test P< 0.05) and four in total with a relaxed Mann Whitney criterion (P< 0.10) (Table 5.3). Of these four genes, one showed up-regulation in the HHG-affected samples and three showed down-regulation in the HHG-affected samples compared to the HHG-unaffected samples. 
 
Discussion HHG is a condition that occurs predominantly in the farmed silver fox population, where HHG appears to have been selected when choosing to breed animals with  
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Table 5.3: Microarray analysis of differential expression of hereditary hyperplastic gingivitis (HHG)-affected foxes to unaffected foxes for genes found in the c-Jun N-terminal kinase (JNK) and p38 portions of the mitogen-activated protein kinase (MAPK) signalling cascade 
  
Gene symbol Gene title Fold change Mann Whitney P 
value CASP6 Caspase 6, apoptosis-related cysteine peptidase -1.213  0.036 IL1B Interleukin 1, beta 1.189 0.036 MAP3K1 Mitogen-activated protein kinase kinase kinase 1 -1.959 0.071 MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 -1.270 0.036               
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longer, denser fur (Dyrendahl and Henricson 1960). HGF is an analogous condition in humans with a complex aetiology. The genetic basis of syndromic HGF associated with hypertrichosis is distinct from the isolated genetic forms of HGF (Coletta and Graner 2006; Mangino et al. 2003). While often viewed as separate but co-occurring, fibromatosis and hypertrichosis may be different phenotypic expressions of a common ectodermal or mesodermal congenital abnormality (Lee et al. 1993). Here we use a canine microarray platform to investigate the aetiology of hypertrichosis with HHG in the context of what is known about the genetic basis of the human syndrome.  
Comparison of HHG microarray gene lists to chromosomal loci of gingival fibromatosis 
associated with hypertrichosis CHL is often referred to as Ambras syndrome after paintings that were discovered in the Ambras castle in Austria depicting the child Peter Gonzales, who had this form of hypertrichosis (Freire-Maia et al. 1976). The main features of CHL are the excessive growth of lanugo hair and dental abnormalities (Garcia-Cruz et al. 2002). Typically the latter involve the delayed presentation of primary and secondary teeth as well as the absence of some teeth (Tadin et al. 2001). However, there has been a report of a sporadic case of CHL with mild gingival hyperplasia (Lee et al. 1993). CHL has autosomal dominant inheritance with the occurrence of sporadic cases (Tadin et al. 2001). The CHL mutation has been mapped to the 8q22-q24 chromosomal region (Tadin et al. 2001). The HHG microarray demonstrated 11 genes with a statistically significant (P<0.10) differential expression between the HHG-affected and HHG-
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unaffected fox samples. While none of these genes is thought to contain the causative mutation, their expression levels and possible contributions to disease phenotype are of note. Of particular interest was the COL14A1 gene. The COL14A1 gene was up-regulated in the HHG-affected foxes compared to the HHG-unaffected foxes. This gene encodes collagen 14 protein produced by fibroblasts, myofibroblasts and hepatic stellate cells during late embryogenesis (Ruehl et al. 2005). It plays a role in cellular quiescence and differentiation, such as during wound healing, and has been known to induce fibroblast differentiation (Ruehl et al. 2005). As HGF is associated with a more friable tissue (Clark et al. 2015) it is plausible that the increased need for wound healing has resulted in the up-regulation of this gene.   Cantu syndrome is classified primarily with hypertrichosis, cardiomegaly and bone abnormalities and can result from autosomal dominant or recessive inheritance (Kurban et al. 2011). While typically not associated with gingival fibromatosis it is thought that Cantu syndrome along with the phenotypes of acromegaloid with or without hypertrichosis and gingival fibromatosis are variations along a spectrum of the same disease (Czeschik et al. 2012). The putative causative mutation of this condition is in the ABCC9 gene, located at 12p12.1. In the silver fox microarray study the gene is up-regulated in HHG-affected compared to the HHG-unaffected fox samples but not significantly so. Although the HHG-affected foxes have both gingival and hair overgrowth they do not show the bone or cardiac abnormalities associated 
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with Cantu syndrome. Hence it is unlikely that ABCC9 is involved in HHG, although RT-qPCR validation of the up-regulation and mutational analysis may challenge this.   Gingival fibromatosis with hypertrichosis is an autosomal dominant condition with terminal hair covering the face, trunk and eyebrows, with progressive gingival hyperplasia starting in childhood (Wendelin et al. 2003). It is associated with chromosomal region 17q24.2-24.3 (Sun et al. 2009). Of interest, this region contains several members of the ATP binding cassette transporter family A (ABCA) family of genes, MAP2K6, and the PITPNC1 gene. The ABCA is a large family of proteins (Albrecht and Viturro 2007).  ABCA5 has been found in lysosomes and endosomes and is thought to be involved in intracellular trafficking (Kubo et al. 2005). In rat mRNA expression the ABCA5 transcript has been identified in Leydig cells where testosterone production occurs (Petry et al. 2006). ABCA5 was down-regulated in both male and female HHG-affected fox samples when compared to the unaffected samples so the gingival fibromatosis phenotype is unlikely to be associated with Leydig cell biological function. However, in dogs, the gingival tissue is androgen sensitive, such that testosterone exacerbates the phenotypic presentation of gingival hyperplasia (Pariser and Berdoulay 2011). If the fox gingival tissues are similar to the canine counterpart then the down-regulation of the ABCA5 gene may be in response to the already hypertrophied androgen-sensitive gingival tissue. ABCA6 is responsive to cholesterol concentrations and is up-regulated during macrophage differentiation (Kaminski et al. 2001).  The up-regulation of ABCA6 in the HHG-affected foxes could be related to disease aetiology, although it is plausible that it 
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may be up-regulated as part of an inflammatory response in the gingival tissue leading to an increase in macrophage differentiation.   In the human genome version 36.3 the PITPNC1 gene is identified in the 17q24.2-24.3 chromosomal region and this gene was up-regulated in the HHG-affected foxes when compared to the HHG-unaffected foxes. The PITPNC1 Ⱦprotein, a Class IIB PIP protein subfamily (Cockcroft 2012)ǤȾtightly regulated, with a substantial level of expression in cardiac and renal tissue (Garner et al. 2011). This protein has been implicated in a variety of processes and the full scope of it biological roles is unknown (Trivedi and Padinjat 2007). One of its roles is during wound healing (Gu and Iyer 2006).  As previously mentioned HGF is a delicate tissue prone to injury (Clark et al. 2015) contributing to an increased need for wound healing, potentially explaining the up-regulation of this gene.  
Candidate gene, microarray, and RT-qPCR analysis of the MAP2K6 gene in HHG-
affected foxes The original interest in the 17q24.2-24.3 chromosomal region was in the MAP2K6 gene (Sun et al. 2009) . While other MAPK pathway proteins have been implicated in both hair growth and gingival overgrowth conditions there was some debate about the MAP2K6 gene involvement in the combined phenotype (Hart et al. 2002; Sun et 
al. 2009). In 2008, a human case was reported with a 2.3Mb deletion encompassing this gene that did not result in either hypertrichosis or gingival overgrowth (Blyth et 
al. 2008). The microarray analysis of this gene showed a differential down-
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regulation in the HHG-affected foxes compared to the HHG-unaffected foxes but this difference was not statistically significant. RT-qPCR however confirmed the differential down-regulation in the HHG-affected fox samples again without statistical significance. Depending on the nature of the mutation however and due to the inherent biological variability this does not definitely rule it out as a putative HHG gene.  Mutational analysis of the coding regions and exon-intron splice sites of the MAP2K6 gene did not show any putative candidate mutations within HHG-affected foxes in this gene. The MAP2K6 gene did demonstrate variability between the fox sequences and the Canis reference sequence. In particular, exon 3 carried a nonsynonymous sequence difference between the dog and the foxes, which was variable within foxes. In dogs, the sequence is CGT (codon for histidine) while in the fox samples the variant form of this same allele was CAT (arginine). Although some foxes were heterozygous for these two alleles, there were no fixed differences between affected and unaffected individuals. While MAP2K6 does not appear to be the causative gene for HHG at least with respect to coding portion of the gene, it is possible that allelic variations contribute to phenotype severity; for example this amino acid change could potentially result in a greater propensity for foxes to develop HGF. The absence of a putative mutation does not completely exclude the possibility of the 
MAP2K6 gene involvement in the phenotype of HHG with hypertrichosis as it is still 
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leads an enhanced expression of the gene. The expression pattern we observe supports the potential involvement of this pathway in the HHG presentation.  
Mitogen activated protein kinase pathway Emphasis has been placed on the MAPK signalling pathway with a direct link to several of the known isolated genetic forms of HGF and again its role in hypertrichosis with gingival fibromatosis, warranting a further examination in the MAPK pathway (Hart et al. 1998; Sun et al. 2009; Xiao et al. 2001). MAPK signalling starts with a signal that is transmitted through a receptor that in turn activates a multi-tier cascade of mitogen-activate protein kinase phosphorylations ultimately resulting in a cellular event at the nucleus (Yang et al. 2013) (Figure 5.3). MAP2K6 signalling occurs in the c-Jun N-terminal kinase (JNK), and p38 sub-pathways in the MAPK signalling schematic (Krishna and Narang 2008; Wang and Tournier 2006). The p38 and JNK pathways are activated by signals such as interleukin B (ILB), transforming growth factor beta (TGFȾ) and stress and end within a common pathway of cell proliferation, differentiation or cellular apoptosis (Kim and Choi 2010). Based on both the microarray and RT-qPCR data there are several genes for both the JNK and p38 pathways demonstrating a differential expression between the HHG-affected and unaffected samples.   
At the start of the JNK pathway is the cellular signal interleukin 1, beta (IL1B) which is up regulated in the HHG-affected foxes. After the receptor the caspase 6, apoptosis-
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!Figure!5.3:!Diagram!of!several!steps!in!the!c;Jun!N;terminal!kinase!(JNK),!and!p38!sub;pathway!of!the!mitogen;activated!protein!kinase!(MAPK)!pathway!in!canines,!highlighting!genes!differentially!expressed!on!the!microarray!or!in!the!RT;qPCR!results!in!foxes!affected!with!hereditary!hyperplastic!gingivitis!(HHG).!Cross!talk!between!the!pathways!not!illustrated.!Adapted!from!Kelder,!van!Iersel,!Hanspers,!Kutmon,!Conklin,!Evelo!and!Pico!2011.!
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related'cysteine'peptidase'(CASP6)!adapter!protein!is!down!regulated!in!the!HHG7affected!foxes.!Subsequent!MAPK!proteins!mitogen6activated'protein'kinase'kinase'
kinase'kinase'1!(MAP4K1)!and!mitogen6activated'protein'kinase'kinase'kinase'
1(MAP3K1)!also!display!down!regulation!in!the!HHG7affected!foxes!all!with!statistical!significance!(P<0.100).!While!the!downstream!portion!of!the!pathway!did!not!display!any!statistically!significant!differential!expression!the!general!trend!appears!to!be!a!down!regulation!of!this!part!of!the!MAPK!pathway.!The!p38!pathway!shows!the!inverse!trend.!This!pathway!had!two!up7regulated!cellular!signals!including!TGFβ3!and!the!previously!mentioned!IL1Bwhich!acts!as!a!signal!for!both!pathways!(Kelder!et'al.!2011).!The!MAP2K6!gene,!which!was!down7regulated!in!the!HHG7affected!foxes.!As!the!end!of!this!and!the!JNK!pathway!is!the!same!we!cannot!comment!on!the!overall!affect!of!the!up7regulation!of!the!upstream!members!of!this!pathway.!One!hypothesis!for!the!combined!trend!is!that!the!JNK!portion!of!the!pathway!is!down7regulated!in!the!HHG7affected!foxes!as!a!compensatory!mechanism!for!the!up7regulation!of!the!p38!portion!of!the!pathway!in!the!HHG7affected!foxes!when!compared!to!the!HHG7unaffected!foxes.!Another!hypothesis!is!that!the!portions!of!the!pathway!that!are!associated!with!apoptosis,!like!CASP6,!are!down7regulated!to!prevent!death!adding!to!the!lifespan!of!the!hypertrophied!cells.!While!DNA!sequencing!has!shown!no!mutation!in!the!coding!region!of!the!MAP2K6!gene!the!overall!pattern!of!differential!gene!expression!in!the!MAPK!pathway!still!calls!its!involvement!into!question.!!!
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Hypertrichosis and gingival hyperplasia have overlapping phenotypic presentations that could support the notion of a shared underlying aetiology. Using the HHG-affected versus HHG-unaffected microarray platform the expression of genes in known hypertrichosis regions were explored. While a putative gene was not determined the expression of various genes helps to uncover potential contributing mechanisms such as the MAPK pathway involvement. While there was no putative mutation found in the MAP2K6 gene in the coding region, the overall differential gene expression trend still suggests involvement of the MAPK pathway. 
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Hereditary!hyperplastic!gingivitis!(HHG)!is!a!rare!disease!that!is!characterized!by!the!progressive!proliferation!of!the!gingival!tissues!with!fibrous!overgrowths!that!inhibit!normal!functions!like!mastication!and!is!found!predominantly!in!ranched!silver!foxes!(Vulpes'vulpes)!(Dyrendahl!and!Henricson!1960).!Despite!the!existence!of!documentation!as!early!as!the!1940s,!little!is!known!about!the!molecular!mechanisms!underpinning!its!prolific!phenotype.!Analogous!conditions!occur!in!both!humans!and!dogs!that!can!aid!in!providing!clues!into!the!silver!fox!variant!using!both!candidate!gene!and!genome!expression!microarray!approaches!(Hale!2004;!Hart!et'al.!1998).!The!first!goal!of!this!thesis!was!to!document!its!emergence!in!Canada!and!perform!a!detailed!examination!on!both!the!genetics!and!histological!features!of!the!disease.!The!second!goal!was!to!explore!the!molecular!mechanisms!underpinning!the!HHG!phenotype,!using!a!combination!of!candidate!gene!studies!and!examination!of!the!HHG!phenotype!at!the!level!of!genome!wide!expression.!!!The!functional!candidate!gene!analysis!was!used!to!examine!the!DNA!sequences!of!the!exonic!coding!regions,!exonOintron!boundaries!and!partial!introns!of!SOS1,!the!known!causative!gene!of!HGF1!in!humans!(Hart!et'al.!2002),!as!well!as!the!closelyOassociated!GRB2,'and'EGFR!genes!from!both!affected!ranched!silver!foxes,!a!coat!colour!variant!of!the!red!fox,!and!unaffected!wild!red!foxes!were!compared.!Inferences!were!also!made!about!the!rates!and!patterns!of!evolution!of!the!SOS1,'
GRB2!and'EGFR'genes.!!!
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Examining!HHG!from!the!genomic!standpoint!allowed!for!the!integration!of!the!current!knowledge!of!the!analogous!condition!in!human,!HGF.!This!exploration!was!divided!into!examining!both!the!known!isolated!genetic!causes!of!HGF!and!the!main!HGFOassociated!syndromes.!For!the!isolated!genetic!causes,!I!explored!the!many!potential!facets!contributing!to!the!HHG!phenotype!by!reviewing!the!literature!and!the!main!cell!signalling!pathway!highlighted!therein,!as!well!as!looking!for!new!insights!by!close!examination!of!each!mapped!HGF!locus.!The!HGFOassociated!syndrome!portion!focused!on!known!genetic!associations!of!syndromes!with!both!gingival!and!hair!overgrowth.!!The!isolated!and!syndromic!facets!were!both!explored!by!comparison!to!HHG!genomeOwide!differential!gene!expression!data.!!Examining!HHG!in!light!of!known!HGF!information!at!both!the!gene!and!genome!levels!created!a!platform!to!gain!a!better!understanding!of!the!silver!fox!HHG!phenotype.!!
HHG'index'case'for'North'America'Prior!to!2004,!there!were!no!documented!cases!of!HHG!in!the!North!American!silver!fox,!Vulpes'vulpes.!After!the!introduction!of!a!Finnish!fox!line,!the!disease!became!evident!not!only!in!the!original!Finnish!foxes!but!also!in!some!of!the!offspring.!Subsequent!to!its!first!appearance!in!Newfoundland!and!Labrador,!HHG!was!extensively!documented.!Histological!studies!of!affected!fox!gum!tissue!showed!a!submucosal!expansion!with!thick!collagen!bundles.!In!response!to!the!increase!in!HHG!prevalence,!a!scoring!system!was!devised!to!rank!the!severity!of!the!disease!
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based!on!gross!appearance.!This!system!will!help!with!future!cases!and!it!will!aid!with!assessing!disease!progression.!Utilizing!coOoperative!strategies!like!candidate!gene!sequencing!and!whole!genome!microarray!expression!techniques!based!on!canine!genome!resources!with!help!to!gain!a!better!understanding!of!the!molecular!mechanisms!underlying!HHG.!!
Candidate'gene'sequencing'HHG!and!HGF!are!analogous!conditions!with!very!similar!manifestations!and!disease!progression.!One!major!research!goal!was!to!use!the!known!molecular!basis!of!one!form!of!HGF!to!perform!a!functional!candidate!gene!analysis!as!a!means!to!establish!or!eliminate!particular!gene!mutations!as!causative!of!HHG!in!foxes.!The!DNA!sequences!of!the!SOS1,!GRB2,!and!EGFR!genes!were!obtained!for!candidate!gene!analysis!of!the!exonic!coding!regions,!exonOintron!boundaries,!and!partial!introns!of!these!three!genes!in!both!affected!ranched!silver!foxes!and!unaffected!wild!and!farmed!red!foxes.!In!addition!to!mutational!analysis,!the!sequences!were!used!in!multispecies!comparisons!for!examination!of!patterns!of!molecular!evolution.!!No!mutational!differences!separated!HHGOaffected!foxes!from!unaffected!ones!for!the!SOS1,!GRB2!or!EGFR!genes.!While!these!findings!do!not!rule!out!the!possibility!that!a!mutation!could!exist!in!the!upstream!promoter/enhancer!regions!for!either!of!these!genes,!or!potentially!elsewhere!in!the!introns,!it!does!conclude!that!there!are!no!amino!acid!differences!in!the!protein!products!of!these!genes!that!could!alter!the!
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protein!function.!The!upstream!region!of!the!EGFR!gene!showed!a!GC!content!similar!to!Canis'familiaris,!which!is!different!from!that!of!humans.!While!canines!demonstrate!fewer!CpG!islands!in!the!promoter!regions!than!humans!(Auton!et'al.!2013),!further!characterization!of!the!promoter!region!is!required!before!its!involvement!in!the!HHG!phenotype!can!be!eliminated.!!The!SOS1!and'GRB2'genes!showed!similar!molecular!evolutionary!patterns!to!each!other,!in!that!both!genes!were!highly!conserved!at!the!intraOspecies,!intraOfamily,!and!interOgenus!levels!in!mammals.!The!nonOsynonymous!substitutions!and!ω!ratios!were!low!for!both!genes,!especially!GRB2,!consistent!with!strong!functional!constraints.!The!involvement!of!protein!products!of!both!genes!in!the!activation!of!multiple!signalling!pathways!and!RAS!pathway!cellular!functions!such!as!proliferation,!transformation!and!survival!(Pierre!et'al.!2011),!is!consistent!with!the!requirement!of!a!high!level!of!functional!constraints,!which!was!demonstrated.!Across!all!measures!of!sequence!diversity!at!all!hierarchical!levels!EGFR!demonstrated!the!highest!level!of!variation!among!the!three!genes,!suggesting!that!the!EGFR!gene!has!been!subject!to!different!molecular!processes!than!the!other!two!genes.!At!this!time!the!reason!for!the!increased!variability!seen!in!the!EGFR!gene!cannot!solely!be!attributed!to!either!a!reduction!in!functional!constrains!or!positive!Darwinian!selection!and!may!involve!elements!of!both.!!The!HHGOaffected!silver!foxes!do!not!carry!the!same!SOS1!mutation!that!causes!HGF!in!humans.!At!this!time!the!involvement!of!coding!region!or!exonOintron!boundary!
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mutations!in!SOS1!and!two!adjacent!RAS!pathway!genes,!EGFR!and!GRB2!can!also!be!ruled!out!as!causative!of!the!HHG!phenotype!in!silver!foxes.!!
Global'HHG'expression'Human!HGF!and!silver!fox!HHG!are!analogous!conditions.!The!aetiology!of!HGF!is!complex,!as!it!presents!in!a!number!of!ways!including!as!an!isolated!genetic!condition,!as!part!of!a!syndrome!or!as!a!pharmaceutically!induced!phenotype!(Shashi!et'al.!1999).!The!silver!fox!presentation!of!HHG!was!not!the!result!of!pharmaceuticals!as!the!animals!were!not!taking!any!medications,!leaving!an!isolated!genetic!condition!or!as!part!of!a!syndrome!as!viable!aetiological!possibilities.!GenomeOwide!HHG!expression!patterns!in!the!silver!fox!were!interpreted!in!the!context!of!both!the!genetics!of!HGF!and!the!most!commonly!associated!syndrome!characteristic!of!hypertrichosis.!Each!evaluation!was!conducted!in!the!context!of!global!differential!gene!expression!patterns!within!gum!tissue!from!farmed!HHGOaffected!and!unaffected!silver!foxes.!In!both!comparisons!portions!of!the!MAPK!signalling!pathway!were!implicated.!Additionally!each!comparison!shed!light!on!genes!expressed!differentially!that!while!they!may!not!contain!causative!mutations!for!HHG,!could!potentially!be!contributing!to!the!overall!molecular!phenotype.!!MAPK!pathway!is!a!cascading!kinase!pathway!that!is!involved!in!a!diverse!array!of!cellular!processes!including!cellular!proliferation,!differentiation!and!cellular!death!(Kim!and!Choi!2010).!Given!its!diversity,!malfunctions!within!the!pathway!are!known!to!cause!numerous!disease!conditions.!Mutations!in!the!EGFR!gene!are!
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associated!with!lung!and!colorectal!cancer!(Kim!and!Choi!2010).!Noonan!syndrome!is!associated!with!mutations!in!any!of!eight!different!MAPK!genes!(Roberts!et'al.!2013).!A!mutation!in!the!SOS1!gene!is!responsible!for!one!of!the!genetic!subtypes!of!HGF!(Hart!et'al.!2002).!The!sequencing!of!this!gene!in!the!silver!fox!did!not!reveal!any!putative!mutations!making!it!an!unlikely!candidate!as!a!causative!gene!for!HHG.!!!The!HHG!comparison!to!the!known!HGF!genetics!revealed!several!interesting!points.!First!it!showed!that!overall!the!ERK!portion!of!the!MAPK!pathway!was!differentially!upOregulated!in!the!HHGOaffected!foxes.!Next!it!showed!that!activators!of!the!RAS!protein!were!downOregulated!while!inhibitors!of!the!same!protein!were!upOregulated!in!the!HHGOaffected!animals!leading!to!the!hypothesis!that!the!mutation!could!be!occurring!at!or!before!the!RAS!protein!in!the!signalling!cascade.!Finally,!while!the!SOS1!gene!was!considered!an!unlikely!candidate!gene!the!SOS2!gene!did!show!upOregulation!in!the!HHGOaffected!foxes.!SOS1!is!required!for!early!development!such!that!large!errors!are!lethal!while!an!error!in!the!SOS2!protein!is!not!be!lethal!(Qian!et'al.!2000).!Given!the!high!level!of!sequence!homology!it!is!possible!that!an!error!in!the!SOS2!gene!would!cause!the!overall!upOregulation!of!the!MAPK!pathway!leading!the!HHG!phenotype,!making!SOS2!a!candidate!gene!for!HHG.!!The!HHG!comparison!to!the!syndromes!with!both!hypertichosis!and!gingival!hyperplasia!also!implicated!the!MAPK!pathway,!more!specifically!the!JNK!and!p38!portions!of!the!pathway.!Initial!emphasis!was!placed!on!the!MAP2K6!gene,!however!DNA!sequencing!identified!no!coding!or!splice!site!mutations!within!this!gene,!
! 158!
rendering!it!unlikely!as!a!candidate!gene!for!HHG.!While!the!end!of!this!portion!of!the!MAPK!pathway!did!not!show!statistically!significant!differential!expression!of!any!genes,!the!overall!trend!showed!that!the!JNK!pathway!was!downOregulated!while!the!p38!portion!was!upOregulated!in!the!HHGOaffected!foxes.!One!hypothesis!is!that!the!downOregulation!of!the!JNK!portion!of!the!pathway!is!a!compensatory!mechanism!for!the!upOregulation!of!the!p38!portion!of!the!MAPK!pathway.!Further!studies!are!required!to!determine!if!this!compensation!is!sufficient!thus!ruling!out!this!portion!of!the!MAPK!pathway!or!if!despite!the!compensation!the!pathway!end!products!are!still!upOregulated!and!thus!contributing!to!the!HHG!disease!phenotype.!While!the!differential!expression!pattern!does!not!implicate!a!singular!gene,!overall!MAPK!pathway!involvement!is!likely.!!In!both!the!isolated!HHG!genetic!and!hypertrichosis!with!gingival!hyperplasia!comparisons!there!were!genes!that!could!be!contributing!to!the!overall!HHG!phenotype.!In!the!HHG!to!known!HGF!genetic!comparison!the!SRD5A2!gene!was!significantly!upOregulated!in!HHGOaffected!foxes!and!it!plays!a!role!in!testosterone!conversion!(Ye!et'al.!2011).!In!an!analogous!canine!condition!of!gingival!hyperplasia,!one!mechanism!for!the!pharmaceuticallyOinduced!phenotype!proposes!that!blocking!of!calcium!channels!interrupts!the!intracellular!calcium!dynamic,!rendering!the!gingival!tissues!sensitive!to!testosterone!(Pariser!and!Berdoulay!2011).!The!potential!involvement!of!androgens!opens!up!a!novel!avenue!for!future!research.!If!HHG!demonstrates!a!variable!penetrance!then!the!higher!levels!of!testosterone!in!the!male!foxes!could!explain!the!sex!bias!observed!originally!in!HHG!(Dyrendahl!and!
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Henricson!1960).!Androgen!receptors!also!participate!in!nonOandrogen!signalling!(Heinlein!and!Chang!2002).!They!have!been!linked!to!the!activation!of!the!MAPK!pathway!and!the!alteration!of!intracellular!calcium!levels.!Further!evaluation!of!the!MAPK!pathway!could!possibly!help!explain!the!HHG!phenotype!and!provide!the!groundwork!for!a!unifying!mechanism!underpinning!all!aetiologies.!!
Conclusions'HHG!is!a!complex!disease!with!analogous!conditions!seen!in!other!animals.!In!both!the!canine!and!human!variants,!the!aetiology!of!the!disease!is!broad.!Candidate!gene!sequencing!eliminates!both!the!SOS1!and!MAP2K6!genes!as!likely!diseaseOcausing!genes.!Overall,!the!genomic!expression!data!points!to!the!involvement!of!the!MAPK!signalling!pathway!and!opens!the!door!for!further!research!into!the!MAPK!pathway!and!its!potential!to!provide!an!allOencompassing!mechanism!underpinning!the!various!aetiologies!in!different!species.!!!!!!!!!!
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Table!A1.1:!Primers!for!PCR!and!sequencing!of!the!epidermal)growth)factor)receptor!gene!in!foxes,!based!on!the!Canis!familiaris!gene!sequence!(NC_006600.3!on!chromosome!18)!!
Exon/&
Intron&&
Forward&primer&(5’53’)& Reverse&primer&(5’53’)& Annealing&temp&(°C)& Product&length&(bp)&1! ACGTAGGACGTTCATGCAGA! TCTGTGCTGCAGGAACTGGA! 57! 670!2! CTAGAAAGCACAGGGTCATG! GGGTCATACAGGGTCCGTCC! 56! 240!3! TTGCTTCCTCTTCCCACCTG! AATGGCTTATGGCTTCCTTC! 57! 482!4! TTCCTGGCCTCCAGTATCTTC! AACAAGGGAGCAATCACTAAG! 57! 346!5! CTCTTACAGCTGTACAGGTGC! TTGTTTGGCCACTTCCTCATT! 51! 217!6/7! TCTCTGTACATGGAGGAAGG! AGAGTCAAGACGCAGGTACT! 55! 770!8! TTCTTGTCGCATTCATCCTAG! CCAGGACACATAACTGCTGTA! 51! 422!9! TAGAGGCAGAAGTACCTGAG! TCTCCATCACCTACTGTCTT! 52! 554!10! AATGTGAAGAAGTATTGCATA! ACATGAACTCTGTTCTCTGTC! 50! 315!11! GGCAGGTTGTCATCAGTTCCT! AGGATGTCATTCACGCAACTG! 54! 257!12! CCAGTGACCAAAATCATCTG! CTTACCAGGCAGTCGCTCTC! 55! 128!13! TCCACAGTTACCACAGTAGT! AGTGAGGCAAATATATGGAC! 50! 555!14! GAACATGAGACAATGGTGTGG! GGCTTCTAATAAGGAGGAGTC! 55! 340!15/16! AGAGTTACCAGTACCCAGCA! GCATCTCCCGGCTCACTCTC! 52! 541!17! ATTCTAGAGGAGAGGCAGGT! TGCGTAGGTGAGATGTTAAC! 52! 466!18! GACTTCCTGCAATATGACTTA! TGATCCATGTGAACCATCTCC! 51! 386!19! CCACTTACAGGAGCGGTCTCA! TTTGTGATTAACAGTTGTCAA! 50! 368!20! AAGGTGACTTGTGTCTGATTA! GGCTTGGTGGCTACAGAGTGT! 50! 296!21! AGTCACATCAAGCAACAGCAG! CCTTGGGATGTGCAGAAATGA! 54! 478!22! CGTCATGCTCTCTCTTTCAAG! CCAGGAGAACCGGTCAAGATA! 51! 274!23! AGAATCCACATGGCATCTAC! TGCCAAGACTTGGCAGGAGA! 55! 356!24! AAGCTCTGAGAAGGTGTGCAT! CCGAACTGTGAGCAACACAGA! 57! 392!25! TTGGAGTGCACAGCTCTGCTC! TGCTGCTGCCAGACACCACAA! 57! 317!26! AATCACAGTTGTGCTTTGCTG! CTCTCCACTTACCTTTGCAAT! 57! 308!27! GTTGCAGGGCATGAACTACC! CTTCTTACTTTGCCTCCTTC! 57! 171!
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28! CCTCAGCTGAGACCTTCATG! CCTGGTGCACTGCAGGATGC! 55! 653!29! CAGGCGTCACCGTGTGGGAG! TTGACCATGATCATGTAGAC! 57! 148!30! GGCGAGATGTCTAGATGTCTA! TTCACCAAGGCTCGCTCTAAC! 55! 396!31! GGAAGGAAGCAGCTGTACCTC! TTATGCTAAGTTCCACTAGGT! 53! 410!32! TTAGCTCCACTCTGTGAGACC! CGGAAGGAACATCAAGGCTAG! 54! 250!33! GGCTTGCTGGAAACGCAGTGT! TATTTCTCCGCCTCTTACTCC! 52! 394!34! TGCCCTCAGCTGCCTCCTGGA! CCAAGAGTTAATGTGGGCATG! 57! 578!!!!!!!!!!!!!!!!!!!!!!!
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Table!A1.2:!Primers!deigned!for!sequencing!growth)factor)receptor)bound)protein)2!gene!in!foxes!based!on!the!Canis!familiaris!gene!sequence!(NC_006591.3!on!chromosome!9)!!
Exon&& Forward&primer&(5’&53’)& Reverse&primer&(5’53’)& Annealing&temp&
(°C)&
Product&length&
(bp)&1! Never!obtained! ! ! !2! GTGCTGGCCACTTCTCTCAC! CTATCCAGAGCCCGCCAGAC! 57! 484!3! ATCCATGTAACTGACCATACTTCAA! TTGGAATAAGCAGATGGGTCTGACT! 52! 239!4! CAAGGAGTGTTCTGTTACTCACATT! TCAGATGAGGAGGGAGAGGACTCCA! 56! 264!5! TCAGAAGATGCCTCCTTGATGTGAG! GAGAGGGTACCTGCCTATCTGAGGA! 56! 336!6! CCACGTAGAGTAGACTTAGGACCTG! CACTCCAACTACAACAGACATTTTG! 54! 715!!!!!!!!!!!!!!!!!!!!
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!Table!A1.3:!Primers!deigned!for!sequencing!SOS1!gene!in!foxes!based!on!the!Canis!familiaris!gene!sequence!(NC_006599.3!on!chromosome!17)!!
Exon/&
Intron&&
Forward&primer&(5’&53’)& Reverse&primer&(5’53’)& Annealing&
temp&(°C)&
Product&
length&
(bp)&1! CCTGATGAGTTGGAAGAGGA! GGATAGGCATGTGATAAAGC! 50! 475!2! GAATAAGCCTAGATGGTATATGTAGCTGGG! GGACTTGAAGAGCAAACTCTTCCGCTGAC! 53! 380!3! GATTTTCCCCTGAGATAATATAAGGG! GAATTTCACCCTTCAACTCACTATCATCC! 51! 470!4! GCATTGTTTCTTTTTAATCGGTGTGTC! GCTATTGGGTTACTGGAAATGTATCCTAAC! 51! 364!5! GGTATTAATGGACATGTTTCATCAAGATG! GAGATCATAGTCACTATGAATTAAATCCCAC! 51! 353!6! CAATGCCGTTTGCTTCATTCACTCAACTG! CAAGGAACAGACAATACGGCTAAGTAGTC! 53! 564!7/8! CTGTATTTCTGGTGGTAGGTTATTTATG! GCAATTAGATATAGACTAATGTTCATGGGTGC! 53! 480!9! GCCTGTCACAAGGCATGACATCTTTTAACAC! CACTTCCTCTGAAAGACCAAGCTTGTCAC! 53! 511!10! GTGAATCTGCATGTCGGTTTTATAGTCAGC! GGCACAATGACCTGTGCAGCAAAGAAAATC! 51! 735!11! CCAAAGCATTCTATGTGGTCAGAACATTTTGGG! GAGAAACATGTAGGATCTTTTAGCTCAATCT! 51! 286!12! GATCCCAATTTTGTTCGGACATTTC! CCTCTCACTGTTCCAATAAATTCTTCCATTCG! 53! 1348!13! GAGGGAAGCAAAAGTGTAAGCCACTG! CAACTTTTTCAAGTGCTTATGCTGCCAC! 53! 387!14! GGTAAAGCAATGAAAAAATGGGTTGAATCC! CTTCTCAAACCACAGAGTGAGATTAGTGG! 54! 1458!15! GTTTTCATAAACCTTTCTGTTGGTGTTC! GGACATGAGGCATACAAAAGCAGAACTGC! 53! 341!16! GATTCTCTCTATAACTATAACCATCTGCCCC! CCAAAGAAAGGCACACATGGTGGATTAATAG! 53! 919!17! GGCTTTATTTTTAGCCCAGCATTTTGGG! GTCCTAATAGAGTAAAATTCTATGGTGATTCAC! 52! 357!18! GGAAATCTGTGCTTTAAATCTGTGGTTATGG! CTTTGATATCTGATTCTACTCGTAAAC! 52! 305!19! CCAGGAATTTATCTAACTAATATCTTG! GACCAAGCCTTTGTGCCTGCGGGAC!CAAATTTAAAGAGGGCTATTCAAACTGG! !50! !2213!
! 167!
20! CGAAGATATTAGTTGAGTTTTACCAGGC! CAAATTTAAAGAGGGCTATTCAAACTGG! 53! 567!21! GACTGCTGCACCATTCTTTACAACTAG! CAAGCAATGTACCAATGCCGCCAGACCC! 53! 287!22! GGATCTGCTTCAGTATCATCTATAAGTTTAACC! CCCTGAAGTTTCAGCCTAACCTGGTGGG! 52! 207!23! CCCCAACTTAATTCATAATATGTTTG! GCATATTTTGAATTACAAAAACTGTC! 52! 954!!!!!!!!!!!!!!!!!!!!!!!!!!
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Table!A1.4:!Primers!deigned!for!sequencing!MAP2K6!gene!in!foxes!based!on!the!Canis!familiaris!gene!sequence!(NC_006591.3!on!chromosome!9)!!Exon!! Forward!primer!!(5’!S3’)! Reverse!primer!!(5’S3’)! Annealing!temp!(°C)! Product!length!(bp)!1! CCACGTTTCCTTAAATCCGAG! ATGCATGCACAACCCTTTG! 53! 458!2! GGCTAGCCCTTTCTCCTTCA! GGCATTGCTCATCAGCCCAA! 58! 257!3! GACTAAATATACCTCATGTTTTTCT! TGCATGAGAAATGGTCAAGA! 52! 147!4! TAGAACGTTGGGAGAAGCAA! AACGGATACACCACAGACAG! 53! 248!5! AGAGCAGTAACCATGCATTT! AGAGCAGTAACCATGCATTT! 52! 202!6! TCCTTTTCTACCCTCTCTAACA! AGACGTCTCATATTCTCCTTGT! 53! 208!7! TTCCAGTGATGGAGAAAAATCT! TGGATTTCATAAAAGGAACAGCC! 53! 140!8! GCCTGGGACCATGGGCTTTT! GCTTTGCTGGCAGCTGCATTT! 58! 219!9! AGCTAAGAACATATCTCATTTGTC! GCCCAGAACCTCACAGTC! 53! 162!10! CACAGCAGATTCCCTAAAGTA! GCAGATGAGGCTCTCTTACC! 53! 238!11! AGATGGTTCTTAGATTTTAACGCA! TACTACCTGTCGGTTTGGAC! 53! 138!12! AGTGGTGAATATTAATACCATGTG! ACAACAGCTGGAACAGGT! 53! 740!!
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Table!A2.1:!Mean!log2!relative!expression!(log2RQ)!values!for!qPCR!genes!in!the!hereditary!hyperplastic!gingivitis!(HHG)Haffected!and!HHGHunaffected!fox!samples!and!corresponding!micraoarray!fold!change!values.!!! ! qPCR% % Microarray%
Gene%
symbol% Gene%Name%
Fold%
change%
Test%
location% T;
test% Probe%ID%
Fold%
change%
Mann%
Whittney%P%
value%COL14A1! Collagen,)type)XIV,)alpha)1) NA! Toronto! NA! Cfa.1972.1.A1_at! 1.242! 0.036!DST! Dystonin) 1.028! Toronto! 0.947! CfaAffx.4544.1.S1_at! 1.216! 0.036!E2F4! E2F)transcription)factor)4) 1.662! Toronto! 0.354! CfaAffx.31199.1.S1_at! H1.234! 0.036!FOS! Finkel–Biskis–Jinkins)murine)osteogenic)sarcoma)virus)) 3.385! St.!John’s! 0.077! CfaAffx.26065.1.S1_at! 2.863! 0.393!GPR110! GDprotein)coupled)receptor)110) 4.247! St.!John’s! 0.261! CfaAffx.4026.1.S1_at! 2.072! 0.393!MAP2K6! MitogenDactivated)kinase)kinase)6) H1.106! Toronto! NA! CfaAffx.16824.1.S1_at! H1.203! 0.250!MAP3K1! MitogenDactivated)kinase)kinase)kinase)1) H2.313! St.!John’s! 0.112! Cfa.19524.1.S1_at! H1.959! 0.071!MMP9! Matrix)metallopeptidase)9) 1.245! St.!John’s! 0.811! Cfa.3470.1.S1_s_at! 2.873! 0.143!NCALD! Neurocalcin)delta) 1.776! Toronto! NA! Cfa.16838.1.S1_at! H1.231! 0.036!OXR1! Oxidation)resistance)1) 1.210! Toronto! 0.531! CfaAffx.1950.1.S1_s_at! H1.288! 0.036!PITPNC1! Phosphatidylinositol)transfer)protein,)cytoplasmic)1) 1.060! Toronto! 0.907! CfaAffx.17853.1.S1_s_at! 1.358! 0.036!PRKCZ! Protein)kinase)C,)ζ)) 1.299! Toronto! 0.382! Cfa.19185.2.A1_at! H1.204! 0.036!PTK2! Protein)tyrosine)kinase)2) 1.477! Toronto! 0.433! Cfa.5377.1.A1_at! 1.207! 0.036!RASA1! RAS)p21)protein)activator)1) 2.058! Toronto! 0.116! Cfa.350.1.S1_at! 1.344! 0.071!ROCK1! RhoDassociated,)coiledDcoil)containing)protein)kinase)1) 1.054! Toronto! 0.837! CfaAffx.27952.1.S1_at! 1.240! 0.036!ROR1! Receptor)tyrosine)kinaseDlike)orphan)receptor)1) H2.394! St.!John’s! 0.237! CfaAffx.28472.1.S1_at! H1.577! 0.393!
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SLC30A3! Solute)carrier)family)30)(zinc)transporter),)member)3) NA! Toronto! NA! Cfa.6122.1.A1_at! 1.234! 0.036!SOS1! Son)of)sevenless)homolog)1)) H1.225! St.!John’s! 0.406! CfaAffx.10496.1.S1_s_at! H1.400! 0.250!SOS2! Son)of)sevenless)homolog)2) 1.214! Toronto! 0.182! CfaAffx.22062.1.S1_s_at! 1.000! 1.000!TGFβ3! Transforming)growth)factor)beta),)3) 3.603! Toronto! 0.026! CfaAffx.26185.1.S1_at! 1.084! 0.786!!!!!!!!!!!!!!!!!!!!!!!!!
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!!Figure!A2.1:!Mean!log2!relative!expression!(log2RQ)!values!for!qPCR!genes!in!the!hereditary!hyperplastic!gingivitis!(HHG)Haffected!and!HHGHunaffected!fox!samples.!Standard!errors!are!indicated!by!the!bars.!!!
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Appendix 3: 
Comprehensive list of statistically significant fold changes form the 
microarray experiment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 174 
Table A3.1: Microarray-identified genes significantly differentially expressed in hereditary hyperplastic gingivitis (HHG)-affected foxes relative to unaffected foxes  
Gene title Affymetrix probe ID 
Fold 
change 
Mann 
Whittney P 
value ATP-binding cassette, sub-family F (GCN20), member 2 CfaAffx.8212.1.S1_s_at -1.180 0.036 v-abl Abelson murine leukemia viral oncogene homolog 2 Cfa.7403.1.A1_s_at 1.301 0.036 Actin binding LIM protein family, member 2 CfaAffx.22406.1.S1_s_at 1.403 0.036 Ankyrin repeat and BTB (POZ) domain containing 1 CfaAffx.7032.1.S1_at 1.986 0.036 Acetyl-CoA acyltransferase 1 Cfa.6351.2.A1_s_at 1.090 0.036 Acetyl-CoA carboxylase alpha CfaAffx.27754.1.S1_s_at 1.247 0.036 Acyl-CoA synthetase long-chain family member 5 CfaAffx.17119.1.S1_s_at -1.681 0.036 ADAM metallopeptidase domain 20 CfaAffx.12696.1.S1_at -1.137 0.036 ADAM metallopeptidase domain 22 CfaAffx.3686.1.S1_at 1.148 0.036 ADAM metallopeptidase with thrombospondin type 1 motif, 20 CfaAffx.15306.1.S1_s_at 1.231 0.036 ADAMTS-like 1 CfaAffx.3277.1.S1_s_at 1.120 0.036 ADAMTS-like 3 Cfa.2566.1.S1_s_at -1.177 0.036 Adenylate cyclase 2 (brain) Cfa.19117.1.S1_s_at -1.143 0.036 Alcohol dehydrogenase 4 (class II), pi polypeptide Cfa.2072.1.S1_at 1.293 0.036 Adiponectin receptor 2 CfaAffx.24419.1.S1_at 1.450 0.036 Activity-dependent neuroprotector homeobox CfaAffx.17978.1.S1_at -1.494 0.036 AF4/FMR2 family, member 3 CfaAffx.4242.1.S1_at -1.121 0.036 AFG3 ATPase family gene 3-like 2 (S. cerevisiae) Cfa.7454.1.A1_at 1.154 0.036 ATP/GTP binding protein-like 3 Cfa.7400.1.A1_s_at 1.296 0.036 Acylglycerol kinase CfaAffx.6782.1.S1_at -2.058 0.036 AT hook containing transcription factor 1 CfaAffx.24433.1.S1_at 1.230 0.036 Androgen-induced 1 Cfa.13228.1.A1_at 1.385 0.036 Akirin 2 Cfa.9601.1.A1_at -1.524 0.036 
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Alkaline phosphatase, liver/bone/kidney Cfa.13804.1.A1_at 1.251 0.036 Adenosine monophosphate deaminase 2 CfaAffx.30325.1.S1_at -1.154 0.036 Angiopoietin-like 6 CfaAffx.27426.1.S1_at -1.243 0.036 Ankyrin repeat and IBR domain containing 1 CfaAffx.3876.1.S1_at -1.235 0.036 Ankyrin repeat domain 13A CfaAffx.16669.1.S1_at 1.138 0.036 Ankyrin repeat domain 13 family, member D CfaAffx.18188.1.S1_s_at -1.195 0.036 Ankyrin repeat domain 31 CfaAffx.14986.1.S1_at 1.100 0.036 AN1, ubiquitin-like, homolog (Xenopus laevis) Cfa.19921.1.S1_s_at 1.116 0.036 Annexin A1 CfaAffx.3571.1.S1_s_at 1.805 0.036 Annexin A2 Cfa.138.1.A1_at 1.104 0.036 Adaptor-related protein complex 4, mu 1 subunit Cfa.18599.1.S1_at 1.141 0.036 Amyloid beta (A4) precursor protein-binding, family B, member 3 Cfa.8054.1.S1_s_at 1.212 0.036 ADP-ribosylation factor 3 Cfa.6419.1.S1_at 1.900 0.036 ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited) CfaAffx.12196.1.S1_s_at -1.215 0.036 Armadillo repeat containing, X-linked 3 CfaAffx.27095.1.S1_s_at -1.316 0.036 Actin related protein 2/3 complex, subunit 5, 16kDa CfaAffx.20654.1.S1_at -1.100 0.036 ADP-ribosyltransferase 1 Cfa.13089.1.A1_at 1.275 0.036 Ankyrin repeat and SOCS box-containing 18 CfaAffx.18888.1.S1_at -1.215 0.036 Activating signal cointegrator 1 complex subunit 3 CfaAffx.6271.1.S1_s_at -1.771 0.036 ATPase family, AAA domain containing 5 CfaAffx.6271.1.S1_s_at -1.771 0.036 Ataxia, cerebellar, Cayman type CfaAffx.29229.1.S1_s_at 1.097 0.036 ATG7 autophagy related 7 homolog (S. cerevisiae) Cfa.14549.1.A1_at 1.257 0.036 Atonal homolog 7 (Drosophila) CfaAffx.20942.1.S1_at 1.174 0.036 ATPase type 13A5 CfaAffx.21810.1.S1_s_at -1.220 0.036 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1 CfaAffx.30193.1.S1_s_at -1.053 0.036 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 CfaAffx.31171.1.S1_s_at 1.270 0.036 ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D Cfa.1081.2.S1_at 1.256 0.036 ataxin 7-like 1 CfaAffx.6925.1.S1_s_at -1.267 0.036 
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AVL9 homolog (S. cerevisiase) CfaAffx.5672.1.S1_s_at 1.306 0.036 Alpha-2-glycoprotein 1, zinc-binding Cfa.11319.1.A1_at -1.133 0.036 Antizyme inhibitor 1 Cfa.4399.1.S1_at -1.228 0.036 BCL2-associated athanogene 4 CfaAffx.10159.1.S1_at -1.259 0.036 BarH-like homeobox 1 CfaAffx.30442.1.S1_at 1.069 0.036 HLA-B associated transcript 2-like 2 Cfa.3163.1.A1_s_at -1.179 0.036 Bromodomain adjacent to zinc finger domain, 2B CfaAffx.14872.1.S1_at -1.503 0.036 Brevican CfaAffx.25582.1.S1_s_at 1.108 0.036 Breast carcinoma amplified sequence 3 Cfa.8596.2.A1_a_at 1.343 0.036 BRCA2 and CDKN1A interacting protein CfaAffx.19936.1.S1_s_at -1.201 0.036 Branched chain ketoacid dehydrogenase kinase CfaAffx.25727.1.S1_at 1.238 0.036 BCL2-associated transcription factor 1 CfaAffx.1327.1.S1_s_at -1.445 0.036 Baculoviral IAP repeat-containing 3 CfaAffx.23263.1.S1_at 1.194 0.036 Biorientation of chromosomes in cell division 1 Cfa.8007.1.A1_at -1.139 0.036 Biorientation of chromosomes in cell division 1-like Cfa.10683.1.S1_s_at -1.382 0.036 Bromodomain containing 2 CfaAffx.2253.1.S1_s_at -1.336 0.036 Bromodomain, testis-specific CfaAffx.30888.1.S1_at 1.115 0.036 Bone marrow stromal cell antigen 1 CfaAffx.23551.1.S1_at 1.314 0.036 Butyrophilin, subfamily 1, member A1 CfaAffx.16956.1.S1_s_at 1.295 0.036 Complement component 5 CfaAffx.6326.1.S1_s_at -1.300 0.036 Complement component 9 Cfa.13405.1.A1_at -1.171 0.036 Carbonic anhydrase XI CfaAffx.6852.1.S1_s_at -2.193 0.036 Calcium channel, voltage-dependent, L type, alpha 1S subunit CfaAffx.17088.1.S1_at 1.234 0.036 Calcyclin binding protein CfaAffx.22188.1.S1_s_at -1.159 0.036 Ca++-dependent secretion activator 2 Cfa.10726.1.A1_s_at 1.541 0.036 Calcitonin/calcitonin-related polypeptide, alpha Cfa.3806.1.S1_at -1.201 0.036 Calcium binding and coiled-coil domain 1 CfaAffx.10971.1.S1_s_at 1.213 0.036 Caspase recruitment domain family, member 11 CfaAffx.24989.1.S1_at 1.217 0.036 CAS1 domain containing 1 CfaAffx.4056.1.S1_s_at -1.793 0.036 
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Caspase 6, apoptosis-related cysteine peptidase CfaAffx.17770.1.S1_at -1.213 0.036 Cation channel, sperm associated 2 CfaAffx.20427.1.S1_at -1.351 0.036 Cation channel, sperm-associated, gamma CfaAffx.9881.1.S1_at 1.277 0.036 Cystathionine-beta-synthase CfaAffx.16501.1.S1_s_at -1.609 0.036 Coiled-coil domain containing 110 CfaAffx.12192.1.S1_at 1.248 0.036 Coiled-coil domain containing 81 CfaAffx.7617.1.S1_s_at -1.051 0.036 Coiled-coil domain containing 88C CfaAffx.26864.1.S1_s_at -1.239 0.036 Chemokine (C-C motif) ligand 3 Cfa.14352.1.A1_at 1.965 0.036 Chemokine (C-C motif) ligand 3 CfaAffx.27805.1.S1_s_at 1.105 0.036 Cell cycle progression 1 CfaAffx.24405.1.S1_at -1.580 0.036 CD300a molecule CfaAffx.7773.1.S1_at -1.338 0.036 Cell division cycle 37 homolog (S. cerevisiae) CfaAffx.27245.1.S1_s_at 1.282 0.036 Chymotrypsin-like elastase family, member 1 Cfa.12.1.S1_s_at 8.778 0.036 CUGBP, Elav-like family member 3 CfaAffx.19849.1.S1_s_at 1.181 0.036 Centromere protein J CfaAffx.11960.1.S1_at -1.353 0.036 Centromere protein M CfaAffx.2400.1.S1_at 1.161 0.036 Ceramide kinase-like CfaAffx.21887.1.S1_at 1.390 0.036 ChaC, cation transport regulator homolog 1 (E. coli) CfaAffx.14841.1.S1_s_at 1.866 0.036 Chondroadherin-like CfaAffx.2541.1.S1_at 1.148 0.036 Choline O-acetyltransferase CfaAffx.10949.1.S1_s_at -1.110 0.036 Chromodomain helicase DNA binding protein 1 Cfa.2790.1.A1_at 1.347 0.036 Chromodomain helicase DNA binding protein 2 CfaAffx.17145.1.S1_at -1.222 0.036 Chromodomain helicase DNA binding protein 6 CfaAffx.14589.1.S1_at -1.520 0.036 Choline phosphotransferase 1 Cfa.9478.1.A1_at 1.196 0.036 Cholinergic receptor, muscarinic 5 CfaAffx.229.1.S1_at 1.137 0.036 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 Cfa.17231.1.S1_s_at -1.127 0.036 Corepressor interacting with RBPJ, 1 CfaAffx.20461.1.S1_at 1.178 0.036 C-type lectin domain family 17, member A CfaAffx.24920.1.S1_at -1.292 0.036 Clathrin, light chain A CfaAffx.4312.1.S1_s_at 1.236 0.036 
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Chymase 1, mast cell CfaAffx.19295.1.S1_s_at 1.372 0.036 Cardiomyopathy associated 5 Cfa.2645.1.S1_at -1.210 0.036 CCR4-NOT transcription complex, subunit 4 CfaAffx.5770.1.S1_s_at 1.132 0.036 CCR4-NOT transcription complex, subunit 7 Cfa.18438.1.S1_s_at -1.197 0.036 Coilin Cfa.20787.1.S1_at -1.306 0.036 Collagen, type XIV, alpha 1 Cfa.1972.1.A1_at 1.242 0.036 Collagen, type XVI, alpha 1 CfaAffx.17108.1.S1_at 1.155 0.036 Collagen, type XIX, alpha 1 CfaAffx.4714.1.S1_s_at -1.138 0.036 Collagen, type XXII, alpha 1 CfaAffx.2659.1.S1_s_at 1.137 0.036 Collagen, type VI, alpha 3 Cfa.99.1.S1_s_at -1.144 0.036 Coenzyme Q3 homolog, methyltransferase (S. cerevisiae) CfaAffx.6146.1.S1_s_at -1.410 0.036 cOR8B15 olfactory receptor family 8 subfamily B-like CfaAffx.548.1.S1_x_at -1.184 0.036 cOR9K3 olfactory receptor family 9 subfamily K-like CfaAffx.14945.1.S1_x_at -1.078 0.036 Carboxypeptidase A5 CfaAffx.3118.1.S1_at 1.423 0.036 Carboxypeptidase O CfaAffx.20812.1.S1_at 2.225 0.036 Cleavage and polyadenylation specific factor 4, 30kDa CfaAffx.23159.1.S1_s_at 1.389 0.036 Carboxypeptidase Z CfaAffx.22474.1.S1_s_at -1.156 0.036 Crumbs homolog 1 (Drosophila) CfaAffx.17703.1.S1_at -1.152 0.036 Cysteine-rich secretory protein LCCL domain containing 1 CfaAffx.13121.1.S1_s_at -1.374 0.036 CSE1 chromosome segregation 1-like (yeast) Cfa.21178.2.S1_at -1.263 0.036 Casein kinase 1, gamma 3 Cfa.18620.1.S1_s_at -1.427 0.036 Cysteine and glycine-rich protein 1 Cfa.15285.3.S1_at -1.079 0.036 Catenin (cadherin-associated protein), alpha 1, 102kDa Cfa.9512.1.A1_at 1.152 0.036 chymotrypsinogen B1 CfaAffx.30742.1.S1_s_at 1.137 0.036 Cathepsin D Cfa.17547.1.S1_at 1.350 0.036 Chemokine (C-X-C motif) receptor 3 CfaAffx.26233.1.S1_s_at -1.114 0.036 Aspartyl-tRNA synthetase CfaAffx.8689.1.S1_s_at -1.357 0.036 Diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) CfaAffx.8277.1.S1_at 1.146 0.036 
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dCMP deaminase Cfa.13873.1.S1_at -1.328 0.036 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 CfaAffx.8348.1.S1_at -1.964 0.036 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 Cfa.19991.1.S1_at -1.285 0.036 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 CfaAffx.2470.1.S1_s_at -1.288 0.036 DEAD (Asp-Glu-Ala-Asp) box polypeptide 56 CfaAffx.5520.1.S1_at 1.220 0.036 Death effector domain containing CfaAffx.19733.1.S1_at 1.170 0.036 DENN/MADD domain containing 1A Cfa.12113.1.A1_at -1.336 0.036 DENN/MADD domain containing 4B CfaAffx.26653.1.S1_s_at -1.256 0.036 Diacylglycerol O-acyltransferase 2 Cfa.21170.1.S1_s_at 1.165 0.036 Dehydrogenase/reductase (SDR family) member 7C Cfa.2916.1.A1_at -1.230 0.036 DEAH (Asp-Glu-Ala-His) box polypeptide 16 CfaAffx.1606.1.S1_s_at -1.388 0.036 DEAH (Asp-Glu-Ala-His) box polypeptide 9 CfaAffx.20455.1.S1_s_at -1.157 0.036 Dihydrolipoamide dehydrogenase Cfa.862.1.S1_s_at -1.157 0.036 Dystrophia myotonica, WD repeat containing CfaAffx.7514.1.S1_s_at -1.346 0.036 DNA replication helicase 2 homolog (yeast) CfaAffx.21183.1.S1_at -1.137 0.036 Dynein, axonemal, heavy chain 10 CfaAffx.11481.1.S1_s_at 1.119 0.036 Dynein, axonemal, heavy chain 14 Cfa.7202.1.S1_a_at -1.375 0.036 DnaJ (Hsp40) homolog, subfamily B, member 12 Cfa.17078.1.S1_s_at 1.088 0.036 DnaJ (Hsp40) homolog, subfamily C, member 15 Cfa.7675.1.A1_s_at 1.145 0.036 DnaJ (Hsp40) homolog, subfamily C, member 16 Cfa.18042.1.S1_s_at -1.218 0.036 DnaJ (Hsp40) homolog, subfamily C, member 19 CfaAffx.18083.1.S1_s_at -1.173 0.036 Deoxyribonuclease I CfaAffx.29403.1.S1_s_at 1.146 0.036 aspartyl aminopeptidase CfaAffx.23735.1.S1_x_at 1.102 0.036 Dipeptidase 1 (renal) CfaAffx.30336.1.S1_at -1.194 0.036 Dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit Cfa.1802.3.S1_s_at -1.297 0.036 Dihydropyrimidinase CfaAffx.1938.1.S1_at 1.247 0.036 Drosha, ribonuclease type III CfaAffx.28945.1.S1_s_at -1.433 0.036 Dystonin CfaAffx.4544.1.S1_at 1.216 0.036 
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Dihydrouridine synthase 4-like (S. cerevisiae) Cfa.2748.1.A1_at -1.317 0.036 E2F transcription factor 4, p107/p130-binding CfaAffx.31199.1.S1_at -1.234 0.036 Early B-cell factor 1 CfaAffx.26525.1.S1_at -1.323 0.036 Extracellular matrix protein 1 CfaAffx.18675.1.S1_s_at 1.622 0.036 Endothelin 2 Cfa.2.1.S1_s_at 1.119 0.036 Epidermal growth factor Cfa.3524.1.S2_at 1.216 0.036 Eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa CfaAffx.7951.1.S1_s_at -1.232 0.036 Eukaryotic translation initiation factor 5A Cfa.8657.1.A1_at 1.213 0.036 Eukaryotic translation initiation factor 5B CfaAffx.4292.1.S1_at -1.272 0.036 ElaC homolog 2 (E. coli) Cfa.12195.10.A1_at -1.274 0.036 Elongation factor RNA polymerase II CfaAffx.22762.1.S1_s_at 1.515 0.036 Elongation protein 2 homolog (S. cerevisiae) Cfa.17346.1.S1_s_at -1.645 0.036 Echinoderm microtubule associated protein like 4 CfaAffx.10731.1.S1_s_at -1.583 0.036 Echinoderm microtubule associated protein like 5 CfaAffx.26723.1.S1_s_at -1.084 0.036 Enolase family member 4 CfaAffx.18482.1.S1_at 1.199 0.036 Erythrocyte membrane protein band 4.1-like 2 CfaAffx.2592.1.S1_s_at -1.070 0.036 Erythrocyte membrane protein band 4.1-like 3 Cfa.2671.2.S1_at 1.130 0.036 Epithelial cell adhesion molecule Cfa.12746.1.S1_at -1.245 0.036 EPH receptor B2 CfaAffx.22516.1.S1_s_at 1.177 0.036 Erythropoietin receptor CfaAffx.26647.1.S1_at -1.200 0.036 Epithelial stromal interaction 1 (breast) CfaAffx.18139.1.S1_s_at -2.300 0.036 Excision repair cross-complementing rodent repair deficiency, complementation group 6 Cfa.1909.1.A1_s_at -1.264 0.036 ERI1 exoribonuclease family member 3 CfaAffx.8156.1.S1_s_at -1.509 0.036 ESF1, nucleolar pre-rRNA processing protein, homolog (S. cerevisiae) CfaAffx.9329.1.S1_s_at -1.778 0.036 Ewing tumor-associated antigen 1 CfaAffx.5785.1.S1_at -1.363 0.036 Ethanolamine kinase 2 Cfa.6777.1.S1_s_at -1.194 0.036 Exocyst complex component 6B CfaAffx.14182.1.S1_s_at 1.398 0.036 Exosome component 8 CfaAffx.10167.1.S1_at -1.232 0.036 
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Exostoses (multiple)-like 2 Cfa.19919.1.S1_s_at -1.216 0.036 Fumarylacetoacetate hydrolase domain containing 2A Cfa.15241.1.S1_s_at 1.289 0.036 Fibulin 2 CfaAffx.7550.1.S1_s_at -1.128 0.036 F-box and WD repeat domain containing 10 Cfa.11549.1.A1_s_at 1.145 0.036 Free fatty acid receptor 2 CfaAffx.11413.1.S1_at 3.257 0.036 Fibroblast growth factor 19 CfaAffx.16710.1.S1_at 1.188 0.036 Four and a half LIM domains 2 Cfa.1493.1.A1_at -1.269 0.036 FK506 binding protein 15, 133kDa CfaAffx.5753.1.S1_at 1.212 0.036 Farnesyltransferase, CAAX box, alpha Cfa.18192.1.S1_at -1.292 0.036 Folate receptor 1 (adult) CfaAffx.9619.1.S1_s_at -1.186 0.036 Forkhead box I3 CfaAffx.11968.1.S1_at -1.078 0.036 Forkhead box K2 Cfa.8775.1.A1_at -1.419 0.036 FERM and PDZ domain containing 2 CfaAffx.10768.1.S1_at 1.287 0.036 Fibroblast growth factor receptor substrate 2 Cfa.1958.1.S1_at -1.490 0.036 FUN14 domain containing 1 Cfa.17008.1.S1_at -1.329 0.036 Fuzzy homolog (Drosophila) CfaAffx.6191.1.S1_at -1.223 0.036 Frataxin Cfa.9049.1.A1_at -1.125 0.036 FYVE and coiled-coil domain containing 1 Cfa.21347.1.S1_s_at 1.528 0.036 FRizzled homolog 7 (Drosophila) Cfa.15623.1.A1_at 1.251 0.036 Glucose-6-phosphatase, catalytic subunit Cfa.204.1.S1_s_at 1.223 0.036 Gamma-aminobutyric acid (GABA) A receptor, delta CfaAffx.29604.1.S1_at -1.262 0.036 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) CfaAffx.12475.1.S1_s_at 1.691 0.036 gGyceraldehyde-3-phosphate dehydrogenase AFFX-Cfa-gapdh-M_x_at 1.316 0.036 GAR1 ribonucleoprotein homolog (yeast) Cfa.21398.1.S1_s_at -1.280 0.036 GATA zinc finger domain containing 1 CfaAffx.3883.1.S1_at -1.272 0.036 Group-specific component (vitamin D binding protein) CfaAffx.5352.1.S1_at -1.173 0.036 Golgi-associated, gamma adaptin ear containing, ARF binding protein 1 Cfa.17715.1.S1_s_at 1.148 0.036 
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Gypsy retrotransposon integrase 1 CfaAffx.12178.1.S1_s_at -1.403 0.036 GINS complex subunit 2 (Psf2 homolog) CfaAffx.30492.1.S1_at -1.265 0.036 Gap junction protein, alpha 1, 43kDa Cfa.119.1.S1_at -5.484 0.036 GLI family zinc finger 3 CfaAffx.6242.1.S1_s_at -1.035 0.036 Glucagon-like peptide 2 receptor CfaAffx.26693.1.S1_at 1.190 0.036 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 CfaAffx.25135.1.S1_s_at -1.870 0.036 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits CfaAffx.11738.1.S1_s_at -1.692 0.036 Golgin A2 Cfa.19862.1.S1_s_at -1.315 0.036 Golgin A3 Cfa.4969.1.A1_at 1.342 0.036 Golgin A4 Cfa.2021.2.S1_at -1.434 0.036 Golgi integral membrane protein 4 Cfa.15237.2.S1_x_at -1.171 0.036 Glucose-6-phosphate isomerase Cfa.11243.2.S1_s_at 1.303 0.036 G protein-coupled receptor 107 CfaAffx.30541.1.S1_s_at 1.387 0.036 G protein-coupled receptor 124 CfaAffx.10264.1.S1_at -1.146 0.036 G protein-coupled receptor 153 CfaAffx.29925.1.S1_at -1.182 0.036 Glutathione peroxidase 2 (gastrointestinal) Cfa.12202.1.A1_at 1.442 0.036 Glutathione peroxidase 7 CfaAffx.6540.1.S1_at -1.313 0.036 GRB2-related adaptor protein 2 CfaAffx.2836.1.S1_s_at 1.242 0.036 Glutamate receptor, ionotropic, kainate 2 CfaAffx.6317.1.S1_at -1.158 0.036 Glutamate receptor, ionotropic, N-methyl D-aspartate 2D CfaAffx.6928.1.S1_at -1.134 0.036 Germ cell associated 1 CfaAffx.20415.1.S1_s_at 1.771 0.036 G1 to S phase transition 2 Cfa.16646.1.S1_at -1.319 0.036 Glutathione transferase zeta 1 CfaAffx.26294.1.S1_at 1.252 0.036 General transcription factor IIIC, polypeptide 2, beta 110kDa Cfa.13466.1.A1_at -1.182 0.036 General transcription factor IIIC, polypeptide 4, 90kDa CfaAffx.30436.1.S1_at 1.368 0.036 GTP binding protein 5 (putative) Cfa.14720.1.A1_at 1.252 0.036 GTP binding protein 6 (putative) CfaAffx.17078.1.S1_at 1.171 0.036 Gycogenin 1 Cfa.4710.1.A1_at 2.078 0.036 
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Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit CfaAffx.7356.1.S1_s_at -1.429 0.036 Hepcidin antimicrobial peptide Cfa.14486.1.S1_at -1.064 0.036 Helicase, lymphoid-specific CfaAffx.12909.1.S1_at -1.208 0.036 Hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing CfaAffx.20065.1.S1_s_at -1.137 0.036 3-hydroxyisobutyryl-CoA hydrolase CfaAffx.14905.1.S1_at 1.192 0.036 MBD2-interacting zinc finger CfaAffx.19014.1.S1_at 1.292 0.036 3-hydroxymethyl-3-methylglutaryl-CoA lyase CfaAffx.20284.1.S1_at 1.586 0.036 HNF1 homeobox B CfaAffx.27789.1.S1_at 1.166 0.036 Heterogeneous nuclear ribonucleoprotein A3 Cfa.4338.1.S1_at -1.253 0.036 Heterogeneous nuclear ribonucleoprotein R Cfa.11232.1.A1_at -1.123 0.036 5-hydroxytryptamine (serotonin) receptor 4 CfaAffx.28081.1.S1_at 1.272 0.036 Isoleucyl-tRNA synthetase CfaAffx.4356.1.S1_s_at -1.223 0.036 Indoleamine 2,3-dioxygenase 2 Cfa.14055.1.A1_at -1.186 0.036 Interferon, alpha 6 Cfa.15825.1.S1_x_at -1.187 0.036 Intraflagellar transport 27 homolog (Chlamydomonas) Cfa.9654.1.S1_at 1.197 0.036 Immunoglobulin superfamily, member 10 CfaAffx.13511.1.S1_at 1.168 0.036 Interleukin 1, beta CfaAffx.11741.1.S1_s_at 1.189 0.036 Interleukin 20 CfaAffx.17816.1.S1_at 1.233 0.036 Interleukin 23, alpha subunit p19 CfaAffx.1156.1.S1_at 4.263 0.036 Interleukin enhancer binding factor 3, 90kDa CfaAffx.27097.1.S1_s_at -1.462 0.036 INO80 complex subunit E CfaAffx.26108.1.S1_s_at -1.378 0.036 Inositol polyphosphate-4-phosphatase, type II, 105kDa CfaAffx.6377.1.S1_s_at 1.282 0.036 Insulin Cfa.18796.1.S1_s_at -1.053 0.036 IQ motif containing E Cfa.16498.1.S1_at 1.360 0.036 Interferon regulatory factor 3 Cfa.18322.1.S1_at 1.237 0.036 Interferon stimulated exonuclease gene 20kDa CfaAffx.17917.1.S1_at 2.777 0.036 Integrin, alpha 7 Cfa.18226.1.S1_s_at -1.064 0.036 
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Integrin, alpha D CfaAffx.22103.1.S1_at -1.119 0.036 Inter-alpha (globulin) inhibitor H2 Cfa.13306.1.A1_s_at -1.190 0.036 Katanin p60 subunit A-like 2 CfaAffx.26904.1.S1_s_at 1.183 0.036 Katanin p80 (WD repeat containing) subunit B 1 Cfa.8784.1.S1_at 1.168 0.036 Kazal-type serine peptidase inhibitor domain 1 CfaAffx.15418.1.S1_at -1.205 0.036 Potassium channel, subfamily T, member 1 CfaAffx.30205.1.S1_s_at 1.148 0.036 Potassium channel tetramerisation domain containing 15 CfaAffx.11895.1.S1_at -1.231 0.036 Potassium channel tetramerisation domain containing 9 CfaAffx.14165.1.S1_s_at -2.251 0.036 Kinesin family member 26B CfaAffx.24281.1.S1_s_at -1.154 0.036 Kinesin family member 6 CfaAffx.3233.1.S1_at 1.130 0.036 Kinesin family member C3 CfaAffx.13645.1.S1_at 1.413 0.036 Kin of IRRE like 2 (Drosophila) CfaAffx.11006.1.S1_at -1.178 0.036 Kinesin light chain 2 CfaAffx.20017.1.S1_at -1.120 0.036 Kelch-like 32 (Drosophila) CfaAffx.6115.1.S1_at -1.196 0.036 KRI1 homolog (S. cerevisiae) Cfa.21226.1.S1_s_at 1.223 0.036 Kinectin 1 (kinesin receptor) CfaAffx.23345.1.S1_s_at -1.114 0.036 Lysosomal-associated membrane protein 1 CfaAffx.10473.1.S1_s_at -2.425 0.036 La ribonucleoprotein domain family, member 7 CfaAffx.18216.1.S1_s_at -1.330 0.036 Lipocalin 2 CfaAffx.30748.1.S1_at 2.561 0.036 Leptin receptor overlapping transcript-like 1 Cfa.9151.1.A1_s_at 1.258 0.036 LETM1 domain containing 1 Cfa.10550.2.S1_at -1.782 0.036 Lectin, galactoside-binding, soluble, 12 CfaAffx.23223.1.S1_s_at 1.119 0.036 Legumain CfaAffx.17218.1.S1_at 1.393 0.036 LIM homeobox 2 CfaAffx.30978.1.S1_at -1.065 0.036 Lens intrinsic membrane protein 2, 19kDa CfaAffx.5185.1.S1_at -1.279 0.036 Lethal giant larvae homolog 2 (Drosophila) CfaAffx.8193.1.S1_at -1.275 0.036 Leiomodin 3 (fetal) Cfa.15741.1.A1_at 1.233 0.036 LON peptidase N-terminal domain and ring finger 2 CfaAffx.4233.1.S1_at 1.191 0.036 Low density lipoprotein receptor-related protein 2 Cfa.14034.1.A1_at 1.372 0.036 
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Leucine rich repeat containing 36 CfaAffx.31181.1.S1_s_at 1.148 0.036 Leucine rich repeat containing 49 CfaAffx.26965.1.S1_s_at 1.316 0.036 Leucine-rich repeats and IQ motif containing 3 CfaAffx.31251.1.S1_at 1.213 0.036 Leucine-rich repeats and IQ motif containing 4 CfaAffx.22698.1.S1_at 1.217 0.036 Leucine rich repeat and sterile alpha motif containing 1 Cfa.17052.1.S1_at -1.347 0.036 LSM10, U7 small nuclear RNA associated Cfa.16663.1.A1_at -1.204 0.036 LUC7-like 2 (S. cerevisiae) Cfa.17776.1.S1_at -1.143 0.036 LysM, putative peptidoglycan-binding, domain containing 2 CfaAffx.23800.1.S1_s_at -1.551 0.036 Leucine zipper transcription factor-like 1 Cfa.17180.1.S1_at 1.289 0.036 Male germ cell-associated kinase CfaAffx.15292.1.S1_at 1.468 0.036 Mitogen-activated protein kinase kinase kinase 10 CfaAffx.9015.1.S1_at -1.168 0.036 Mitogen-activated protein kinase kinase kinase kinase 1 CfaAffx.9778.1.S1_s_at -1.270 0.036 Microtubule-associated protein 6 CfaAffx.9005.1.S1_at 1.319 0.036 Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) CfaAffx.21414.1.S1_s_at -1.190 0.036 Methionine adenosyltransferase I, alpha Cfa.18757.1.S1_at 1.130 0.036 Matrin 3 Cfa.4360.1.S1_s_at -1.141 0.036 Minichromosome maintenance complex component 4 Cfa.18077.1.S1_s_at -1.432 0.036 Microspherule protein 1 Cfa.18343.1.S1_at 1.181 0.036 Multiple C2 domains, transmembrane 1 CfaAffx.12819.1.S1_s_at -1.233 0.036 Mediator complex subunit 30 Cfa.21628.1.S1_at -1.789 0.036 Mediator complex subunit 7 CfaAffx.26895.1.S1_s_at -1.110 0.036 Methyltransferase like 14 Cfa.10848.1.S1_at -1.177 0.036 Melanoma inhibitory activity 2 CfaAffx.21431.1.S1_at 1.177 0.036 Microtubule associated monoxygenase, calponin and LIM domain containing 2 CfaAffx.12627.1.S1_at -1.121 0.036 Myo-inositol oxygenase CfaAffx.1775.1.S1_s_at -1.192 0.036 Microphthalmia-associated transcription factor CfaAffx.10709.1.S1_s_at 1.203 0.036 Myeloid leukemia factor 1 Cfa.20466.1.S1_at 1.272 0.036 
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MTOR associated protein, LST8 homolog (S. cerevisiae) CfaAffx.29667.1.S1_at 1.095 0.036 Monoacylglycerol O-acyltransferase 3 Cfa.13722.1.A1_s_at 1.146 0.036 Mov10, Moloney leukemia virus 10, homolog (mouse) CfaAffx.20801.1.S1_at -1.126 0.036 M-phase phosphoprotein 6 Cfa.1229.2.S1_a_at -1.283 0.036 Mercaptopyruvate sulfurtransferase Cfa.21333.1.S1_at 1.143 0.036 Myelin protein zero-like 1 CfaAffx.23659.1.S1_at -1.488 0.036 Mitochondrial ribosomal protein L14 Cfa.307.9.A1_s_at 1.286 0.036 Mitochondrial ribosomal protein L4 CfaAffx.27357.1.S1_at -1.316 0.036 Mitochondrial ribosomal protein S28 CfaAffx.13318.1.S1_s_at -1.240 0.036 MRS2 magnesium homeostasis factor homolog (S. cerevisiae) CfaAffx.16047.1.S1_at -1.220 0.036 Membrane-spanning 4-domains, subfamily A, member 4 Cfa.15710.1.A1_at 1.328 0.036 Methionine sulfoxide reductase B3 CfaAffx.1500.1.S1_s_at 2.560 0.036 Serine/threonine protein kinase MST4 CfaAffx.28751.1.S1_at 1.193 0.036 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase Cfa.4755.1.A1_at 1.119 0.036 Myotubularin related protein 11 CfaAffx.18111.1.S1_s_at 1.237 0.036 Myotubularin related protein 4 CfaAffx.26777.1.S1_s_at -1.455 0.036 Myotubularin related protein 9 CfaAffx.12888.1.S1_at -1.203 0.036 Metastasis suppressor 1-like CfaAffx.30863.1.S1_at 1.182 0.036 Mucin 19, oligomeric CfaAffx.15555.1.S1_at 1.096 0.036 Mucin 5B, oligomeric mucus/gel-forming CfaAffx.15591.1.S1_at -1.070 0.036 Myogenic factor 5 CfaAffx.9675.1.S1_at 1.207 0.036 Myosin, heavy chain 9, non-muscle CfaAffx.3434.1.S1_at -1.888 0.036 Myosin IIIB CfaAffx.19378.1.S1_at 1.108 0.036 Myomesin family, member 3 CfaAffx.20206.1.S1_at -1.083 0.036 N(alpha)-acetyltransferase 16, NatA auxiliary subunit CfaAffx.8127.1.S1_s_at -1.270 0.036 N(alpha)-acetyltransferase 35, NatC auxiliary subunit CfaAffx.2910.1.S1_at -1.176 0.036 N-acetylneuraminic acid synthase Cfa.16909.1.S1_s_at 1.438 0.036 
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Neurocalcin delta Cfa.16838.1.S1_at -1.231 0.036 Neural cell adhesion molecule 2 CfaAffx.13380.1.S1_at 1.213 0.036 Non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) CfaAffx.9335.1.S1_at 2.758 0.036 Nuclear receptor coactivator 6 Cfa.12454.1.A1_at -1.209 0.036 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa Cfa.10920.1.S1_x_at -1.090 0.036 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 17.3kDa Cfa.4152.1.A1_s_at 1.111 0.036 Nebulette CfaAffx.7112.1.S1_s_at 1.107 0.036 Nei endonuclease VIII-like 2 (E. coli) Cfa.2134.1.S1_at -1.176 0.036 Nuclear factor, interleukin 3 regulated Cfa.6371.1.A1_at 1.789 0.036 Ninein (GSK3B interacting protein) CfaAffx.22466.1.S1_at -1.178 0.036 NME1-NME2 readthrough CfaAffx.26483.1.S1_s_at 1.290 0.036 N-myristoyltransferase 1 Cfa.17031.1.S1_at 1.318 0.036 Neuronatin CfaAffx.13888.1.S1_at -1.226 0.036 Nucleolar and coiled-body phosphoprotein 1 CfaAffx.15780.1.S1_s_at -1.937 0.036 Nuclear protein localization 4 homolog (S. cerevisiae) CfaAffx.9604.1.S1_at 1.251 0.036 Natriuretic peptide precursor C CfaAffx.17373.1.S1_at -1.262 0.036 Nik related kinase CfaAffx.27370.1.S1_at 1.212 0.036 Non-SMC element 1 homolog (S. cerevisiae) Cfa.6987.1.S1_at 1.120 0.036 5'-nucleotidase, ecto (CD73) CfaAffx.5438.1.S1_at 1.244 0.036 N-terminal asparagine amidase CfaAffx.28681.1.S1_at 1.268 0.036 NudC domain containing 3 Cfa.18578.1.S1_at -1.081 0.036 Nudix (nucleoside diphosphate linked moiety X)-type motif 9 Cfa.1573.1.S1_s_at -1.175 0.036 Numb homolog (Drosophila)-like CfaAffx.8624.1.S1_at 1.195 0.036 Nucleoporin 210kDa CfaAffx.7516.1.S1_at -1.131 0.036 Nucleoporin 214kDa CfaAffx.30488.1.S1_s_at -1.376 0.036 Nucleoporin 54kDa Cfa.17092.1.S1_at -1.175 0.036 Nucleoporin 93kDa CfaAffx.14363.1.S1_at -1.306 0.036 Nucleoporin like 2 CfaAffx.5029.1.S1_at -1.203 0.036 Allergen Can f 4 CfaAffx.17457.1.S1_at 1.175 0.036 
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Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF CfaAffx.2641.1.S1_at 1.202 0.036 Otoconin 90 CfaAffx.2523.1.S1_s_at 1.179 0.036 OCIA domain containing 1 Cfa.18958.2.S1_at 1.381 0.036 Outer dense fiber of sperm tails 1 CfaAffx.1877.1.S1_s_at 1.216 0.036 Oral-facial-digital syndrome 1 CfaAffx.18295.1.S1_s_at -1.266 0.036 Opsin 4 CfaAffx.24493.1.S1_at 1.159 0.036 Olfactory receptor CfaAffx.24879.1.S1_at -1.083 0.036 Olfactory receptor CfaAffx.29984.1.S1_at 1.129 0.036 Olfactory receptor CfaAffx.17625.1.S1_at 1.112 0.036 Olfactory receptor CfaAffx.16866.1.S1_at 1.113 0.036 Origin recognition complex, subunit 5 Cfa.16807.2.S1_at -1.257 0.036 OTU domain containing 5 CfaAffx.24037.1.S1_at -1.357 0.036 Oxidation resistance 1 CfaAffx.1950.1.S1_s_at -1.288 0.036 Platelet-activating factor acetylhydrolase 2, 40kDa Cfa.18324.1.S1_s_at 1.489 0.036 Phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase Cfa.1028.1.A1_s_at -1.154 0.036 Poly (ADP-ribose) polymerase 1 Cfa.21541.1.S1_s_at -1.436 0.036 Pyruvate carboxylase Cfa.18692.1.S1_s_at 1.166 0.036 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) CfaAffx.18467.1.S1_at -1.631 0.036 Protein-L-isoaspartate (D-aspartate) O-methyltransferase CfaAffx.1550.1.S1_at -1.376 0.036 Programmed cell death 1 CfaAffx.20414.1.S1_at 1.165 0.036 Phosphodiesterase 4D interacting protein Cfa.20329.1.S1_at 1.140 0.036 Peptide deformylase (mitochondrial) CfaAffx.31057.1.S1_at -1.317 0.036 PDZ domain containing 1 CfaAffx.17419.1.S1_s_at -1.119 0.036 Proenkephalin Cfa.1416.1.A1_at 1.228 0.036 Peptidase D CfaAffx.11958.1.S1_s_at 1.329 0.036 Peroxisomal biogenesis factor 19 Cfa.11963.1.A1_at -1.082 0.036 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 Cfa.13232.1.A1_at -1.274 0.036 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Cfa.21468.1.S1_at -1.359 0.036 
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Peptidoglycan recognition protein 2 CfaAffx.24479.1.S1_s_at -1.144 0.036 PHD and ring finger domains 1 CfaAffx.10774.1.S1_s_at -1.246 0.036 Phosphatidylinositol glycan anchor biosynthesis, class M CfaAffx.18440.1.S1_at -1.404 0.036 Protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) CfaAffx.9310.1.S1_x_at -1.309 0.036 Phosphatidylinositol-4-phosphate 5-kinase, type I, gamma CfaAffx.29305.1.S1_at -1.112 0.036 Phosphatidylinositol-4-phosphate 5-kinase-like 1 CfaAffx.30766.1.S1_at -1.373 0.036 Pirin (iron-binding nuclear protein) CfaAffx.18617.1.S1_at 1.184 0.036 Phosphatidylinositol transfer protein, cytoplasmic 1 CfaAffx.17853.1.S1_s_at 1.358 0.036 Polycystic kidney disease 2-like 2 CfaAffx.2600.1.S1_s_at -1.233 0.036 Polycystic kidney and hepatic disease 1 (autosomal recessive) CfaAffx.4150.1.S1_s_at -1.170 0.036 Phospholipase A2, group VI (cytosolic, calcium-independent) CfaAffx.3029.1.S1_s_at -1.181 0.036 Plasminogen activator, urokinase receptor CfaAffx.8028.1.S1_s_at 2.816 0.036 Pleckstrin homology domain containing, family M (with RUN domain) member 1 CfaAffx.21270.1.S1_at 1.643 0.036 Polo-like kinase 1 substrate 1 Cfa.9547.1.A1_at 1.097 0.036 Phospholamban Cfa.3165.2.A1_at 1.207 0.036 Phospholipid scramblase 4 CfaAffx.12996.1.S1_at -1.694 0.036 Pro-melanin-concentrating hormone CfaAffx.11803.1.S1_at 1.243 0.036 Phosphomannomutase 2 CfaAffx.29042.1.S1_at 1.377 0.036 Peripheral myelin protein 22 CfaAffx.27421.1.S1_at 1.453 0.036 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) CfaAffx.14811.1.S1_at -1.220 0.036 Pancreatic lipase Cfa.3882.3.S1_at -1.123 0.036 Patatin-like phospholipase domain containing 5 CfaAffx.2256.1.S1_s_at 1.109 0.036 POC1 centriolar protein homolog A (Chlamydomonas) CfaAffx.15464.1.S1_s_at 1.324 0.036 POC1 centriolar protein homolog B (Chlamydomonas) CfaAffx.10156.1.S1_at -1.566 0.036 Phosphatidic acid phosphatase type 2C Cfa.18746.1.S1_s_at 1.510 0.036 Peroxisome proliferator-activated receptor alpha Cfa.3519.1.S1_s_at -1.129 0.036 Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha CfaAffx.25283.1.S1_at -1.133 0.036 
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Protein phosphatase 4, regulatory subunit 1 Cfa.12339.1.A1_at 1.326 0.036 Protein kinase C, zeta Cfa.19185.2.A1_at -1.204 0.036 Protein kinase D1 Cfa.12558.1.A1_s_at -1.612 0.036 PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae) Cfa.3344.1.S1_at -1.239 0.036 Proline rich Gla (G-carboxyglutamic acid) 2 CfaAffx.6355.1.S1_at -1.262 0.036 Protease, serine, 42 CfaAffx.21079.1.S1_s_at -1.604 0.036 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 CfaAffx.15655.1.S1_s_at -1.197 0.036 Proteasome (prosome, macropain) activator subunit 4 CfaAffx.4992.1.S1_s_at 1.357 0.036 Prostaglandin E receptor 3 (subtype EP3) Cfa.132.2.S1_a_at 1.134 0.036 Parathyroid hormone 1 receptor Cfa.3643.1.S1_s_at -1.449 0.036 PTK2 protein tyrosine kinase 2 Cfa.5377.1.A1_at 1.207 0.036 Protein tyrosine phosphatase, mitochondrial 1 CfaAffx.13364.1.S1_at 1.264 0.036 Protein tyrosine phosphatase, non-receptor type 14 CfaAffx.19519.1.S1_s_at -1.220 0.036 Protein tyrosine phosphatase, non-receptor type 2 CfaAffx.28811.1.S1_at 1.506 0.036 PWP1 homolog (S. cerevisiae) Cfa.10480.1.A1_at -1.257 0.036 Pygopus homolog 2 (Drosophila) CfaAffx.26250.1.S1_at -1.220 0.036 Glutamine rich 2 CfaAffx.8523.1.S1_s_at -1.281 0.036 queuine tRNA-ribosyltransferase domain containing 1 CfaAffx.16818.1.S1_at -1.456 0.036 RAB4B, member RAS oncogene family CfaAffx.8550.1.S1_s_at 1.217 0.036 RAB, member RAS oncogene family-like 5 CfaAffx.21318.1.S1_at 1.191 0.036 RalA binding protein 1 Cfa.14547.1.A1_at 2.421 0.036 Receptor (G protein-coupled) activity modifying protein 2 Cfa.11182.1.A1_s_at -1.934 0.036 RAS association (RalGDS/AF-6) domain family member 6 CfaAffx.5490.1.S1_at 1.205 0.036 RNA binding protein, fox-1 homolog (C. elegans) 1 CfaAffx.29131.1.S1_s_at 1.136 0.036 RNA binding motif protein 34 Cfa.2425.1.S1_s_at -1.335 0.036 Retinol binding protein 1, cellular CfaAffx.12273.1.S1_s_at 1.398 0.036 Retinol binding protein 2, cellular Cfa.6245.1.A1_at 1.288 0.036 Reticulocalbin 2, EF-hand calcium binding domain Cfa.21641.1.S1_at -1.335 0.036 REST corepressor 3 CfaAffx.18828.1.S1_s_at -1.264 0.036 
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Retinol dehydrogenase 5 (11-cis/9-cis) CfaAffx.1065.1.S1_at 1.230 0.036 REV1 homolog (S. cerevisiae) CfaAffx.4279.1.S1_s_at -1.368 0.036 Regulatory factor X, 2 (influences HLA class II expression) CfaAffx.28610.1.S1_s_at 1.341 0.036 Regulatory factor X, 4 (influences HLA class II expression) CfaAffx.3623.1.S1_at -1.208 0.036 Ral guanine nucleotide dissociation stimulator-like 3 CfaAffx.26633.1.S1_s_at 1.170 0.036 Regulator of G-protein signaling 6 Cfa.1840.1.S1_s_at 1.193 0.036 Rh blood group, D antigen CfaAffx.19949.1.S1_at -1.196 0.036 RAS homolog gene family, member T1 CfaAffx.28233.1.S1_s_at -1.449 0.036 Resistance to inhibitors of cholinesterase 3 homolog (C. elegans) CfaAffx.11252.1.S1_s_at -1.280 0.036 Rab interacting lysosomal protein-like 1 CfaAffx.12089.1.S1_s_at -1.245 0.036 Retinaldehyde binding protein 1 CfaAffx.18016.1.S1_at 1.224 0.036 Ring finger protein 144A CfaAffx.5868.1.S1_at -1.106 0.036 Ring finger protein 148 CfaAffx.6272.1.S1_at 1.364 0.036 Ring finger protein 213 CfaAffx.9471.1.S1_s_at -1.783 0.036 Ring finger protein 217 CfaAffx.2434.1.S1_at 1.228 0.036 Ring finger protein 25 Cfa.11589.1.A1_at 1.192 0.036 RNA guanylyltransferase and 5'-phosphatase CfaAffx.5573.1.S1_at -1.383 0.036 Roundabout, axon guidance receptor, homolog 1 (Drosophila) CfaAffx.12712.1.S1_s_at -2.098 0.036 Rho-associated, coiled-coil containing protein kinase 1 CfaAffx.27952.1.S1_at 1.240 0.036 Reactive oxygen species modulator 1 Cfa.8706.1.S1_at 1.129 0.036 Ribonuclease P/MRP 21kDa subunit Cfa.8855.2.S1_at -1.216 0.036 Regulation of nuclear pre-mRNA domain containing 1B CfaAffx.13968.1.S1_at -1.165 0.036 RNA pseudouridylate synthase domain containing 2 Cfa.4769.1.A1_at 1.551 0.036 Ras-related associated with diabetes Cfa.17583.1.S1_at 1.874 0.036 RRN3 RNA polymerase I transcription factor homolog (S. cerevisiae) CfaAffx.28690.1.S1_at -1.555 0.036 Ribosomal RNA processing 15 homolog (S. cerevisiae) CfaAffx.16920.1.S1_at -1.579 0.036 Retinoschisin 1 CfaAffx.19864.1.S1_at -1.189 0.036 Rhotekin 2 CfaAffx.20164.1.S1_at -1.235 0.036 Shwachman-Bodian-Diamond syndrome Cfa.17197.1.S1_at -1.183 0.036 
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Saccharopine dehydrogenase (putative) Cfa.5433.1.A1_at 1.514 0.036 Sodium channel, voltage-gated, type IX, alpha subunit CfaAffx.17961.1.S1_at 1.109 0.036 Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) CfaAffx.24257.1.S1_s_at 1.129 0.036 SEC14-like 2 (S. cerevisiae) Cfa.10916.1.A1_s_at -1.224 0.036 SECIS binding protein 2 Cfa.14796.1.S1_at -1.061 0.036 SEH1-like (S. cerevisiae) Cfa.18120.1.S1_s_at -2.035 0.036 SUMO1/sentrin specific peptidase 6 CfaAffx.4947.1.S1_at -1.244 0.036 Serpin peptidase inhibitor, clade B (ovalbumin), member 6 Cfa.6273.1.S1_at 1.444 0.036 SET translocation Cfa.73.1.S1_x_at -1.233 0.036 SET domain containing 6 CfaAffx.13402.1.S1_at -1.441 0.036 SET domain, bifurcated 2 Cfa.1534.1.A1_at 1.138 0.036 Seizure related 6 homolog (mouse) CfaAffx.28798.1.S1_at -1.382 0.036 SH3-domain GRB2-like 3 CfaAffx.20540.1.S1_at 1.159 0.036 Src homology 2 domain containing E CfaAffx.26278.1.S1_at -1.147 0.036 Sucrase-isomaltase (alpha-glucosidase) CfaAffx.22283.1.S1_s_at 1.204 0.036 Sialic acid acetylesterase CfaAffx.17446.1.S1_at 1.159 0.036 Stem-loop binding protein Cfa.15304.1.A1_at -1.187 0.036 Solute carrier family 13 (sodium/sulfate symporters), member 4 CfaAffx.5962.1.S1_at 1.267 0.036 Solute carrier family 16, member 10 (aromatic amino acid transporter) CfaAffx.6815.1.S1_at -1.650 0.036 Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 CfaAffx.15821.1.S1_s_at 1.231 0.036 Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8 CfaAffx.11134.1.S1_at -1.123 0.036 Solute carrier family 22 (organic anion/urate transporter), member 11 CfaAffx.22191.1.S1_s_at 1.131 0.036 Solute carrier family 22 (organic anion transporter), member 6 Cfa.14330.1.A1_at -1.183 0.036 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 CfaAffx.3350.1.S1_at 1.189 0.036 Solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), member 19 CfaAffx.8076.1.S1_s_at 1.259 0.036 
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Solute carrier family 25, member 27 Cfa.2665.1.A1_at 1.319 0.036 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 CfaAffx.6830.1.S1_at -1.129 0.036 Solute carrier family 25, member 34 Cfa.17246.1.S1_s_at -1.139 0.036 Solute carrier family 26, member 4 CfaAffx.6797.1.S1_at 1.310 0.036 Solute carrier family 30 (zinc transporter), member 3 Cfa.6122.1.A1_at 1.234 0.036 Solute carrier family 33 (acetyl-CoA transporter), member 1 Cfa.593.1.A1_at -1.224 0.036 Solute carrier family 35, member D3 CfaAffx.1344.1.S1_at -1.292 0.036 Solute carrier family 36 (proton/amino acid symporter), member 2 Cfa.5442.1.A1_at 1.164 0.036 Solute carrier family 9 (sodium/hydrogen exchanger), member 2 CfaAffx.4098.1.S1_at -1.155 0.036 Slowmo homolog 1 (Drosophila) CfaAffx.28774.1.S1_at 1.190 0.036 Structural maintenance of chromosomes 3 CfaAffx.16837.1.S1_at -1.250 0.036 SMEK homolog 1, suppressor of mek1 (Dictyostelium) CfaAffx.26905.1.S1_at 1.171 0.036 Smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) Cfa.1924.1.A1_at -1.183 0.036 Small nuclear RNA activating complex, polypeptide 2, 45kDa Cfa.18618.1.S1_s_at -1.227 0.036 Small nuclear RNA activating complex, polypeptide 4, 190kDa Cfa.16205.1.S1_at -1.151 0.036 SNAP-associated protein Cfa.6879.1.A1_at -1.163 0.036 Small nuclear ribonucleoprotein polypeptide N /// SNRPN upstream reading frame CfaAffx.928.1.S1_at 1.143 0.036 Sorting nexin 14 Cfa.2011.1.S1_s_at -1.100 0.036 Sorting nexin 5 CfaAffx.9150.1.S1_s_at -1.231 0.036 SP100 nuclear antigen CfaAffx.16746.1.S1_at -1.261 0.036 Spermatogenesis associated 18 homolog (rat) CfaAffx.3931.1.S1_s_at 1.115 0.036 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) CfaAffx.26814.1.S1_at 1.346 0.036 Sulfide quinone reductase-like (yeast) CfaAffx.21303.1.S1_at 1.261 0.036 Steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) Cfa.3579.1.S1_s_at 1.162 0.036 SRSF protein kinase 2 Cfa.10743.1.S1_s_at 1.410 0.036 
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Serine/arginine-rich splicing factor 2 Cfa.10605.1.S1_at -1.286 0.036 Serine/arginine-rich splicing factor 6 Cfa.277.1.S1_at -1.252 0.036 Somatostatin receptor 3 CfaAffx.3154.1.S1_at -1.097 0.036 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 Cfa.15365.1.A1_at -1.418 0.036 SH3 and cysteine rich domain 2 CfaAffx.25236.1.S1_s_at 1.130 0.036 StAR-related lipid transfer (START) domain containing 3 Cfa.20925.1.S1_s_at 1.314 0.036 StAR-related lipid transfer (START) domain containing 9 CfaAffx.17398.1.S1_s_at 1.107 0.036 Syntaxin 16 CfaAffx.18848.1.S1_s_at -1.440 0.036 Syntaxin 17 CfaAffx.4679.1.S1_at 1.504 0.036 Syntaxin 6 CfaAffx.19887.1.S1_at 1.258 0.036 Succinate-CoA ligase, GDP-forming, beta subunit Cfa.1485.1.S1_at -1.137 0.036 Sulfotransferase family, cytosolic, 1C, member 3 CfaAffx.3994.1.S1_s_at 1.263 0.036 Sulfotransferase family, cytosolic, 6B, member 1 CfaAffx.10100.1.S1_at 1.106 0.036 Sad1 and UNC84 domain containing 3 CfaAffx.21815.1.S1_at 1.255 0.036 Suppressor of variegation 3-9 homolog 1 (Drosophila) CfaAffx.23834.1.S1_s_at -1.169 0.036 Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 Cfa.2424.1.S1_at 1.555 0.036 Syncollin Cfa.16560.1.S1_at -1.117 0.036 Spectrin repeat containing, nuclear envelope 1 Cfa.14004.1.A1_at 1.276 0.036 Synaptogyrin 1 CfaAffx.2905.1.S1_s_at 2.048 0.036 SYS1 Golgi-localized integral membrane protein homolog (S. cerevisiae) Cfa.4337.1.A1_at 1.316 0.036 synaptotagmin-like 5 CfaAffx.21552.1.S1_s_at -1.252 0.036 TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 80kDa CfaAffx.22602.1.S1_at -1.164 0.036 Taste receptor, type 2, member 40 Cfa.12619.1.A1_at -1.056 0.036 T-box 4 Cfa.11.1.S1_s_at 1.372 0.036 Trichohyalin CfaAffx.20088.1.S1_x_at 1.425 0.036 Tectonic family member 2 Cfa.5605.1.A1_at 1.678 0.036 Tyrosyl-DNA phosphodiesterase 1 CfaAffx.26760.1.S1_s_at -1.301 0.036 
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thyrotrophic embryonic factor CfaAffx.2512.1.S1_s_at 1.164 0.036 Thrombospondin, type I, domain containing 4 CfaAffx.26988.1.S1_at -1.187 0.036 Thiamine triphosphatase CfaAffx.18104.1.S1_at -1.280 0.036 THUMP domain containing 1 CfaAffx.27547.1.S1_at -1.225 0.036 Tubulointerstitial nephritis antigen CfaAffx.4346.1.S1_s_at -1.103 0.036 TCDD-inducible poly(ADP-ribose) polymerase CfaAffx.14014.1.S1_at 1.459 0.036 Tousled-like kinase 1 CfaAffx.19441.1.S1_at -1.338 0.036 Toll-like receptor 3 CfaAffx.11983.1.S1_at -2.115 0.036 Transmembrane and coiled-coil domains 3 Cfa.9679.1.S1_at -1.297 0.036 Transmembrane protein 110 CfaAffx.13932.1.S1_at 1.342 0.036 Transmembrane protein 138 CfaAffx.24818.1.S1_at -1.306 0.036 Transmembrane protein 161B CfaAffx.13247.1.S1_s_at -1.523 0.036 Transmembrane protein 165 CfaAffx.4052.1.S1_at -1.283 0.036 Transmembrane protein 176B CfaAffx.7828.1.S1_at -1.398 0.036 Transmembrane protein 195 Cfa.14573.1.A1_s_at 1.138 0.036 Transmembrane protein 51 CfaAffx.25028.1.S1_at -1.354 0.036 Transmembrane protein 70 CfaAffx.12987.1.S1_s_at -1.150 0.036 Tumor necrosis factor (ligand) superfamily, member 15 CfaAffx.5977.1.S1_at 1.220 0.036 Two pore segment channel 1 CfaAffx.14287.1.S1_at 1.167 0.036 Tropomyosin 1 (alpha) CfaAffx.25960.1.S1_at 1.250 0.036 Triadin CfaAffx.2407.1.S1_s_at -1.184 0.036 Thyrotropin-releasing hormone CfaAffx.7825.1.S1_at -1.881 0.036 Tribbles homolog 1 (Drosophila) Cfa.12502.1.A1_at 1.542 0.036 Tripartite motif-containing 10 CfaAffx.18982.1.S1_s_at -1.117 0.036 Tripartite motif-containing 22 CfaAffx.10368.1.S1_s_at -1.923 0.036 Tripartite motif-containing 45 CfaAffx.15460.1.S1_at -1.541 0.036 Tripartite motif-containing 68 CfaAffx.10097.1.S1_at -1.112 0.036 Tripartite motif family-like 1 CfaAffx.11713.1.S1_at 1.138 0.036 TSC22 domain family, member 1 CfaAffx.7831.1.S1_s_at -1.259 0.036 
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Tetraspanin 17 Cfa.21314.1.S1_at 1.305 0.036 Translocator protein (18kDa) Cfa.16771.1.S1_s_at 1.334 0.036 Tetratricopeptide repeat domain 19 Cfa.17411.1.S1_at -1.472 0.036 Tubulin tyrosine ligase-like family, member 3 CfaAffx.8903.1.S1_s_at -1.182 0.036 Titin CfaAffx.21671.1.S1_s_at -1.064 0.036 Tubulin, gamma complex associated protein 4 CfaAffx.19226.1.S1_at -1.443 0.036 Tubulin, gamma complex associated protein 6 CfaAffx.1962.1.S1_at -1.150 0.036 Taxilin gamma CfaAffx.19577.1.S1_at -1.176 0.036 Ubiquitin associated protein 2-like CfaAffx.26406.1.S1_at 1.171 0.036 UBX domain protein 1 Cfa.13688.1.A1_s_at 1.181 0.036 Upper zone of growth plate and cartilage matrix associated CfaAffx.8054.1.S1_s_at 1.112 0.036 Unc-5 homolog C (C. elegans) CfaAffx.16004.1.S1_s_at 1.187 0.036 Ubiquinol-cytochrome c reductase core protein I Cfa.794.1.A1_at 1.107 0.036 URB1 ribosome biogenesis 1 homolog (S. cerevisiae) Cfa.4795.1.A1_at -1.342 0.036 USO1 vesicle docking protein homolog (yeast) CfaAffx.13431.1.S1_at 1.371 0.036 Ubiquitin specific peptidase 1 Cfa.19994.1.S1_s_at -1.434 0.036 Ubiquitin specific peptidase 20 CfaAffx.30576.1.S1_s_at 1.707 0.036 Ubiquitin specific peptidase 36 CfaAffx.9238.1.S1_at -1.335 0.036 USP6 N-terminal like Cfa.19504.1.S1_at 1.392 0.036 Vesicle-associated membrane protein 8 (endobrevin) Cfa.8500.1.A1_at 1.279 0.036 Ventricular zone expressed PH domain homolog 1 (zebrafish) CfaAffx.14042.1.S1_at 1.129 0.036 Vezatin, adherens junctions transmembrane protein CfaAffx.10479.1.S1_s_at 1.537 0.036 visinin-like 1 CfaAffx.5538.1.S1_s_at 1.186 0.036 von Willebrand factor A domain containing 3B Cfa.16521.1.S1_s_at 1.212 0.036 WAS protein family, member 2 CfaAffx.18830.1.S1_s_at -1.281 0.036 WAS protein family, member 3 CfaAffx.11185.1.S1_s_at -1.148 0.036 WW domain binding protein 11 Cfa.8372.1.S1_s_at -1.446 0.036 WD repeat domain 11 Cfa.8362.1.A1_at 1.226 0.036 WD repeat domain 12 Cfa.10515.1.S1_at -1.215 0.036 
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WD repeat domain 48 Cfa.2333.2.S1_s_at -1.654 0.036 WD repeat domain 62 Cfa.6553.1.S1_s_at -1.181 0.036 WD repeat domain 82 pseudogene 1 Cfa.19770.1.S1_s_at -1.204 0.036 WD repeat domain 87 CfaAffx.9944.1.S1_at 1.157 0.036 Wolf-Hirschhorn syndrome candidate 1 CfaAffx.23014.1.S1_s_at 1.291 0.036 Wolf-Hirschhorn syndrome candidate 2 CfaAffx.22972.1.S1_s_at -1.215 0.036 X-ray repair complementing defective repair in Chinese hamster cells 4 CfaAffx.13644.1.S1_at -1.538 0.036 5'-3' exoribonuclease 2 Cfa.10494.1.A1_s_at -1.107 0.036 YLP motif containing 1 CfaAffx.25973.1.S1_s_at -1.594 0.036 YME1-like 1 (S. cerevisiae) Cfa.1083.1.S1_at -1.161 0.036 Zonadhesin CfaAffx.21670.1.S1_s_at -1.163 0.036 Zinc finger, BED-type containing 1 CfaAffx.17291.1.S1_s_at -1.634 0.036 Zinc finger and BTB domain containing 1 Cfa.1992.1.S1_at -1.160 0.036 Zinc finger CCCH-type containing 13 Cfa.3076.1.S1_at -1.171 0.036 Zinc finger, CCHC domain containing 6 CfaAffx.2895.1.S1_s_at -1.290 0.036 Zinc finger, CW type with PWWP domain 1 CfaAffx.22353.1.S1_at 1.254 0.036 Zinc finger, DHHC-type containing 2 Cfa.9227.1.A1_s_at 1.361 0.036 Zinc finger, MYM-type 3 CfaAffx.26083.1.S1_s_at -1.349 0.036 Zinc finger protein 132 CfaAffx.598.1.S1_at -1.260 0.036 Zinc finger protein 157 CfaAffx.23137.1.S1_at 1.403 0.036 Zinc finger protein 227 CfaAffx.7983.1.S1_s_at -1.348 0.036 Zinc finger protein 280D CfaAffx.24776.1.S1_s_at -2.201 0.036 Zinc finger protein 283 CfaAffx.8009.1.S1_s_at -2.294 0.036 Zinc finger protein 295 CfaAffx.16005.1.S1_s_at -1.418 0.036 Zinc finger protein 362 CfaAffx.16127.1.S1_at -1.463 0.036 Zinc finger protein 43 CfaAffx.692.1.S1_x_at -1.453 0.036 Zinc finger protein 470 CfaAffx.4569.1.S1_s_at -1.207 0.036 Zinc finger protein 471 CfaAffx.4586.1.S1_s_at -1.368 0.036 Zinc finger protein 644 CfaAffx.30924.1.S1_s_at -1.320 0.036 
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Zinc finger protein 684 CfaAffx.5406.1.S1_x_at -1.356 0.036 Zinc finger protein 691 CfaAffx.4632.1.S1_at 1.275 0.036 Zinc finger protein 705A CfaAffx.13503.1.S1_s_at -1.510 0.036 ZInc finger protein 835 CfaAffx.156.1.S1_at 1.138 0.036 Zona pellucida binding protein 2 CfaAffx.24994.1.S1_s_at -1.121 0.036 Zinc finger and SCAN domain containing 10 CfaAffx.29433.1.S1_s_at -1.085 0.036 
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